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Data clearly indicate that there is a high burden of metabolic disease including gout, type 2 
diabetes, and cardiovascular heart disease, among Polynesians. Many of the metabolic diseases 
have a shared aetiology and often present as comorbidities. To date, a number of studies have 
been undertaken, with varying success, attempting to disentangle the genetic and environmental 
components of these complex diseases. 
 
The high disease burden has led some to propose that Pacific populations possess a ‘Thrifty 
Genotype’. Here I argue that not only do the data not support this hypothesis, but that this is not 
in line with what is known of the evolutionary history of the region. Instead, a model for 
selection by a mechanism of infectious disease resistance is proposed. All of these metabolic 
conditions have a significant immunological component, namely the involvement of the NLRP3 
inflammasome, an important component of innate immunity. 
 
A number of recent studies have indicated that mitochondria play an integral role in the 
activation of the NLRP3 inflammasome. Thus, a study of mitochondrial genetic variation was 
undertaken, exploring how genetic variation in mitochondrial DNA (mtDNA) could contribute to 
differences in immune response and altered metabolic efficiency. Gout was used as a proxy for 
altered immune response and obesity as an indicator for metabolic efficiency. Whole 
mitochondrial genome sequencing was undertaken on 442 Māori and Polynesian men, selected 
from a cohort of individuals participating in a study of gout genetics.  
 
Few genetic associations were detected between either of these proxies, however there was a 
statistically significant association detected between variation in the region of the poly-cytosine 
tracts (16179-16189) in hypervariable region 1 (HVR1) and gout status. There was some 
indication that sequence length heteroplasmy in this region (which coincided with individuals 
possessing mitochondrial genomes belonging to the B macrohaplogroup) was associated with 
gout. 
 
Mitochondrial DNA copy number was also examined in the context of gout. Quantitative PCR was 
undertaken to measure the relative amount of mtDNA in 484 Polynesians. There appeared to be 
a general reduction in the amount of mtDNA in participants with gout compared to healthy 
controls. Given the involvement of the mitochondria in the co-localisation of components of the 
 ii 
NLRP3 inflammasome, this novel finding may explain some of what is occurring in the 
inflammatory processes underlying gouty disease, and possibly other metabolic diseases more 
generally.  
 
From this preliminary study, it appears that mitochondrial genetics may provide insights into 
susceptibility to metabolic conditions. This has wider implications when it comes to considering 
genetic ancestry and disease susceptibility, and may explain some of the high prevalence of 
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1.1 Opening statements 
This thesis is founded on two undeniable facts: 1) Metabolic disease is a problem among Māori 
and Pacific peoples; 2) These populations share a common ancestry that may be contributing to 
the development of these diseases. As such, exploring ancestry, the process of colonisation and 
the evolutionary history of the people living in this geographic region is pertinent to 
understanding their health. This thesis explores the genetic predisposition to metabolic disease, 
its prevalence and epidemiology in the Pacific, and aims to propose and test some hypotheses 
regarding the geographic patterning of disease in the region. 
 
Figure 1.1: Dates for the Pacific settlement. Blue lines indicate the timing and expansion of the first groups of 
people into what was then Sahul (prior to sea level rise), while the red lines indicate the movement of 
Austronesian-speaking colonists (Modified from Matisoo-Smith, 2015). Base map courtesy of Ceridwen 
Fraser. 
1.2 Background 
The Pacific region spans a huge geographical area and is the home to a large number of 
culturally diverse people. Here I focus mainly on Pacific Islands, in particular Polynesians. When 
considering human variation in the Pacific it is important to consider how the region was settled 
(Figure 1.1). There have been multiple movements of people into the Pacific region throughout 
the 50,000 year history of human occupation. People first arrived on the continent of Sahul, 
which became New Guinea and Australia with subsequent sea level changes, at least 49,000 








multiple populations involved in these Late Pleistocene and Early Holocene migrations out into 
New Guinea and the Solomon Islands, a region known as Near Oceania (Rasmussen et al., 2011). 
Subsequently, there have been several influxes of people from the Island Southeast Asia region 
into the islands of the Bismarck Archipelago and beyond as early as 5,000 years ago but 
certainly by some 3,350 years ago with the appearance of the Lapita cultural complex 
(Summerhayes et al., 2010a, Kirch et al., 1989). These people mixed with resident coastal 
populations prior to expanding out into the wider Pacific where they were the initial colonists 
on the previously unoccupied islands of Remote Oceania. The archaeological sites associated 
with these early Lapita colonists have distinctive trademarks, including highly decorated 
dentate-stamped pottery, which has been identified in sites from the Bismarck Archipelago, the 
Reef Santa Cruz (Southeast Solomon Islands), Vanuatu, Fiji, New Caledonia (Bedford et al., 2006) 
and as far east as Tonga (Burley et al., 2012) and Samoa (Spriggs, 2011). This settlement 
occurred very rapidly – with the earliest Lapita sites in New Ireland dating to ~3,350 years ago, 
and the latest settlements in Tonga only 2830-2846 years ago (Burley et al., 2012). There was a 
delay before the settlement of East Polynesia, where all the main island groups were settled 
within a three hundred year window between AD 1025-1290 (Wilmshurst et al., 2011). 
While there is likely to have been ongoing small-scale movements of people between 
archipelagoes with continuous contact and trade networks, the next major movement of people 
into the region were the 18th and 19th century movements of Europeans. This has had a more 
profound effect in some populations than others. For instance, in New Zealand and Hawai’i there 
was largescale European settlement compared to Tonga which maintained its own sovereignty, 
which has likely resulted in differing amounts of acculturation and admixture.  
The recent nature of the initial settlement of Remote Oceania has significant implications 
surrounding the cultural and genetic similarities and differences between populations in the 
region. Polynesians and Micronesians have been found to be more genetically similar to certain 
Asian populations than to many Near Oceanic populations which are highly heterogeneous 
(Friedlaender et al., 2008). Phenotypic and genotypic differences within Polynesia are more 
subtle but evident (Phipps-Green et al., 2010). Because of these differences in ancestry, there are 
both genetic and phenotypic differences between Pacific populations, even those within a 
reasonably close geographical distance to one another and with shared Lapita ancestry. 
Overlying this shared ancestral background of Polynesians and other Pacific people, there is an 
overrepresentation of metabolic disease burden. This is particularly evident among Māori and 








(Figure 1.2). Included in this bundle of metabolic diseases are gout, type 2 diabetes, obesity and 
cardiovascular disease, conditions which often present as comorbidities (Winnard et al., 2013).  
 
Figure 1.2: Age-standardised prevalence of metabolic diseases among New Zealanders of different ancestry 
(Winnard et al., 2013) 
The Merriman Laboratory and their collaborators have collected DNA samples from a large 
cohort of Māori and Pacific people for the purposes of gout research. As such, gout will be 
primarily focussed on in this thesis, however, the other prevalent metabolic diseases will be 
discussed at points because of the likelihood of shared aetiological factors between them. 
Gout is a chronic metabolic disease defined by inflammatory arthritis, with a prerequisite state 
of hyperuricaemia (serum urate levels exceeding 0.42 mmolL-1). High serum urate (SU) levels 
can result in nucleation and formation of monosodium urate (MSU) crystals, which accumulate 
in synovial joints. The subsequent inflammatory response to these crystals results in the onset of 
gouty symptoms, including inflamed joints and extreme pain. Usually gout presents as a series of 
acute attacks, which appear swiftly and are reasonably rapidly resolved. However, when left 
untreated, chronic gout may develop where bouts are more prolonged and damage to bony 
tissue may result (Dalbeth et al., 2009).  
The aetiology of gout is not well understood; MSU crystals have been isolated from 
hyperuricaemic patients not suffering gout, so clearly there are other unknown factors 
contributing, however its development is reliant on elevated SU levels in the patient. The 
development of hyperuricaemia is better understood and is known to have a multifactorial 























(Köttgen et al., 2012). Variants in the genes SLC2A9 and ABCG2, in particular, have been found to 
have strong effects, accounting for ~4% of variation in serum urate levels in European 
Caucasians (Köttgen et al., 2012), and are a significant cause of gout in Māori and Pacific Island 
New Zealanders (Hollis-Moffatt et al., 2009, Phipps-Green et al., 2010).  
In New Zealand, gout is of particular interest because of its previously mentioned high 
prevalence among Māori and Pacific people, particularly Polynesians (Winnard et al., 2012). 
Recently, it was found that not only do Māori and Pacific people in New Zealand have a higher 
gout prevalence, but they also have an earlier age of onset of gout (on average earlier by 9 
years), a higher flare frequency and more features of joint inflammation than non-Māori/Pacific 
(Dalbeth et al., 2013a). 
Given the shared ancestral background of Māori and Polynesians, it is reasonable to suggest that 
there is a shared innate genetic predisposition contributing to the higher prevalence of gout. 
While this concept has been widely accepted, it has often been assumed that gout in the Pacific is 
a phenomenon related to the changes away from traditional diets and lifestyles impacting upon 
a genetic predisposition, with some commentators (Lenane et al., 1960, Rose, 1975, Johnson & 
Rideout, 2004, Schlesinger, 2005, Álvarez-Lario & Macarrón-Vicente, 2010, Merriman & Dalbeth, 
2011) suggesting that gout prior to the twentieth century was uncommon. Contact with 
Europeans has changed traditional life particularly in terms of diet and activity patterns 
(Waqanivalu, 2010). This is most evident in places like New Zealand and Hawai’i, where the 
indigenous peoples have become a minority within the entire population, and significant 
urbanisation and industrialisation have been introduced. Mo st Pacific Islands have similarly 
been influenced by western cultures, becoming more dependent on imported foods, as the 
populations have risen beyond what the traditional agricultural practices can support. The high 
prevalence of a range of metabolic diseases including type 2 diabetes, obesity and 
cardiovascular disease can be attributed to the high energy foods and increasingly sedentary 
lifestyles in modern Pacific nations (Sundborn et al., 2008). Gout is part of this spectrum of 
diseases. 
There have been a number of studies identifying genetic variants that appear to be contributing 
to the elevated urate levels that underlie the high gout prevalence. These are also increasingly 
focusing on population-specific effects (Phipps-Green et al., 2010, Hollis-Moffatt et al., 2012, 
Flynn et al., 2013, Phipps-Green et al., 2016). However, when, how and why this probable 
genetic predisposition to hyperuricaemia and gout developed is something that has not been 
explored extensively. Further consideration of the population histories of Pacific people may 








Not all possibilities of genetic inheritance in relation to gout have undergone systematic 
analysis. Most of the loci which have previously been found to be contribute to gout or 
hyperuricaemia susceptibility in Polynesians as yet, have previously been identified in larger 
cohorts elsewhere (e.g. (Dehghan et al., 2008, Woodward et al., 2009, Köttgen et al., 2012), etc.). 
This is consistent with the common disease, common variant hypothesis, wherein common 
disease-causing alleles will be found in all human populations, though may exist at varying 
frequencies (Pritchard & Cox, 2002). 
Mitochondrial DNA (mtDNA), a small extra-nuclear genome within the mitochondria of each cell, 
has not undergone systematic testing in relation to gout, despite its adaptive potential. 
Mitochondria are organelles that play an essential role in energy production and immune 
processes. mtDNA encodes genes that are essential for mitochondrial function and population-
specific variation is known to exist within mitochondrial genomes worldwide. Genetic variation 
within this DNA may influence immune response, something that is salient in auto-inflammatory 
conditions like gout and other metabolic diseases. 
1.3 Motivation for the study 
Ethnographic studies carried out in Māori gout sufferers suggest that there is a great sense of 
embarrassment, self-blame and guilt associated with gouty disease (Lindsay et al., 2011, Te Karu 
et al., 2013). This, in some, leads to a reluctance to seek medical help to manage the disease, 
which would improve the quality of life of the gout sufferers. Urate-lowering therapies can 
significantly reduce the likelihood of gout flares. This reluctance to seek help is not unique to 
gout, and crosses over to other metabolic conditions such as type 2 diabetes where there is a 
three- and four-fold higher prevalence of undiagnosed disease among Māori and Pacific people 
compared to New Zealand Europeans respectively (Joshy & Simmons, 2006). Through this work 
of examining the evolutionary context in which susceptibility to gout and other metabolic 
disease-contributing variants may have developed, it is hoped that it may lessen some of this 
stigmatisation.  
One aim is to investigate a historic precedent for gout among Māori and other Pacific people, 
something that has been hinted at in the palaeopathological literature (Buckley, 2011), but 
which has not yet been fully embraced by the medical community. Establishing and 
understanding the history of this disease would imply that it is not only changes in the dietary 
environment and lifestyle habits of gout sufferers that is contributing to disease, but there is 
likely a pre-existing genetic predisposition which pre-dates Polynesian settlement. Raising 
awareness of this history of gout may take some of the onus off the individuals themselves and 








Also, by studying gouty disease in Polynesians, it may be possible to identify fundamental 
metabolic and immunological processes that contribute to the development of disease. 
Understanding these underlying immunological processes may allow for alternative drug 
therapies to be applied. It may also allow for the identification of other at-risk Pacific 
populations, allowing targeted education and awareness before the levels of disease increase to 
a level at which they will be recognised.  
1.4 Purpose of the study 
Seldom in academia does something fall firmly within a single field of research. With the 
increasing amounts of knowledge accumulating as academic pursuits continue, there is a 
growing need for interdisciplinary research. Genetics, immunology, archaeology, rheumatology; 
these all have facets which are shared and feed into the other, embroidering each other to make 
the complex picture that exists in the world around us. It is naive to work on the genetics of 
metabolic diseases without considering the people who are suffering these diseases, the 
populations to which they belong, the cultural and physical environments they inhabit, and their 
evolutionary histories. It is also naive to study the genetics of metabolic disease without 
considering the biology of the diseases themselves, the interactions between innate immunity 
and the metabolic system, the immune pathways, the role of organelles like mitochondria, and 
the complex and bemusing web of cytokine interactions.  
While interdisciplinary research has increased in recent times, there are still distinct divisions 
between fields of research. Reading widely in multiple disciplines, in the case of this thesis in the 
fields of archaeology, biological anthropology, medical genetics and immunology, assists in the 
synthesis of diverse ideas and the development of new hypotheses that may contribute to our 
understanding of disease. This effectively is the purpose of this thesis. 
The evolutionary and biocultural perspectives of biological anthropological research have the 
potential to enhance medical genetics studies. There has been increasing recognition of the need 
to consider inter-population differences in medical genetics studies because of differences in 
population histories contributing to variation in allele frequencies of risk variants and even 
novel risk loci (Rosenberg et al., 2010). While Homo sapiens as a species arose in Africa some 
200,000 years ago, there have been multiple migrations out of Africa, with populations both 
within and outside of Africa being exposed to different environments, pathogens (Fumagalli et 
al., 2011, Karlsson et al., 2014), subsistence patterns (Hancock et al., 2010), with different 
timings of migrations and interactions with extinct hominin species (Reich et al., 2011, Huerta-
Sanchez et al., 2014) – all things that are likely to be contributing to genotypic and ultimately 








and changing lifestyles following increasing industrialisation, this variation contributes to 
metabolic disease susceptibility. These are all things that require acknowledgment when dealing 
with human variation, whether looking at human variation from an anthropological viewpoint 
or from a medical one. 
The study aims to examine the population history and the patterning of disease prevalence 
across the Pacific region to see whether there are trends that make sense in an evolutionary 
context. The prehistoric settlement of the Pacific is a process which is increasingly being 
disentangled with ongoing archaeological, linguistic and genetic studies, and incorporating this 
knowledge into studies of medical genetics may help elucidate reasons for the high prevalence of 
metabolic conditions in these peoples. 
An understanding of the population histories in the region allows for the generation of 
evolutionary explanations for the high burden of metabolic disease. There are a number of pre-
existing hypotheses, such as the ‘Thrifty Genotype’ hypothesis,  which have been put forth which 
will be assessed in light of the evolutionary history of the region. A novel hypothesis is suggested 
which poses that selection by infectious disease exposure may have contributed to susceptibility 
to metabolic disease, particularly via selection of genetic variants contributing to the NLRP3 
inflammasome, an important innate immune response which is inherently involved in the 
inflammation characteristic of metabolic diseases such as gout and type 2 diabetes.  
1.4.1 Specific aims 
- To establish a historical precedent for the high rates of gout through examination of the 
historic literature – is gout really a modern phenomenon and something just seen in a 
few remarkable archaeological sites? 
- To explore potential evolutionary explanations for the elevated prevalence of gout and 
other metabolic diseases among Polynesian populations; 
- To investigate how the mitochondrial genome may affect metabolic disease, including 
susceptibility to gout. 
1.5 Significance of the research 
The significance of the research is twofold. A new hypothesis regarding the susceptibility to 
hyperuricaemia and gout is proposed with consideration of the evolutionary history of the 
region. While this does not get tested using selection statistics such as the integrated haplotype 
score (iHS) (Voight et al., 2006) or extended haplogroup homozygosity (Sabeti et al., 2002), it 
represents an alternative to the current out-dated models such as the ‘Thrifty Genotype’ which 
are widely accepted but have remained virtually untested in the 53 years since it was first 








Second, the mitochondrial DNA component of this thesis constitutes the single largest study of 
mitochondrial diversity in Polynesia thus far. There have been few complete mitochondrial 
genomes sequenced in Polynesians thus far (Pierson et al., 2006, Duggan et al., 2014), so the 
data produced may be able to give pertinent information not only on disease susceptibility, but 
the settlement of the Pacific region.  
 
1.6 Thesis structure 
This thesis is divided into seven chapters.  A large portion of this thesis comprises a review of the 
literature. This is primarily because of the attempt to bridge multiple disciplines. The first three 
chapters (Chapters 2-4) comprise a thorough review of the literature, synthesising material 
from diverse fields, and sets the context for the laboratory work described in Chapters 5 and 6. 
Three academic publications (attached in Appendix 1) have arisen from the literature reviewing 
the Chapters 2 and 3. 
In Chapter 2, a genetic predisposition to the high prevalence of gout among Pacific people is 
established by a review of the epidemiological literature. In particular, hyperuricaemia and 
elevated serum urate levels are explored, not only in the Pacific but also on a worldwide scale. 
While elevated urate levels alone are not sufficient to cause gout – it still requires an 
inflammatory immune response - urate levels are something more easily quantified and 
examined on a population level than immune function. Further, the chapter outlines the 
historical and prehistoric evidence for gout among Pacific populations. Establishing a historic 
genetic predisposition to gout in these early periods of pre- and post-European contact is 
important as it suggests that the genetic background is having a large contribution to phenotype 
in absence of the westernised diets that have been recently introduced to many contemporary 
Pacific populations.  
In Chapter 3, current hypotheses surrounding the high prevalence of metabolic disease among 
Pacific people are explored and contextualised with reference to current knowledge 
surrounding the settlement processes and prehistory of the region. In particular, the oft-cited 
‘Thrifty Genotype’ hypothesis is a particular focus. In this section, a novel hypothesis is also put 
forward to explain the high rates of hyperuricaemia, which contribute to the high burden of 
metabolic disease in the region. 
Chapter 4 acts as a bridge between the literature reviewing and hypothesis building from 
Chapters 2 and 3, and the laboratory work later in the thesis. This chapter focuses on the innate 








thesis, and introduces the link to mitochondria and mitochondrial variation. The NLRP3 
inflammasome is thought to be responsible for a number of auto-inflammatory conditions, 
including gout, and the role of mitochondria in this immune pathway is explored. 
Mitochondrial genetic variation and its potential role in disease is focussed on in Chapter 5 and 
the results of sequencing 442 whole mitochondrial genomes from Polynesian gout cases and 
controls are discussed. Because variation in the mtDNA sequence is not the only form of genetic 
variation, Chapter 6 explores the potential effect of mitochondrial DNA copy number (as a proxy 
for mitochondrial mass) on susceptibility to gout.  


















2 Gout and metabolic diseases among Pacific peoples 




This chapter comprises a synthesis of the following three publications, which are included in 
Appendix 1. 
- Gosling, AL., Matisoo-Smith, E. and Merriman, TR. 2014. Hyperuricaemia in the Pacific: why the 
elevated serum urate levels? Rheumatology International 34(6): 743-757 
- Gosling, AL., Matisoo-Smith, E. and Merriman, TR. 2014. Gout in Māori. Rheumatology 54(5): 
773-774 
- Gosling, AL., Buckley, HR., Matisoo-Smith, E. and Merriman, TR. (2015). Pacific populations, 
metabolic disease and ‘Just-So Stories’: a critique of the ‘Thrifty Genotype’ hypothesis in Oceania. 
Annals of Human Genetics 79(6): 470-480 
 
2.1  Introduction 
This chapter aims to contextualise metabolic disease in the Pacific, to establish the region-wide 
trends and to explore the history of this phenotype in the region. Establishing the existence of 
the phenotype prior to the influences of westernisation and the changes in diet and lifestyles 
which accompanied European contact is important in suggesting that selection is something that 
may have contributed to the development of the phenotype. It is imperative when carrying out 
any genetic study to take into consideration the context in which the disease is occurring.  
 
2.2 Epidemiology of metabolic disease in Pacific populations 
As previously mentioned in Chapter 1, it is well established in the literature that there is a high 
metabolic disease burden among Pacific peoples, including Māori. This is particularly evident 
when looking at the breakdown of disease prevalence in mixed populations such as in New 








Additionally, the World Health Organization has raised concerns over the increasing rates of 
chronic diseases including type 2 diabetes and cardiovascular diseases. Here, I have broken 
these diseases down and looked at the prevalence of certain conditions across the Pacific, and in 
the context of other populations worldwide, where there are data available.  
2.2.1 Gout and hyperuricaemia 
As previously discussed, gout is an inflammatory arthritis characterised by the accumulation of 
MSU crystals in synovial joints which results in an inappropriate inflammatory response. As 
such, a state of hyperuricaemia (serum urate levels exceeding 0.36 mmolL-1 or 6 mg/dL (Bardin, 
2015)), is generally necessary for gout to develop. In this section, the prevalence of both of these 
are discussed in the context of the Pacific. 
It was noted relatively early on that the Pacific people seemed to be “one large gouty family” 
(Kellgren, 1964, p. 116), and there were quite a number of studies carried out assessing gout 
prevelance by Isadore Rose, Ian Prior and others (e.g. Lenane et al., 1960, Rose & Prior, 1963, 
Prior & Rose, 1966, Prior et al., 1966, Rose, 1975). The findings of these early studies have stood 
the test of time and even today, a high prevalence of gout is seen among many Pacific 
populations, particularly those with high western influences, such as New Zealand, where Māori 
and Pacific Islanders have a much higher prevalence of disease compared to their New Zealand 
European and Asian counterparts (Winnard et al., 2012). The presently available prevalence 
data for populations throughout the Pacific region is presented in Table 2.1 (though the date of 
publication of the studies should be kept in mind, as the prevalence of gout is likely to have 
increased with increasing sedentism and dietary change (Klemp et al., 1997)). 
Given the role of elevated serum urate levels in the aetiology of gout, it is perhaps not surprising 
that many Pacific populations have high urate levels compared to many other populations 
worldwide (Figure 2.1)(Gosling et al., 2014). To this end, a summary of the published data 
available on the mean serum urate levels worldwide is provided in Appendix 1. Only male data, 
unless otherwise stated, have been presented because of the confounding effect of hormones on 
urate levels in pre-menopausal women (Hak & Choi, 2008). 
Examination of these data show that most Pacific Island populations (Polynesians and 
Micronesians) and their possible ancestral populations (Taiwanese aboriginals) in particular, 
have higher rates of hyperuricaemia, with few other populations showing high mean serum 
urate levels (in the 6.5 mg/dL + range). Most populations have average serum urate 
concentrations of between 4 and 6 mg/dL, below the hyperuricaemic threshold. While some of 
this variation could relate to differences in lifestyles, subsistence and environment, ancestry is 








worldwide since the expansions out of Africa, it is feasible that higher serum urate 
concentrations may have been positively selected under certain environmental conditions, 
leading to the variability which we see in modern populations globally. This idea will be 
explored further in the Chapter 3. 
 
Table 2.1: Prevalence of gout in Pacific and related populations 
Locality Population Gout %  
(men only) 
References 
New Zealand Māori 11.7% (Winnard et al., 2012) 
 Pacific Islanders 13.5% (Winnard et al., 2012) 
 European 3.7% (Winnard et al., 2012) 
 Asian 3.7% (Winnard et al., 2012) 
Cook Islanders Rarotonga 2.4% (Prior & Rose, 1966) 
 Pukapuka 5.3% (Prior & Rose, 1966) 
Tonga Tongans 2.8% (Finau et al., 1983) 
Tokelau Migrants in NZ 5.3% (Wigley et al., 1987b) 
 Non-migrant 0.7% (Wigley et al., 1987a) 
Tuvalu Funafuti 0.0% (Zimmet & Whitehouse, 1981) 
Samoa Rural 6.2% (Zimmet & Whitehouse, 1981) 
 Urban 7.2% (Zimmet & Whitehouse, 1981) 
Fiji Urban (Suva) 0.002% (Tuomilehto et al., 1988) 
Nauru Nauruans 6.9% (Zimmet et al., 1978) 
Mariana Islands Guam  1.5% (Reed et al., 1972) 
 Rota 4.1% (Reed et al., 1972) 
Java “Malayo-Polynesians” 1.7% (Darmawan & Lutalo, 1995) 
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Figure 2.2: Summary of distribution of mean serum urate levels (in men) from throughout the Pacific. 
Modified from Gosling et al. (2014). Base map courtesy of Les O’Neill. 
Though Polynesian populations tend to show high levels of serum urate, there is reported 
variation (Figure 2.2). For instance, the urate levels from a small sample of 49 Polynesians in 
Hawai’i (5.4 mg/dL), none of which showed any gouty disease, are unexpectedly low (Healey et 
al., 1966)– this has been used to argue that this population may be metabolically different than 
other Polynesian populations (Prior, 1981). These unusual results have not been revisited in the 
literature despite the study being carried out nearly 50 years ago. Currently there is a relatively 
high disease burden of gout in Indigenous Hawaiians (Pers. Comm.: K. Chong-Hanssen), and 
likely gout has been identified in skeletal remains from ancient Hawaiians (Suzuki, 1993). A high 
disease burden of gout can be taken as an indication of a high rate of hyperuricaemia in 
Indigenous Hawaiians.  
Environment clearly also has an effect on serum urate levels; a number of studies have sampled 
from both urban and rural cohorts from within the same population, presumably to help 
understand the effects of urbanized living (Healey et al., 1967, Duff et al., 1968, Reed et al., 1972, 
Wyatt et al., 1980, Jackson et al., 1981, Finau et al., 1983, Tuomilehto et al., 1988, Prior et al. , 
1987). Higher urate levels were generally observed in those inhabiting an urban environment. 
For instance, Tongan men from urban areas had mean serum urate levels of 6.5 mg/dL 
 
 




compared with 5.3 mg/dL in those living in rural areas (Finau et al., 1983). Similar trends were 
seen in Papua New Guinea, with an urban Melanesian population living in Port Moresby having 
mean serum urate levels of 6.2 ± 1.3 mg/dL, compared to 4.2 ± 1.3 mg/dL in a rural cohort 
(Wyatt et al., 1980), though this could also be related to genetic differences between the Port 
Moresby population and the rural population given the heterogeneity in Papua New Guinea. In 
general, living in an urban environment exacerbates the tendency toward elevated serum urate 
levels, concomitant with the increased consumption of foodstuffs (such as sugar-sweetened 
beverages and alcohol) that increase urate (Choi et al., 2004, Choi & Curhan, 2008, Batt et al., 
2014). However, the fact that even those living rurally and with more traditional lifestyles in 
Polynesia have high rates of hyperuricaemia, compared to other populations worldwide, 
suggests a genetic predisposition. 
2.2.2  Obesity 
Defined by having a body mass index (BMI) exceeding 30 kg/m2, obesity, particularly abdominal 
obesity, is considered a risk factor for most other metabolic syndromes, including type 2 
diabetes and cardiovascular disease (Mokdad et al., 2003, Despres & Lemieux, 2006). However, 
BMI is certainly not the best measure of metabolic fitness, with studies suggesting that 
populations can have different lean mass: fat mass ratios (Swinburn et al., 1999). Rush et al. 
(2009) found that Pacific people have less adipose mass than other ethnicities when normalised 
for gender and BMI. They found that for a given body fat content, the BMI for the NZ Asian 
population was 25 kg/m2, for Europeans 30 kg/m2, and for Māori and Pacific Islanders 35 
kg/m2. Thus, the utility of BMI as a marker of adiposity has been contested. However, others 
have argued that the undeniable statistics surrounding the high type 2 diabetes and heart 
disease prevalence among Pacific people suggest that whether BMI varies in relation to body fat 
is immaterial (Taylor et al., 2010).  
In the 2014 OECD obesity report, New Zealand had the third highest prevalence of obesity 
(below Mexico and the USA) (Ng et al., 2014). In general, obesity in New Zealand is on the rise, 
with the Ministry of Health reporting that 31% of adults are obese and a further 34% are 
overweight (http://www.health.govt.nz/nz-health-statistics/health-statistics-and-data-
sets/obesity-data-and-stats). These statistics may be contributed to by the significant portion of 
New Zealanders being of Māori or Pacific ancestry (~22% according to 2013 census data; 
http://www.stats.govt.nz/Census/2013-census/profile-and-summary-reports/infographic-
culture-identity.aspx). The New Zealand Ministry of Health reports that 48% of Māori and 68% 
of Pacific adults in New Zealand are obese. These trends of high rates of obesity translate out to 
the wider Pacific region. 
 
 





Figure 2.3: Prevalence of type 2 diabetes and obesity in the Pacific. The dashed line indicates the division 
between near and remote Oceania. (From Gosling et al., 2015). 
The increasing rates of obesity among Pacific Island countries have come to the attention of the 
World Health Organization and have been highlighted as a concern (Waqanivalu, 2010). Figure 
2.3 shows prevalence data for obesity throughout the Pacific region. Like the serum urate levels 
and gout discussed in the previous section, there are some large-scale region-wide trends, with 
the highest prevalence existing among Polynesian and Micronesian populations. As shown, nine 
of the populations for which data exist, possess a prevalence exceeding 50%. In Near Oceania, 
there are lower rates of obesity. This is likely due to a combination of less penetrance of 
westernised diets and lifestyles, and also a different genetic background. This will be more 
extensively explored in Chapter 3.  
This epidemic of obesity is likely to be something that has arisen out of changes in lifestyle since 
contact with Europeans and with increasing amounts of foreign foods being imported into many 
localities (World Health Organization, 2012). A 1978 study of urban and rural populations in 
three areas in Samoa showed large differences in the prevalence of obesity, with 74% of women 
in Apia (urban) being obese, compared to 62% and 56% in Putasi and Tuasivi (rural) 
respectively. The data for the men was comparable with 57%, 44% and 36% obesity being 
measured in Apia, Poutasi and Tuasivi respectively (Dowse et al., 1995). Between the years of 
1978 and 1991, there was a marked increase in obesity prevalence, particularly in rural areas. In 
 
 




Poutasi (Samoa), the rate of obesity increased 297% in men and 115% in women (Hodge et al., 
1994). 
2.2.3 Type 2 diabetes 
As previously mentioned in Chapter 1, another metabolic condition that disproportionately 
affects Māori and Pacific people in New Zealand is type 2 diabetes. The New Zealand Ministry of 
Health reports that belonging to this ancestral group is associated with a three times higher risk 
of developing disease compared to other New Zealanders (http://www.health.govt.nz/your-
health/conditions-and-treatments/diseases-and-illnesses/diabetes). The International Diabetes 
Federation reported that in 2014, 138 million people in the Western Pacific region alone suffer 
diabetes. While their classification includes East and South East Asia in the Western Pacific 
region, the prevalence data for Pacific Island nations make up some of the highest in the world 
(Chan et al., 2014).  
Studies of populations from the region report an increase in disease over the last 30 years or so. 
For instance, in Tonga the prevalence has increased from 7.5% in 1973 to 15.1% in 1998 
(Colagiuri et al., 2002). Similar escalations in disease frequency have also been observed among 
three Samoan populations (Collins et al., 1994). In Apia (urban), prevalence increased from 8.1 
to 9.4% in men and 8.2 to 13.4% in women between 1978 and 1991. In Poutasi (rural), 
prevalence increased from 0.1 to 5.3% in men and 5.4 to 5.6% in women, while in Tuasivi, men’s 
prevalence increased from 2.3 to 7.0% in men, and 4.4 to 7.5% in women. This mimics the trend 
of increasing obesity in the same populations. 
The geographic distribution of high prevalence of diabetes follows very similar patterns to those 
of obesity and serum urate levels (Figure 2.3), where high prevalences are seen almost 
universally throughout Polynesia and Micronesia (although in this case, the Samoans do have 
slightly lower prevalence), and lower rates of diabetes are seen in areas which were settled 
earlier, for instance the Solomon Islands and Papua New Guinea. This lends credence to the 
hypothesis that these may be interrelated and there may be a shared evolutionary origin for 
them.  
2.2.4 Ischemic heart disease 
As mentioned in Chapter 1, Māori and Pacific people in New Zealand have a higher incidence of 
ischemic heart disease than their New Zealand Asian and European counterparts (Winnard et 
al., 2013). A study from Wallis Island suggests that while the prevalence of hypertension and 
heart disease were low during the early 1980s, social and economic changes over the last 30 
years have lead to a dramatic increase in the rate of cardiovascular disease (Linhart et al., 2015). 
Unfortunately there is not a lot of epidemiological data presently available on prevalence in 
 
 




different Pacific populations, however the World Health Organization advise that alongside 
diabetes and hypertension, cardiovascular disease accounts for three quarters of all deaths 
throughout the Pacific (Waqanivalu, 2010). 
2.2.5 Discussion  
From where data are available, there do appear to be region-wide trends with these related 
metabolic conditions discussed here. The high serum urate levels and the prevalence of gout, 
obesity and type 2 diabetes are almost universal across the Pacific, with the notable exception of 
Near Oceanic regions, which broadly do not show this trend. This may partly be a result of 
differences in the penetrance of westernisation, but it may also be because of genetic differences 
in populations which arise from the settlement patterns in the region (discussed in Chapter 1).  
Polynesian and Micronesian peoples speak languages belonging to the Austronesian language 
family. Austronesian languages are thought to have originated in Island South East Asia (ISEA), 
perhaps Taiwan, around 5000 years ago before being dispersed throughout ISEA, Oceania and 
beyond (Gray et al., 2009). Non-Pacific Austronesian-speaking populations also have elevated 
serum urate levels. Taiwanese aborigines have particularly high serum urate concentrations 
(Chang et al., 1997, Chou & Lai, 1998), while Filipinos also seem to have elevated serum urate 
levels (Healey et al., 1967). The Merina population in the Highlands of Madagascar, who have 
also been ancestrally linked to an Austronesian expansion out of ISEA (Cox et al., 2012), have 
likewise been observed to have high rates of gout and hyperuricaemia (Capdevielle et al., 1980). 
Similarly, the Seychellois, who may also have an ancestral genetic contribution from 
Austronesian-speaking colonists (Fitzpatrick & Callaghan, 2008) exhibit elevated serum urate 
concentrations (Conen et al., 2004). 
Mitochondrial DNA analyses indicate that Polynesian and many other Austronesian-speaking 
populations have a significant genetic contribution from South East Asia (Kayser, 2010), where 
mean SU levels range from 5.5 mg/dL to 6.5 mg/dL (Appended data from hyperuricamia in 
Pacific paper). Y-chromosome STR analyses of Polynesians show that there is also a significant 
ancestral contribution from ancient Melanesian or Near Oceanic, non-Austronesian-speaking 
populations (Kayser, 2010). This is supported by genome-wide SNP data that indicate a genetic 
contribution from these ancient Near Oceanic lineages of around 13% in Polynesians (Wollstein 
et al., 2010), though it should be noted that there was minimal sampling from East Polynesia in 
this analysis. Figure 2.2 shows that the hyperuricaemic phenotype does not seem to be present 
in many Melanesian populations on the mainland of New Guinea and in the Solomon Islands, 
where sampled populations show mean SU concentrations ranging from 4.2 mg/dL to 6.2 
mg/dL, compared with Polynesians whose mean SU range from 5.3 mg/dL to 7.1 mg/dL. Near 
 
 




Oceanic populations are not genetically homogenous (Friedlaender et al., 2007), so these data 
should not be taken to be representative of all populations living in this area. However, the 
raised urate levels as seen in other Austronesian-speaking populations predominate over the 
lower serum urate concentrations in non-Austronesian speakers. Indeed, anecdotal data from 
personal communication with a physician working in the New Britain province of Papua New 
Guinea suggests that there are differences in gout and diabetes prevalence between populations 
of different ancestral backgrounds; he reported relatively high rates of diabetes among the Tolai 
(an Austronesian-speaking population) which did not occur in the Baining (a non-Austronesian-
speaking population) (Pers. Comm.: Tim Fletcher). Further anecdotal reports have arisen 
through communication with physicians in the New Ireland province, where there are 
populations with a high Austronesian-influence and increasing prevalences of metabolic disease 
(Pers. Comm.: Lisa Matisoo-Smith). This indicates that this is an area that requires more 
research. 
Together, the data suggests that there is a broad geographic trend of heightened susceptibility to 
metabolic disease, which may be underwritten by the almost uniformly high serum urate levels 
among the Austronesian-speaking populations in the region. Because of the wide distribution of 
the phenotype, it seems that the genetic variants contributing to this were likely to be increased 
in frequency prior to the settlement of the region. This may have resulted from selection to a 
more hyperuricaemic phenotype, or more broadly, a phenotype susceptible to metabolic 
disease, in Austronesian populations. This possibility will be elaborated on in Chapter 3. If this 
hypothesis is correct, it might be expected to see traces of metabolic disease in early skeletal 
material from the region. This will be explored in the coming section. 
 
2.3 A history of gout? 
It is widely accepted that Māori and Polynesians share an innate genetic predisposition 
contributing to the higher prevalence of gout. Despite this, much emphasis has often been placed 
on the changes away from traditional diets and lifestyles, with many commentators (Lenane et 
al., 1960, Rose, 1975, Johnson & Rideout, 2004, Schlesinger, 2005, Álvarez-Lario & Macarrón-
Vicente, 2010, Merriman & Dalbeth, 2011) suggesting that gout prior to the twentieth century 
was uncommon. Contact with Europeans has changed traditional life particularly in terms of diet 
and activity patterns (Waqanivalu, 2010), which is evident in places like New Zealand and 
Hawai’i, where the indigenous peoples have become a minority, and there has been significant 
urbanisation and industrialisation. As previously noted in Chapter 1, most Pacific Islands have 
similarly been influenced, becoming reliant on imported foods. The high prevalence of a range of 
 
 




metabolic diseases including type 2 diabetes, obesity and cardiovascular disease is influenced by 
over-consumption of high energy foods and the increasingly sedentary lifestyles in modern 
Pacific nations (Sundborn et al., 2008). Gout is part of this spectrum of metabolic diseases.  
The assertion that modernity alone is responsible for the high rates of gout in Māori has been 
brought into question by recent bioarchaeological studies of prehistoric Māori which have 
identified bony lesions that are thought to be signs of gout (Buckley et al., 2010, Campbell & 
Hudson, 2011). The gouty immune response can result in osteological damage and the formation 
of sclerotic lesions (Figure 2.4) – it is these lesions which can be observed in skeletal analysis 
(Buckley, 2007). Typically, lesions are located on the margins of the first metatarso-phalangeal 
joint, as this joint seems to be the most common site of the development of gouty tophi. In dry 
bone, these lesions are distinguishable from other forms of arthritis because of the particular 
types of bony changes. Osteoarthritis, for instance, appears as polishing of the articular surfaces 
of a synovial joint, while the lesions attributed to gout by bioarchaeologists have a combination 
of osteoblastic (bone formation) and osteoclastic (bony destruction) changes associated with 
them. 
 
Figure 2.4: Examples of eroded holes that are characteristic of gout. The bones shown are those that make up 
the metatarso-phalangeal joint. From (Campbell & Hudson, 2011) (Used here with iwi permission) 
Six of the forty-two (14%) individuals, all six of whom were male, recovered in archaeological 
excavations from Wairau Bar, the oldest known archaeological site in New Zealand, were found 
to possess these osteoclastic lesions (Buckley et al., 2010). Furthermore, eleven of the fifty-three 
(21%) adult individuals excavated from the Ihumatao site in Mangere, near Auckland, showed 
evidence of gout, including two of the fourteen identified females (14%) and four of the 
seventeen identified males (23.5%) (Campbell & Hudson, 2011). The tendency towards males 
possessing the lesions rather than the females, and the location of the lesions, which were 
predominantly located on the margins of the first metatarso-phalangeal joint, in both 
 
 




assemblages, are consistent with the hypothesis that the lesions are a consequence of gout. It 
should also be noted that while the individuals from Wairau Bar were likely part of an 
immigrant population (dating to 1288 to 1300 AD) making them amongst the first New 
Zealanders (Buckley et al., 2010), the Ihumatao site dates to the 1620-1690 AD (Campbell & 
Hudson, 2011) by which time Māori populations were well established in New Zealand.  
In light of this archaeological evidence for gout, it is clear that Māori suffered from gout prior to 
contact with Europeans. This challenges the view that the elevated prevalence of gout in 
contemporary NZ Māori is attributable primarily to Western influences on lifestyle. It is 
important that this paradox is resolved in order to better understand the causes of gout in 
Māori, both pre- and post-European contact. Examination of the historical literature sheds light 
on how the idea that gout is a disease of modernity has been perpetuated, so as to become the 
orthodox view. 
2.3.1 The historical literature 
The earliest reports of health in the Pacific by observers such as Sir Joseph Banks, who 
accompanied Captain James Cook in the Endeavour in 1769 (Hooker, 1896, p. 239-240), 
describe the excellent fitness of the Māori and other Polynesians. However, the episodic nature 
of gout (Prior, 1981), as well as the practice of moving chronically unwell individuals to special 
purpose-built dwellings away from the main settlement (Goldie & Best, 1904, Buck, 1910), 
would have reduced the likelihood of these earliest of spectators to witness gout if it were 
present. William Colenso (1868, p. 20), a missionary in the Hawke’s Bay region, noted that Māori 
“rarely ever died in a good house; mostly in the open air, or under some wretched shed; this was 
done because the house in which anyone died would have to be forsaken to tapu”.  
Another confounding factor could be that during this early nineteenth century period, there 
were two co-existing schools of medical thought. Brought in by the colonising Europeans was 
Westernised medicine, which put the causation of disease as having a biological basis. Access to 
westernised medical practitioners, particularly for Māori, was limited as there were often long 
distances required to travel in order to see a doctor (with many Māori living rurally, while most 
doctors lived in cities or towns). Alongside this, there were also the pre-existing traditional 
medicines centred around more esoteric causes of illness (Buck, 1910). The underlying idea of 
the traditional Māori perception of medicine is that there was no natural disease: illness was a 
result of either transgression against an atua by the means of breaking some law of tapu, or else 
was the result of witchcraft or makutu (Buck, 1910). A tohunga or priest would be consulted in 
order to determine the cause of the complaint, and appropriate action was taken to either 
appease the atua or to remove the makutu. Thus, illnesses were often perceived as being either 
 
 




mate Māori (traditional Māori conditions) or mate Pakeha (diseases brought in by the 
Europeans), and whether the disease was considered mate Māori or mate Pakeha had some 
influence over who Māori consulted in order to get rid of it (Best, 1904).  
Given the archaeological evidence for gout in prehistoric Māori, the disease may have been 
considered mate Māori, especially given that gout did not have an obvious physical cause (i.e. 
not like a physical injury). This is supported by Sir Peter Buck’s (1910, p. 43) recounting of how 
the Tohourangi iwi from the central North Island, had a god which they called Tatariki who they 
thought caused the swelling of the big toe joint and ankle. This, in itself, is compelling evidence 
that this particular iwi must have had enough of a history of gout for there to be an atua 
implicated in its causation to be passed on to Buck with the transmission of oral histories. What 
may also be surmised is that other iwi had attributed the disease to different atua, meaning that 
there was no universal term (or disease-atua) for the disease – this is supported by the late 
entry of a term for gout (porohau) in a Māori-English dictionary (Tregear, 1891). This word 
differs from the most frequently used Māori term in contemporary times (kaute – a 
transliteration of the word ‘gout’) (Ryan, 2008). Interestingly, other Polynesian languages (but 
not Māori) do have a shared cognate for rheumatic pain, swelling to the joints and gout-like 
symptoms (*ŋu-ŋu), which indicates that the disease was likely ancient and not uncommon in the 
Austronesian world (Osmond, In Press). 
Western medical care available to Māori during the earliest times post-European contact was via 
the missionaries. This was predominantly through providing pharmaceutical products. The 
missionaries themselves were not trained in medicine, and most made little mention of the state 
of health in Māori, let alone discuss the presence or absence of gout (e.g. Colenso, 1868, p. 7; 
Taylor, 1855, p. 253). The earliest official inquiry into the state of Māori health was a survey 
carried out by Dr Fairfowl in 1821 (Fairfowl, 1908). Being a physician, Dr Fairfowl presumably 
was better positioned to recognise the symptoms of gout; however it was not one of the common 
diseases that were mentioned in his report. It is interesting to note, however, that rheumatism 
was reported as being prevalent (Fairfowl, 1908). This apparent high frequency of rheumatism 
was also commented on almost two decades later by John Bright (1841), but again, no specific 
mention of gout was made. 
The next accounts of health, and probably the most thorough account of Māori health dating 
back to this pre-twentieth century era, are the observations of Arthur S. Thomson, Surgeon of 
the 58th Regiment of Foot. Thomson wrote a detailed two-volume work on New Zealand, with 
much focus on the indigenous peoples (Thomson, 1859), in addition to a series of articles he 
wrote specifically on Māori health (Thomson, 1854, p. 361). It was in one of these articles that he 
 
 




stated that “gout is unknown” among the Māori (p. 361). However, like Fairfowl before him, he 
noted a high frequency of “rheumatic affections”. Thomson’s observations of the absence of gout 
among native New Zealanders were rapidly picked up by others writing on the geographic 
distribution of various pathologies (Hirsch, 1885). 
Thomson was not alone in describing this apparently high rate of rheumatism among Māori – Dr 
Alfred Newman (1883, p. 499) also noted this trend, while also indicating that Māori “show 
scant tendency to the gouty diathesis”. “When gout does appear”, Newman (1883, p. 499) states, 
“it is always in the person of an immigrant”. 
Belying some of these statements of apparently non-existent gout among the Māori are a 
smattering of reports of gout in Māori men in regional newspapers from around this period 
(Table 1). For instance, in 1885, the Grey River Argus (1885) reported the suicide of Ihaia 
Tainui, at the Māori School House, and a recent attack of gout was cited as a possible 
contributing factor to his “despondency and gloomy forebearings.” Topai Turoa, a chief of high 
rank, was described as “the oldest and most infirm member of the embassy. He is afflicted with 
rheumatic gout, leans heavily on a stick, and moves about with some difficulty”(Wanganui 
Herald, 1884). The northern chief, Paora (Paul) Tuhaere of Orakei, was on multiple occasions 
reported to suffer from bouts of gout. In 1879, he was part of a greeting party for Sir George 
Grey, and was “mounted on a charger, as he suffer[ed] acutely from gout” (Thames Advertiser, 
1879), and in 1884, a further attack of gout forced him to abandon the notion of visiting England 
(New Zealand Herald 1884). In this account, it was said that “the natives are not all satisfied on 
that head, and are under the belief that the Government in order to prevent Paul from going, 
have employed other Māoris to makutu him, and give him rheumatism and gout” (New Zealand 
Herald, 1884). This supports the idea that Māori may not have perceived gout as a disease in its 
own right, rather something that is caused by more spiritual means, whether it be disease atua 
or makutu and witch-craft. This possibility is supported by the previously mentioned 
Tohourangi iwi, who attributed gout to a god. 
2.3.2 Disparities in the historic definitions of gout 
Many of the historic documents discussing health in indigenous New Zealanders in the 
nineteenth century have been interpreted by more contemporary commentators (Lenane et al., 
1960, Rose & Prior, 1963) to indicate that gout was not a health concern for Māori prior to the 
twentieth century. Given that the apparent absence of gout has been explicitly mentioned in 
many of these accounts (Thomson, 1854, Newman, 1883, Hirsch, 1885), this is not surprising. 
Rose (1975) argues that because gout was familiar to European colonists arriving in New 
Zealand they would have recognised its symptoms in the indigenous population. Therefore, he 
 
 




argues, these historic accounts of people denying the presence of gouty symptoms among Māori 
can be taken seriously. However, it could also be argued that the definition of gout in the 
nineteenth century is quite different to what it is now, and that the reported high prevalence of 
rheumatism in Māori during this period may in fact reflect a misdiagnosis of gout as 
rheumatism.  
Since the perception at the time was that gout was a disease that chiefly affected those living an 
affluent lifestyle (Hirsch, 1885), enjoying the “luxuries of civilised life” (Garrod, 1859), gouty 
pathologies observed in indigenous peoples in apparently “uncivilised” countries may not have 
been regarded as being the same disease, and thus were described as rheumatism instead. 
Garrod, who was the first to describe high uric acid levels in the blood of individuals suffering 
from gout (Garrod, 1848) and thus a contemporary authority and influential on the matter, 
stated (Garrod, 1859) “among nations in an uncivilised state, living chiefly on the produce of the 
chase obtained by personal exertion, or subsisting at least on the simplest fare, gout, according 
to the reports of eminent travellers, is entirely unknown even at the present day; but in our own 
country [England], and in many other parts of the civilised world, the case is far otherwise” (p. 
2).  
 
In their review of the history of gout, Porter and Rousseau (1998, p. 167) describe how in the 
mid-nineteenth century, gout was used as “a makeshift or umbrella diagnosis for all manner of 
aches, pains and complaints” in the wealthier echelons of society, with the prevailing perception 
being that while there was a hereditary element, luxurious living could also trigger the disease. 
Indeed, as early as 1816, Heberden bemoaned the fashionable nature of the diagnosis, reporting 
“I have seen several intoxicate themselves with strong liquors for two or three days together, 
upon presumption that they wanted a gouty fit, and that this was a proper way of procuring 
one”, and further suggested that physicians allow “the criteria of [diagnosis] to be very obscure… 
I think hardly any which give us ground to suspect this disease, where there is no pain, nor 
redness, nor swelling in the first joint of the great toe, or in any other part of the foot…” 
(Heberden, 1816, p. 36-37). Even by 1914, Wohlmann (1914, p. 89) observed that “nowhere else 
in medicine is there such confusion of terminology. Thus the unqualified names ‘gout’, 
‘rheumatism’, and ‘rheumatoid arthritis’ are almost without meaning, for they may bear 
absolutely different interpretations to different readers”. Indeed, this perceived link between 
gouty pathology and social status is evident in the contemporary literature from New Zealand; in 
a description of a Court proceedings published in the New Zealand Herald in 1865, the link 
between gouty pathology and social status made in conjunction with a Māori chief, who 
apparently came to Court “with a long pole and his boot off, actually troubled by that peculiar 
 
 




disease only claimed by English aristocracy as their hereditary right – the ‘gout’.” The reporter 
commented that the chief, Winiata, was probably “aware of this complaint being a sign of good 
blood” and an attending physician, Dr Nicholson was quoted saying that “it was the only case he 
ever met with among the natives, and is conclusive evidence that we can boast of the best blood 
among our Kaipara natives as well as amongst the Pakehas” (New Zealand Herald, 1865). 
 
2.3.3  Gout and prehistoric diet 
While the lifestyles of Māori had undoubtedly been influenced by European contact, on average, 
most Māori would not have been living the way of life that the physicians thought contributed to 
the development of gout. This is supported by a statement by Dr Newman (1879, p. 434) who 
considered that “not one of all the descendants of the canoes that came from Hawaiki ever 
suffered from gout... Imagine an old Māori Chief suffering from rich gout, when he had for food 
irregular and scanty allowances of fern root, dried eels……; his favourite tipple being a mild 
infusion of tutu berries, or perchance a little pure water, weakly flavoured with the juice of flax 
flowers. Of course no genuine Māori ever had gout”. Clearly the state of living of the Māori did 
not align with the expectations of the British doctors in terms of what predisposes one to gout, 
thus they may not have diagnosed it on these grounds, lumping any gouty episodes into the 
broader term of rheumatism. 
 
There is no way now to determine for sure whether or not the prevalence of gout in Māori has 
been understated due to a misdiagnosis of the disease during this period. However, given how 
little is written on the matter, the ambiguity in the definition of the terms in medical 
encyclopaedias from the time and the fact that there is archaeological skeletal evidence for gout 
in Māori populations well before the arrival of Europeans (Buckley et al., 2010, Campbell & 
Hudson, 2011), it is not intuitive to believe that there would have been a lack of gout directly 
after the arrival of Europeans.  
 
Contemporary epidemiological data support the hypothesis that at least part of the cause of gout 
is the impact of diet (sugar-sweetened beverages, alcohol, purines) on an individual with a 
genetic predisposition to elevated serum urate (Dalbeth et al., 2013b) and to risk of gout in 
Māori (Batt et al., 2014). Presumably the fundamental cause of gout in non-Westernised Māori 
also held – impact of a (different) environment on individuals with a similar genetic 
predisposition.  
 
Much time and energy was required for the production and preparation of food in prehistoric 
New Zealand. Horticultural production of kumara and taro were important in subsistence in 
 
 




northern regions, however was marginal in the northern part of the South Island and completely 
absent to the south of Banks Peninsula due to climatic factors (Burtenshaw & Harris, 2007). 
Hunting of forest and sea birds, gathering of shellfish and seasonal fruit, and exploitation of both 
marine and freshwater fish contributed to the diets of prehistoric Māori (Buck, 1949). The 
absence of fermented beverages and other stimulants such as kava, was commented on in a 
number of the earliest reports on Māori (Colenso, 1868, Hooker, 1896), however, sugars were 
available for consumption. Studies have shown that the stems and rhizome of the ti or cabbage 
tree (Cordyline australis) are high in fructans, which when cooked in an umu-ti or earth-oven 
hydrolyse to fructose (Fankhauser, 1986). Fruit such as the drupes of the karaka tree 
(Corynocarpus laevigata) (Klinac et al., 2009) have also been found to be high in sucrose (a 
disaccharide consisting of both fructose and glucose). Both of these plants are thought to have 
been economically important and have a wide distribution throughout New Zealand (Leach & 
Stowe, 2005, Brooker et al., 1989). Since high sugar intake in modern populations, the intake of 
sweet sugary beverages for instance, has been found to contribute to higher serum urate levels 
(Choi & Curhan, 2008), it may be that the high sugar content of some of these traditional foods, 
such as the ti and the karaka berries, likewise contributed to higher urate levels in prehistoric 
Māori. There may well be other contributing factors that have been overlooked because of the 
reported apparent absence of gout in prehistory. 
 
2.3.4  Conclusion 
Palaeopathological evidence indicates that gout is a condition that has been present in New 
Zealand since the very first people arrived on the shores. Given the paucity of archaeological 
skeletal assemblages which have undergone systematic analysis, it is of note that the two best 
described skeletal assemblages both have a relatively high proportion of individuals with 
presumptive gouty lesions (14% at Wairau Bar and 21% at Ihumatao)(Buckley et al., 2010, 
Campbell & Hudson, 2011). The fact that these assemblages date to different time periods in 
prehistory, and are from quite different parts of the country, is also notable, as it shows a 
diversity in the conditions contributing to prehistoric gout. One can therefore assume that 
people who had recently arrived in a virgin land had different lifestyles and diets than those 
living in an established, horticultural society, and furthermore, that the lifestyles of both groups 
differed markedly from the lifestyle of excess and extravagance which typified gout in Europe at 
the time.  
The under-representation of gout as a serious pathology in Māori as reported in historic 
documents, is likely related to a combination of factors: the episodic nature of the condition in 
its initial phases (Prior, 1981), a lack of epidemiological study of these populations prior to the 
 
 




mid-twentieth century, as well as the perceived prerequisite lifestyle conditions for the 
development of gouty pathology, leading to a misdiagnosis of the condition in indigenous 
peoples. 
2.4  Concluding remarks 
I have presented here significant evidence that gout has a long history in Pacific populations, 
dating back at least 3000 years. Other metabolic complaints have a similarly long history in the 
Pacific. Analysis of the skeletal population at Teouma, Vanuatu shows evidence of diffuse 
idiopathic skeletal hyperostosis (DISH) (Pers. Comm.: Hallie Buckley), which is thought to be an 
indicator of underlying metabolic disease (Mader et al., 2013). While prevalence has been on the 
increase over the past 50 years since there have been systematic studies of the phenomenon, the 
occurrence of metabolic diseases has a deep history in the Pacific. 
Modern epidemiology has demonstrated that raised serum urate levels have a multifactorial 
aetiology, with both environmental and genetic factors contributing. It must be recognised that 
lifestyle, diet in particular, influences not only the prevalence of obesity, but also the 
concentration of SU – more specifically, the consumption of purine and fructose-rich foods (Choi 
et al., 2004, Choi & Curhan, 2008, Batt et al., 2014). The last five decades in particular have seen 
radical changes in dietary habits in the Pacific. This is most evident in urban settings, but these 
changes are also occurring in many rural communities. There is now a reliance on the 
importation of foreign foodstuffs, because population sizes have reached points where the 
islands are now no longer self-sustainable (Hughes & Marks, 2009). Exacerbating this shift in 
subsistence practices is the decreasing popularity of traditional production practices and diets 
(Hanna et al., 1986, Coyne et al., 2000). Many of the imported foods are high in fat and sugar, 
leading to the coining of terms such as “dietary colonisation”, “Coca-colonisation” and “dietary 
genocide” (Hughes & Marks, 2009). 
It is undeniable that these shifts in dietary and activity patterns are having an adverse effect on 
health, however these are not acting in isolation. The existence of prehistoric cases of disease, in 
particular gout which is more easily identified, suggests that there is a longstanding genetic 
predisposition to disease. Genes encoding proteins involved in renal and gut excretion of uric 
acid have a strong effect on serum urate levels, though genes involved in glycolysis are also 
associated (Köttgen et al., 2012). There have been several studies carried out on Māori and 
Pacific Island people living in New Zealand which have found that at least some of these genetic 
variants contribute to the risk of gout (Hollis-Moffatt et al., 2009, Phipps-Green et al., 2010, 
Hollis-Moffatt et al., 2012, Phipps-Green et al., 2016). 
 
 




Collectively, the evidence suggests an inherent biological (genetic) predisposition to 
hyperuricaemia, and probably other metabolic conditions, in Polynesians. How might this have 
occurred? There are a number of processes by which genetic variants contributing to these 
phenotypes may have increased in frequency at the population level, including ancestry, random 
genetic drift and natural selection. The circumstances under which these may have operated will 
be discussed in the next chapter.  
 
 
















This chapter comprises a synthesis of material from the following two publications, which are 
included in Appendix 1. 
- Gosling, AL., Matisoo-Smith, E. and Merriman, TR. 2014. Hyperuricaemia in the Pacific: why the 
elevated serum urate levels? Rheumatology International 34(6): 743-757 
- Gosling, AL., Buckley, HR., Matisoo-Smith, E. and Merriman, TR. (2015). Pacific populations, 
metabolic disease and ‘Just-So Stories’: a critique of the ‘Thrifty Genotype’ hypothesis in Oceania. 
Annals of Human Genetics 79(6): 470-480 
 
3.1 Introduction 
The antiquity of metabolic conditions in the Pacific, as evidenced by the identification of gouty 
lesions among prehistoric Pacific people and the historic evidence summarised in Chapter 2, 
suggests that there is likely to be a stronger genetic predisposition to gout and metabolic disease 
among the people living in this region. There are a number of different (not mutually exclusive) 
possibilities for how genetic variants contributing to this high metabolic disease burden may 
have reached appreciable frequency. This chapter assesses proposed hypotheses and puts forth 
a new one. 
3.1.1 The settlement of the Pacific and possibility of founder effects and drift 
One of the explanatory models put forward for the high rates of metabolic disea se is that they 
are due to founder effects (Merriman & Dalbeth, 2011). As summarised in Chapter 1, Pacific 
settlement has been a long process, involving multiple movements of people out of continental 
Asia, starting very early in human history. The migration of people onto the ancient 
subcontinent of Sahul (which is now Australia and New Guinea) around 49 thousand years ago 
(Summerhayes et al., 2010b) represents one of the most significant migrations both in terms of 
distance travelled and technology. These peoples are genetically heterogeneous, and there are 
few mitochondrial and Y-chromosome haplogroups shared between the indigenous inhabitants 
 
 




of Australia and New Guinea, despite their ancient shared ancestry (Duggan & Stoneking, 2014). 
As established in Chapter 2, high rates of metabolic disease have not been observed among these 
populations in Papua New Guinea.  
 
Many Pacific populations, at least in part, are descended from peoples associated with the 
archaeologically defined Lapita cultural complex. The spread of the Lapita culture is thought to 
accompany the movement of Austronesian languages through the region (Gray et al., 2009) and 
represents the movement of a genetically distinct population from a more recent Asian source. 
There was some admixture and cultural exchange between the pre-existing people in the region 
and the incoming Austronesians, as evidenced by the abundance of ancient Near Oceanic derived 
Y-chromosomes in Polynesian populations (Kayser, 2010) and genome-wide SNP analysis 
showing a genetic contribution of around 13% (Wollstein et al., 2010). The Lapita culture first 
appeared in the Bismarck Archipelago approximately 3350 years ago and people carrying this 
culture rapidly sailed eastwards colonising the Reef Santa Cruz (Southeast Solomon Islands), 
Vanuatu and New Caledonia (Spriggs, 2011) within a few hundred years. Lapita expansion 
stopped at the edge of Polynesian Triangle, in Tonga, which was settled by 2830-2846 years 
before present (BP)(Burley et al., 2012), and Samoa, settled at a similar time (Petchey, 2001) 
(Spriggs, 2011). The most recent dates for settlement of East Polynesia suggest that around 
1200 to 1500 years later, further migrations were undertaken from Samoa into Central and East 
Polynesia, the Marquesas and the Cook and Society Islands (Kirch & Kahn, 2007), and even later 
into the more remote islands, with settlement of Rapa Nui at 800 BP (Hunt & Lipo, 2006), 
Hawai’i between 800 - 1200 BP (McCoy, 2007), and New Zealand around 700 BP (Higham et al., 
1999, Walter et al., 2010, Wilmshurst et al., 2011).  
 
Hence modern Polynesians are the end product of a voyaging process that occurred over many 
thousands of years. Often founder effects are employed to explain an apparent lack of genetic 
variation in Polynesian populations and the apparent dissimilarity phenotypically between 
Polynesia and Melanesia (Pietrusewsky, 1996) – though continuous contact and voyaging would 
have reduced these effects. The basis of the underlying idea of limited genetic diversity in the 
Pacific resulting from founder effects lies in the observation that on average 94% of the 
mitochondrial variation in Polynesian populations are derived from East Asian haplogroups 
specifically those derived from the B4a1a1 haplotype (Kayser et al., 2006). However, to suggest 
that these founder effects have led to the chance emergence of a hyperuricaemic phenotype 
susceptible to a wide range of metabolic diseases in Polynesians is simplistic and unlikely. Also, 
when the data from the wider region is reviewed, the Polynesian serum urate levels and high 
rates of metabolic disease are not out of context (Chapter 2, Figures 2.2 and 2.3) because the 
 
 




phenotype seems to be present in other populations in the homeland region, Taiwanese 
aboriginals for instance, who were unlikely to have had the same demographic founder 
alterations resulting from serial migration. 
 
3.1.2 Natural Selection 
Another mechanism by which genetic variants contributing to elevated serum urate may have 
come to prominence is natural selection. Natural selection describes the differential survival or 
reproductive success of individuals with phenotypic traits that contribute to fitness under 
specific environmental parameters. It may be expected that individuals who have greater fitness 
in a given environment will have a greater number of offspring and thereby be more successful 
in transmitting their genotype onto the next generation. Over time, this differential reproductive 
success would cause a shift in the allele frequencies of genetic variants underlying the 
phenotypic variation.  
Natural selective forces arising from exposure to different environments worldwide likely 
contribute to the inter-population differences in genetic variation and disease-related 
phenotypic diversity (Barreiro et al., 2008). Evidence already exists that certain human 
phenotypes, such as resistance to malaria (Higgs & Weatherall, 2009) and lactase-persistence in 
adulthood (Sabeti et al., 2006, Tishkoff et al., 2007) have resulted from natural selection in 
response to certain environmental conditions. There has been growing interest in selection, and 
as a result, various algorithms have been formulated in an attempt to quantify the likelihood of a 
locus having been subject to selection (Sabeti et al., 2002, Voight et al., 2006, Karlsson et al., 
2013). 
In next section, a number of hypotheses based on the concept of selection are discussed, 
including the frequently applied ‘Thrifty Genotype’. Later in the chapter, a novel hypothesis to 
explain the high serum urate levels so common in the Pacific region is proposed. 
3.2 A critique of the ‘Thrifty Genotype’ Hypothesis 
3.2.1 Background to the ‘Thrifty Genotype” Hypothesis 
In 1962, the American geneticist, James Neel, put forth a revolutionary hypothesis that the 
increasing prevalence of type 2 diabetes among many indigenous populations was a result of an 
evolutionary adaptation to periods of famine (Neel, 1962). Thus, the ‘Thrifty Genotype’ 
hypothesis, which also relates to other metabolic conditions, was born. The hypothesis was an 
important first step in employing evolutionary explanations for differences in disease 
prevalence between populations. Over the following fifty years, the hypothesis was modified in 
conjunction with advances in understanding of the complexity of metabolic disease and the 
 
 




anthropology of hunter-gatherer and early Neolithic cultures and their subsistence patterns 
(Neel, 1982, Neel, 1999, Corbett et al., 2009). 
The premise of the original hypothesis was that contemporary type 2 diabetes was caused by a 
disjunction between genes and environment. Specifically, variation in genes which facilitated 
survival during periods of famine in pre-industrialised societies, by allowing for the more 
efficient storage of energy during periods of plenty, were at odds with a modern, industrialised 
environment of plenty (Neel, 1962). Consequent to the replacement of traditional diets with a 
Westernised diet, these so-called ‘thrifty genes’ were proposed to contribute to the onset of 
diabetic symptoms. Following the publication of the hypothesis, other possible explanations 
relating to reasons for metabolic disease were discussed in the literature. These include the 
‘Thrifty Phenotype’ hypothesis wherein inadequate nutrition early in life predisposes an 
individual to type 2 diabetes (Hales & Barker, 1992), and the ‘Drifty Genotype’ hypothesis which 
postulates that the removal of heavy predation pressure resulting from increased social 
behaviour, the use of fire and invention of weapons removed selective pressures permitting 
genetic drift which has allowed for genetic variants causal of obesity and type 2 diabetes to 
accumulate (Speakman, 2008). 
Despite many critiques of the hypothesis (Speakman, 2006, Paradies et al., 2007, Beil, 2014, 
Sellayah et al., Benyshek & Watson, 2006), and a general lack of genetic evidence, for instance, 
the detection of selection signatures in metabolic genes (Helgason et al., 2007, Steinthorsdottir 
et al., 2014, Ayub et al., 2014), the ‘Thrifty Genotype’ hypothesis continues to be cited as a 
reason for disparities in metabolic health between populations. In their seminal paper, Gould 
and Lewontin warned against the acceptance of evolutionary narratives without due testing and 
critical thought (Gould & Lewontin, 1979), and this sentiment remains as true now as it did in 
1979 (Nielsen, 2009).  
The ‘Thrifty Genotype’ hypothesis is merely another ‘Just-So Story’ (to borrow the analogy used 
by Gould and Lewontin in their critique of the ‘adaptationist programme’ (Lewontin, 1991, 
Gould, 1997)), a possibility but one for which there is little or no supporting data.  This is 
particularly true for Pacific Island populations, for whom the ‘Thrifty Genotype’ hypothesis has 
been a recurring theme in describing reasons for the high rates of type 2 diabetes, obesity and 
other metabolic disorders; Pacific Island populations, along with Pima Indians, have long been 
considered archetypal examples of a ‘Thrifty Genotype’ in action (Zimmet et al., 1990, Bindon & 
Baker, 1997, Diamond, 2003, Myles et al., 2007). Other populations, such as Australian 
aborigines (O'Dea, 1992), Asian Indians (Mohan et al., 2007), sub-Saharan Africans (Van der 
Sande, 2003), and Latin Americans (Filozof et al., 2001), have also been subject to the 
 
 




hypothesis. It seems that the ‘Thrifty Genotype’ hypothesis has been used in a piecemeal, one-
hypothesis-fits-all manner, where one of the few populations that seems exempt from these 
‘thrifty genes’ are European-derived populations. As Allen and Cheer (1996) pointed out, it may 
be that the Europeans themselves were subject to some selection process which caused this 
discrepancy. But does the ‘Thrifty Genotype’ hypothesis fit the genetic and anthropological data? 
As discussed in Chapter 2, there are indeed high rates of obesity, type 2 diabetes and 
hyperuricaemia (Gosling et al., 2014) among many populations throughout the Pacific – both 
among those still living in their ancestral homelands, and those who have migrated to urban 
centres in places such as New Zealand, the United States and Australia. While the prevalence of 
disease is higher among those living in more westernised contexts, the occurrence of metabolic 
disease in those living a more traditional lifestyle (pre-mid twentieth century and prehistoric) 
suggests a genetic contribution to disease. This is supported by skeletal indicators of metabolic 
disorders (gout and diffuse idiopathic skeletal hyperostosis (DISH) in particular) in 
bioarchaeological assemblages from the region (Buckley, 2007, Buckley et al., 2010, Buckley, 
2011) and the epidemiological evidence of Ian Prior and colleagues from the 1950s through to 
the 1970s (Prior et al., 1966, Prior, 1981). Although it is reasonable to expect that indigenous 
Pacific populations will have diabetes and obesity risk alleles at a higher prevalence and 
penetrance (I note that there are currently no systematic genome-wide studies on genetics of 
diabetes and obesity in any Pacific population) the theory that this is due to selection as a result 
of food deprivation is not supported when one considers the population history, settlement 
process and environment of the Pacific in more depth.  
3.2.2 The Migratory History of the Pacific 
Understanding the evolutionary history of the region and the colonisation process is 
instrumental to place the ‘Thrifty Genotype’ hypothesis in a better context when applied to 
Oceanic populations. As previously discussed, there have been multiple movements of people 
into the Pacific region throughout the 50,000 year history of human occupation. Given this time 
depth and population diversity, it might be expected to see significant differences in the 
metabolic disease frequencies in the various populations – i.e. prevalences are likely to be 
influenced more by the genotype of ancestral populations rather than events occurring during 
the migratory history per se. People first arrived on the continent of Sahul, which became New 
Guinea and Australia with subsequent sea level changes, at least 49,000 years ago 
(Summerhayes et al., 2010b). Genetic analyses have shown that there were probably multiple 
populations involved in these Late Pleistocene and Early Holocene migrations out into New 
Guinea and the Solomon Islands, a region known as Near Oceania (Rasmussen et al., 2011). 
Subsequently, there have been several influxes of people from the Island Southeast Asia region 
 
 




into the islands of the Bismarck Archipelago and beyond as early as 5,000 years ago but 
certainly by some 3,350 years ago (Summerhayes et al., 2010a, Kirch et al., 1989). These people 
mixed with resident coastal populations prior to expanding out into the wider Pacific where 
they were the initial colonists on the previously unoccupied islands of Remote Oceania. Thus, 
Polynesians and Micronesians have been found to be more genetically similar to certain Asian 
populations than to the general Near Oceanic populations which are highly heterogeneous 
(Friedlaender et al., 2008). Because of these differences in ancestry, there are both genetic and 
phenotypic differences between Pacific populations, even those within a reasonably close 
geographical distance to one another. The implication of this is that population history should be 
a major consideration when discussing differences in disease prevalence in the Pacific. For 
instance, while rates of type 2 diabetes and obesity are high among Polynesian and Micronesian 
populations, the rates are much lower in Papua New Guinea (Figure 2.3), whose general 
population has a larger proportion of their ancestry being derived from the earliest inhabitants 
of the region than the later Austronesian-speaking colonists. A proponent of the ‘Thrifty 
Genotype’ hypothesis might suggest other explanations for this phenomenon – namely the 
selection for ‘thrifty genes’ occurred after moving through this region, but these arguments are 
inconsistent when examined in context of the Pacific archaeology and anthropology.  
3.2.3 ‘Thrifty Genotypes’ and Oceanic Voyaging 
One of the inherent weaknesses of the ‘Thrifty Genotype’ hypothesis in the context of the Pacific 
is the reliance on significant population loss mediated by restricted food supply. A number of 
mechanisms describing how the hypothesis might operate in the Pacific have been put forth. The 
scenario laid out by Bindon and Baker (1997) is that the selection for these ‘thrifty’ traits 
occurred during the voyaging and settlement of the Pacific. This is based on the assumption that 
the voyaging process was perilous and that there was a reasonably high mortality rate. Diamond 
(2003) takes this a step further by stating that ‘in many attested examples of such lengthy 
voyages, many or most of the canoe occupants died of starvation, and only those who were 
originally the fattest survived’. No citations were given for this claim. However, given that 
colonisation voyages are not something that have happened for at least a couple of centuries 
(Irwin, 1989), it is likely that Diamond is referring to more recent examples of people who have 
not intentionally ventured out and are not necessarily prepared for long periods in a boat in the 
middle of the ocean (for instance, fishermen lost at sea). It is certainly not in line with studies 
which have found that the process of colonising the Pacific is likely to have involved safe, 
systematic and planned exploration prior to the colonisation (Hiroa, 1954, Irwin, 1994). Quite 
simply, the speed at which successful settlement of the wider Pacific region occurred could not 
be sustained if there was great loss of life. While there had been some doubt during the 1950s 
 
 




and 1960s about the deliberate nature of Pacific voyaging and navigation, with theorists such as 
Sharp (1956) arguing for ‘accidental voyaging’, most scholars now agree that preliminary scouts 
were sent out on two-way exploratory voyages prior to the departure of a well-provisioned 
colonisation party who were travelling to a known destination with known resources and for a 
known period of time (Kirch, 2000). These colonisation events may have been assisted by 
weather patterns such as El Niño (Goodwin et al., 2014), which would have made the voyaging 
times faster. 
Starving at sea is not the only voyaging-related proposal put forth to explain genetic diversity in 
the Pacific. Houghton (1990, 1996) and Bindon and Baker (1997) have suggested that the 
increased body mass among New Zealand Māori and other Polynesian populations is a result of 
selection due to the cold temperatures faced during open ocean voyaging, the premise being that 
higher body mass would insulate one against wind chill and ocean spray (an adaption of a 
hypothesis known as Bergmann’s rule). Supporting this hypothesis, sophisticated calculations 
were devised to show the likelihood of survival for 10 days voyaging on open ocean at various 
latitudes (Houghton, 1996). These calculations assume naked bodies that have no cold 
protection, which does not fit with knowledge of Polynesian voyaging and evidence for 
protective clothing (Hiroa, 1924) or structures in the canoe allowing for some weather 
protection (van Dijk, 1991). Similarly, these simulations are undermined by the recent 
archaeological data supporting a general shortening of Polynesian prehistory (Wilmshurst et al., 
2011). For rapid, successive population movements, a larger founding population would be 
expected, which in turn would require voyaging to have a much reduced mortality rate than this 
particular application of Bergmann’s rule. This is supported by a recent study investigating the 
cold induced vasodilation response in a number of populations worldwide, which has indicated 
that the cold adaptation seen in Polynesian populations is likely an ancestral trait which evolved 
in Asia, prior to the start of the Pacific colonisation process (Wilberfoss, 2012). 
There is also archaeological evidence to support extensive sailing between archipelagos 
(Collerson & Weisler, 2007), at least in the early periods of colonisation, though this interaction 
dropped off in later prehistory (Irwin, 1994). This reduction in inter-island contact may be due 
to the development of greater socio-political complexity in some of these island groups, possibly 
triggered by climatic change (Field & Lape, 2010). The focus of the island communities turned 
inwards, rather than maintaining strong links with distant islands. Thus, it seems improbable 
that the voyaging process would be a strong selective pressure. The mortality rates described to 
select for the postulated ‘thrifty’ traits indicate a lack of appreciation for the sophistication of 
sailing technology and expertise of early Pacific Islanders (Hiroa, 1954) and is inconsistent with 
the speed of settlement based on the archaeological record. 
 
 




3.2.4 Fragile island environments 
It has been argued that Pacific Island populations might be subject to more famine events 
because of their relative isolation and their susceptibility to cyclonic weather patterns and 
tsunami (Zimmet et al., 1990, McGarvey, 1994). This might result in the destruction of 
horticultural crops and impact staple foods such as shellfish and other marine foods, which were 
mainstays to many prehistoric Pacific Island populations. As evidenced by the devastation 
caused by these sorts of phenomena in modern times (for example, the Samoan tsunami in 
2009), it is not unreasonable to assume that such occurrences have been persistent but 
intermittent and relatively localised problems for many populations since initial colonisation. 
Indeed, skeletons from archaeological sites in the region show skeletal pathology consistent 
with nutritional deficiencies (Snow, 1974, Buckley, 2000, Buckley et al., 2014). The 
palaeopathology record can indicate other skeletal and dental changes reflecting growth 
disruption for assessing periods of food insufficiency in the past (Goodman et al., 1984). 
However, these signs of growth disruption may also be a response to infection, especially in a 
tropical environment where pathogen loads are high (Buckley, 2006). Therefore these growth 
disturbances are generally considered to be a reflection of non-specific or more generalised 
stress during growth. 
This permutation of the hypothesis does not appreciate the variation in subsistence patterns 
across the Pacific, partly as a result of the different geological origins of the inhabited islands. 
Pacific peoples have taken to inhabiting atolls, volcanic and continental islands (Neall & Trewick, 
2008), and these different island-types offer different subsistence opportunities due to variation 
in ecological diversity (Kirch, 2000). Factors such as water availability and soil composition alter 
what horticultural domesticates are likely to grow, and any surpluses which might be produced. 
As such, different islands are likely to have had different levels of vulnerability when faced with 
natural disasters. The distribution of obesity-prone populations throughout the Pacific, under 
this model, would require multiple independent episodes of selection for a ‘Thrifty Genotype’, to 
which end we would expect to see different genetic contribution to phenotype and not the broad 
patterning to their distribution which present today.  
The high prevalence of obesity throughout the Pacific seems indicative of increased body mass 
index (BMI) being an ancestral trait, which was already present among the colonising 
population rather than selection for ‘thrifty’ traits in situ. Finally it has remained largely 
unrecognised that in the context of Pacific prehistory, the scale of population loss needed to 
result in the selection of so-called ‘thrifty genes’ is simply not supported by demographic models 
of colonisation and pre-European population estimates. 
 
 




3.2.5 Genetic studies of ‘Thrifty Genes’ in the Pacific 
It seems telling that despite multiple genetic studies (Ohashi et al., 2007, Furusawa et al., 2010, 
Myles et al., 2011), there is no direct evidence for ‘thrifty genes’ among Pacific Islanders or other 
related populations, as manifest by signatures of selection at known diabetes and obesity loci. 
Furthermore, loci which have been strongly associated with obesity among European 
populations, for instance intronic variants in the FTO gene (Frayling et al., 2007, Dina et al., 
2007), have been found to have allele frequencies consistent with what is seen among Asian 
populations, so have been argued to be unlikely ‘thrifty’ candidates (Ohashi et al., 2007). 
The Gln223Arg variant of LEPR has also been suggested as a ‘thrifty gene’ on the basis of 
differences in allele frequency across Oceania (Furusawa et al., 2010). LEPR encodes a protein 
which is the receptor for the fat cell-specific hormone leptin which regulates satiety, and is 
associated with BMI (Park et al., 2006). An elevated allele frequency would be expected in 
specific populations if the locus had indeed been subject to selection. However, there are other 
explanations for differences in allele frequency, such as genetic drift. This variation in allele 
frequency could very well be related to serial founder effects – as indicated by other genetic 
markers, for instance, mitochondrial genome haplogroups which show a similar gradient across 
the Pacific (Kayser et al., 2006). This, indeed, seems more likely than selection when one 
considers the lack of evidence for a functional effect of alleles at this particular locus 
(Stratigopoulos et al., 2009).  
Some variants have been associated with metabolic traits in certain populations and not others, 
for instance the Gly482Ser variant in PPARGC1A, a gene involved in energy metabolism, has been 
found to associate with high BMI among Tongans but not New Zealand Māori (Myles et al., 2011) 
although this is not necessarily indicative of this being a ‘thrifty gene’ per se. A recent study has 
demonstrated no evidence for a selection signature at the PPARGC1A locus, nor was the 
association with BMI in Tongans able to be replicated (Cadzow, Merriman & Wilcox, 
unpublished data). The higher allele frequency of the PPARGC1A variant (Myles et al., 2011) in 
islands colonised relatively late, such as New Zealand (670-720 BP (Wilmshurst et al., 2011)) 
compared with Tonga (2838 ± 68 BP (Burley et al., 2012)), one of the first Polynesian islands 
colonised, is consistent with the manifestation of serial founder populations, though inconsistent 
with a population model of return voyaging and sustained contact between populations which 
has been suggested through the archaeological evidence.  
The higher allele frequency of the Gly482Ser variant in PPARGC1A has also been cited as a 
potential ‘thrifty gene’ on the basis of its higher allele frequency among Tongans compared with 
Han Chinese and Papua New Guinean Highlanders (Myles et al., 2007). This same study 
 
 




suggested that this locus has been subject to selection based on the application of FST analyses 
on these populations – a rather high FST value was generated when comparing Highland New 
Guineans with Tongans (0.703). However, no recognition is given to the fact that these are 
populations with vastly different ancestral backgrounds. Polynesian populations have been 
found to have a higher degree of Asian ancestral contribution to their autosomal DNA than Ne ar 
Oceanic (New Guinea)(Wollstein et al., 2010). Given their dissimilar histories, it would therefore 
be expected to observe genetic differences between these populations. Additionally, the small 
sample sizes used in this study are unlikely to capture the genetic variation in any of the 
populations - data from only 23 Polynesians (nine Cook Islanders, eight Samoans, four Tongans 
and two Niueans), 23 Highland New Guineans and 19 Han Chinese were used (Myles et al., 
2007). A better approach for detecting more recent selection (i.e. selection consistent with the 
‘Thrifty Genotype’ hypothesis in the Pacific) is probably the haplotype-based Extended 
Haplotype Homozygosity (EHH) concept (Sabeti et al., 2002). 
There is evidence for founder effects in Remote Oceania, Polynesians in particular (Kayser, 
2010). This has significant implications when it comes to impact on genome-wide variation and 
may complicate the detection of signatures of selection if relying on tools that detect changes in 
allele frequency. Focused, large-scale genetic studies of populations worldwide with known 
founder effects, for instance Ashkenazi Jews and Icelandic populations, have assisted in 
identification of important susceptibility loci associated with other complex phenotypes 
(Helgason et al., 2005, Steinthorsdottir et al., 2007, Guha et al., 2012). The only such study that 
has been carried out in the Pacific was a genome-wide association study of a cohort from Kosrae, 
an isolated island located in the Federated States of Micronesia (Lowe et al., 2009). This study 
found a relatively genetically homogenous population and showed that a majority of the 
common variants contributing predisposition to disease in Europeans have little effect on 
Kosraens. Novel disease associations were identified which further underlines the need for 
studies focused on populations with well-defined ancestry and population history. 
3.2.6 The ‘Thrifty Genotype’ Hypothesis worldwide 
The lack of support for the ‘Thrifty Genotype’ hypothesis is a pattern which has emerged from 
other studies of populations worldwide, including Europeans and Asians (Helgason et al., 2007, 
Southam et al., 2009, Steinthorsdottir et al., 2014, Ayub et al., 2014, Koh et al., 2014). Ayub et al. 
(2014) critically evaluated the hypothesis by testing for signatures of selection at type 2 
diabetes loci (‘thrifty genes’). They examined 65 loci and found a lack of consistent evidence for 
selection; when the loci were collectively tested, there were no signatures of selection. Although 
when scrutinized on a locus-by-locus basis, some nominal evidence for positive selection was 
detected. Furthermore, Koh et al. (2014) looked for signatures of selection at loci associated 
 
 




with obesity and type 2 diabetes identified in a genome wide association study of an East Asian 
cohort and likewise did not find consistent support for the ‘Thrifty Genotype’ hypothesis. 
Together, the findings of these studies indicate that the ‘Thrifty Genotype’ hypothesis should be 
reassessed as a way of considering evolutionary explanations for higher rates of obesity and 
type 2 diabetes among various populations. 
The ‘Thrifty Genotype’ hypothesis does not account for the fact that famines are likely to have 
been a periodic problem for all human populations even before the emergence of our species 
from other hominins (Prentice, 2005). Mathematical modelling suggests that if ‘thrifty genes’ did 
exist, given the number of famine-events faced by Homo sapiens since the divergence from our 
hominin ancestors these alleles would likely have reached fixation (where the advantageous 
allele becomes homozygous) (Speakman & Westerterp, 2013). This is in line with the recent 
suggestion that we should perhaps be looking deeper in human evolution for these ‘thrifty 
genes’. Uricase has been highlighted as a putative ‘thrifty gene’ (Kratzer et al., 2014), but given 
that the inactivation of the gene occurred during the Miocene, prior to the divergence of humans 
from the ape lineage, uricase is also unlikely to account for differences in metabolic health 
between modern populations – nor is there any direct evidence that the loss of uricase function 
was driven by periods of famine. In other words, it ‘assume[s] rather than demonstrate[s] the 
operation of natural selection’ (Pigliucci & Kaplan, 2000). Given the multiple roles of urate (as an 
anti-oxidant, an adjuvant and in maintaining blood pressure (Gosling et al., 2014)), there may 
have been selective forces at work other than nutritional stress. 
This is not to say that nutritional exposures have not led to the selection of certain genetic 
variants (Stover, 2006). Variation in allele frequencies for enzymes involved in the digestion of 
lactose (Bersaglieri et al., 2004), starch (Perry et al., 2007), and the metabolism of alcohol (Eng 
et al., 2007) and fructose (Ali et al., 1998) have been detected between populations. That some 
populations have locally adapted genetically to optimise their nutrient-uptake is unsurprising 
given the role of food in health and wellbeing, and indeed survival in general. The array of 
different adaptations is symptomatic of the diversity in subsistence patterns and nutritive 
resources available in different geographical regions. Some might argue that these variants 
themselves could be classed as ‘thrifty genes’, since the ability to digest lactose from cow’s milk 
or to better break down starches from tubers and grains would undoubtedly be advantageous in 
situations of famine, though being advantageous is not the same as being ‘thrifty’.  
3.2.7 Concluding comments  
The ‘Thrifty Genotype’ hypothesis overlooks other important factors that are likely to have had 
more significant impacts on populations and their genetic diversity, such as migration and 
 
 




disease epidemics (O'Rourke, 2012). As discussed previously in relation to genetic differences 
between New Guinean and Tongan populations, genetic ancestry and the specific evolutionary 
history of a population has a huge impact on the particular variants present within a population 
and indeed the relative proportions of various alleles. Founder effects are clearly something that 
require consideration in Oceanic populations, as serial migrations have played a large part in the 
settlement of the area. Admixture, and the degree and nature of that admixture, is another factor 
which impacts the genetic variability of a population.  
Infectious disease is one of the strongest drivers of genetic change (Karlsson et al., 2014): major 
human pathogens such as malaria (Kwiatkowski, 2005) and HIV (Schliekelman et al., 2001, 
Nkenfou et al., 2013) have shaped the genome in exposed populations. Given the links that are 
increasingly being made between metabolic diseases and innate immunity (Pickup & Crook, 
1998, Lumeng & Saltiel, 2011, Robbins et al., 2014), genetic selection resulting from infectious 
disease exposure may contribute to an underlying susceptibility of certain populations to 
metabolic diseases. An example of the striking effect that infectious disease can have on a 
population is the introduction of Western diseases including measles, whooping cough and 
influenza to the Pacific during the 19th century; it is thought that these introductions caused up 
to 75% mortality in some East Polynesian populations (Harrison et al., 1988). Clearly this is 
likely to have had a large impact on the genetic diversity in the modern population. 
For its time, the ‘Thrifty Genotype’ hypothesis was revolutionary. It reflected one of the first 
efforts to integrate our knowledge of modern epidemiology with human evolution. However, the 
hypothesis is also inherently reductionist and does not recognise other factors which are likely 
to have a greater impact on the development of genetic traits. In the 53 years since its 
introduction, contributions by archaeology and biological anthropology to our understanding of 
colonisation processes and prehistoric demography have remained overlooked in genetic 
studies and other reviews exploring the possibility of ‘thrifty genes’ among Pacific Islanders – 
and indeed, among other populations globally. When the evolutionary and cultural history of 
Pacific people is considered, the application of the ‘Thrifty Genotype’ hypothesis is no longer 
useful; the scenario certainly does not mesh with our current understandings. The continued 
reiteration of the ‘Thrifty Genotype’ hypothesis in general and in its application to Pacific 
populations in particular gets in the way of our formulating alternative, better supported and 
testable hypotheses based on our knowledge of the context and histories of the populations in 









3.3 An alternative hypothesis 
 
In this section, the obesity phenotype will largely be ignored. Instead, the uniformly high serum 
urate levels will be focussed on for the reason that the high rates of hyperuricaemia underpin 
the high prevalence of gout among many Pacific peoples. However, given that elevated urate 
levels have been suggested to be a predictor of weight gain (Masuo et al., 2003), the high rates of 
obesity in the Pacific may in part be contributed to by this genetic predisposition to 
hyperuricaemia. Elevated urate levels have also been detected in those who suffer other 
metabolic conditions such as type 2 diabetes (Hayden & Tyagi, 2004). 
 
In order to assess the possibility of selection for heightened serum urate concentrations, it is 
necessary to consider the different biological roles of urate in humans. What follows is a brief 
description of these roles and how these may have provided a selective advantage to those with 
hyperuricaemia.  
3.3.1 Antioxidant effect of urate 
Urate can function as an antioxidant (Ames et al., 1981, Scott & Hooper, 2001). Antioxidants are 
very important, as radical oxygen species can cause irreversible  oxidative damage to cellular 
organelles and DNA, which can impair the function of the individual and result in death. Urate 
accounts for up to 60% of total plasma antioxidant activity (Ames et al., 1981). This may help 
protect endothelial function, and combat oxidative stress associated with aging (Ames et al., 
1981). It has also been implicated as being neuro-protective. Unusually low SU levels have been 
associated with diseases such as multiple sclerosis (Spitsin et al., 2001, Rentzos et al., 2006), 
Parkinson’s disease (de Lau et al., 2005) and Alzheimer’s disease (Kim et al., 2006). The brain is 
particularly vulnerable to oxidative damage because of its high metabolic rate and the high lipid 
content of brain tissue (Kutzing & Firestein, 2008). The antioxidant activity of urate seems an 
unlikely selective force specifically in the Pacific, as there is no reason to believe that people 
dwelling in the Pacific, or more precisely Polynesia, should face any more oxidative stress than 
any other island dwelling population. In addition, most of the diseases associated with low SU 
levels have impacts in post-reproductive periods of the lifecycle. 
3.3.2 Urate and Hypertension 
There is a strong association between hyperuricaemia, hypertension and cardiovascular risk 
(Cannon et al., 1966, Jossa et al., 1994, Johnson et al., 2003), which has led to the hypothesis that 
in the course of human evolution, urate may have played an important role in maintaining blood 
pressure in conditions of low salt ingestion (Watanabe et al., 2002). Through an animal 
experimental model, Watanabe et al (Watanabe et al., 2002) found that urate helps maintain 
 
 




blood pressure both acutely, by stimulating the renin angiotensin system, and chronically, by 
inducing salt sensitivity.  
There is evidence to suggest that during the Miocene epoch, which is when the series of 
mutations leading to the inactivation of the uricase gene in Hominids are thought to have 
occurred, salt consumption among our pre-human ancestors was considerably lower than in 
modern day societies (Watanabe et al., 2002). In this situation, the increase in blood pressure 
associated with raised serum urate levels was advantageous (Watanabe et al., 2002). However, 
again, with the ready availability of salt in Pacific Island environments, this seems an unlikely 
evolutionary force in the Pacific. 
3.3.3 Uric Acid as a Physiological Alarm 
(Johnson et al., 2009) have proposed that under conditions of environmental stress and 
starvation, urate may have had a beneficial effect as a physiological alarm. Studies have shown 
an increase of urate concentration under conditions of fasting (Gumaa et al., 1978) or starvation 
(Lennox, 1924), may have a number of beneficial effects, including increasing locomotor activity 
necessary for foraging, stimulating hypertriglyceridaemia, fatty liver and weight gain to help re-
establish fat stores, and to increase salt sensitivity to help protect against dehydration (Johnson 
et al., 2009). They further suggest that the development of insulin resistance, which is also 
associated with many metabolic diseases, could also be beneficial, by reducing glucose uptake 
into skeletal muscle and adipose tissue, thus preserving glucose for utilisation by the brain 
where glucose uptake is insulin independent. 
This potential role of urate has more credibility as a possible selective force in Pacific Island 
peoples. Island environments, such as those we see in the Pacific, are vulnerable to catastrophic 
events such as cyclones and tsunami, which are capable of wiping out not only food supplies but 
also sources of fresh, potable water on islands, causing periods of famine. It is possible that such 
events in the past have caused some selection for those with apparently enhanced genetic 
fitness. These sorts of catastrophic events can also result in population bottlenecking events, 
thus changing allele frequency. The widespread nature of the hyperuricaemic phenotype in 
Austronesian-speaking populations across Oceania and beyond, however, does suggest that any 
population bottlenecking to cause a hyperuricaemic phenotype would have had to occur early 
on prior to population expansion into ISEA and the Pacific for all of the descendant populations 
to be affected or else to have happened numerous times across the Pacific.  
3.3.4 Urate as an Adjuvant 
Urate plays a significant role in immune regulation (Shi et al., 2003). When crystallised, it has 
been found to activate innate host defence mechanisms in multiple ways and triggers a robust 
inflammatory response (Shi et al., 2010, Rock et al., 2013). For this reason, crystallised urate 
 
 




(monosodium urate; MSU) is considered to be an important natural endogenous adjuvant and 
has been employed in vaccinations to help stimulate a host response against antigens which may 
otherwise be considered innocuous. Not only can MSU crystals stimulate phagocytes and 
monocytes, but also they can activate the NLRP3 inflammasome, both the classical and 
alternative complement pathways, interact with antibodies, as well as a number of other 
immune pathways (Martinon, 2010). Absence of urate inhibits the immune response associated 
with clearing debris from damaged cells.  
As previously discussed, infectious disease is one of the strongest forces of selection (Sabeti et 
al., 2006). The genes associated with immunity are under selective pressure, as contact with an 
infectious agent requires an appropriate immune response. It is possible that urate-raising 
genetic variants may be selected for by infectious disease.  
There are a number of events in the history and prehistory of the Pacific which may have 
resulted in the selection of genetic variants which could contribute to the inherently high mean 
urate levels throughout the region. Discussed below are two possible periods of selection for 
genetic variants contributing to inherently high serum urate levels, one deep in prehistory with 
the exposure of ancestral Polynesian populations to malaria prior to their arrival in the malaria-
free islands of Polynesia, and the more recent exposure of these populations to novel diseases 
post-European contact. 
3.3.4.1 Malaria as a means of selection 
Malaria is possibly the most serious infectious disease currently known to humankind, killing on 
the order of 2 million people annually (Schofield & Grau, 2005). Malaria is not a new 
immunological challenge: humans and malaria-causing Plasmodium species parasites have had a 
long evolutionary host-parasite relationship (Conway et al., 2000). Malaria is known to have 
influenced the human genome, with disorders like sickle cell anaemia, alpha- and beta-
thalassaemia, glucose-6-phosphate dehydrogenase (G6PD) deficiency and band 6 ovalocytosis 
having been attributed to malarial selective forces (Kwiatkowski, 2005). It is possible that the 
inherent hyperuricaemia seen in Polynesian populations is another such adaptation. 
 
Malaria is a disease transmitted to humans by the bite of a Plasmodium-parasite bearing female 
mosquito of the genus Anopheles. The saliva of an infected mosquito contains malarial 
sporozoites, which travel through the blood vessels to the liver where they invade hepatocytes 
and reproduce asexually to produce thousands of merozoites. At this point, the malaria parasite 
is effectively immunologically invisible. The merozoites infect erythrocytes and undergo a 
number of asexual cycles of replication, producing yet more infective merozoites, before 
rupturing the cell and infecting yet more erythrocytes. Some of the merozoites develop into 
 
 




immature gametocytes in preparation of infecting a mosquito host to allow the sexual phase of 
the Plasmodium lifecycle, and the eventual infection of more human hosts.  It is during this 
cyclical blood phase of infection that the immune system detects the presence of the pathogen 
(Cowman et al., 2012).  
 
Urate plays an important role in the innate immune response (Figure 3.1), and has been found to 
induce host inflammatory responses in malaria (Griffith et al., 2009, Shio et al., 2010). There 
appear to be a number of sources of urate during malaria infection, all of which occur during the 
final cyclical blood phase. Firstly, the malarial parasites sequester xanthine and hypoxanthine 
inside the erythrocytes at high concentration in order to make nucleic acids during parasite 
proliferation. When the infected erythrocytes are ruptured, this xanthine and hypoxanthine is 
released and broken down by extracellular xanthine oxidase to produce urate (Orengo et al., 
2008, Orengo et al., 2009). Secondly, in vitro studies have found uric acid precipitate 
accumulations inside Plasmodium falciparum-infected erythrocytes (van de Hoef et al., 2013). 
When the erythrocytes burst, these precipitates are released into the extracellular matrix where 
they can be encountered by antigen presenting cells including dendritic cells and macrophages. 
van de Hoef et al. (2013) found that incubation of human dendritic cells with fractionated lysates 
from these infected erythrocytes (fractionated to remove haemozoin but to retain the uric acid 
precipitates) was found to induce maturation, with the upregulation of co-stimulatory molecules 
(CD80, CD86) and major histocompatibility complex class II molecules (human leukocyte 
antigen [HLA] in humans). Finally, haemozoin, a malarial pigment, also appears to directly 
stimulate the release of urate from the endothelial cells in a murine model (Griffith et al., 2009). 
Allopurinol (a urate-lowering drug which inhibits xanthine oxidase) treatment in a mouse model 
of malaria lead to an increased parasite burden (Büngener, 1974), which indicates that urate 
may be critical in the development of an immune response against the parasite. Since an early 
and robust inflammatory response is critical for controlling the infection, inherently high serum 
urate levels may be advantageous for those living in malarial environments and could have been 
selected for, as fewer host erythrocytes would need to rupture before the innate immune 










Figure 3.1: a role for serum urate in innate immune responses to malaria infection  
 
While malaria is not present, nor has probably ever been present, in Polynesia, the ancestral 
populations passed through and may have originated in areas with endemic malaria (namely 
New Guinea, the Solomon Islands and Vanuatu) (Buckley, 2006). Malaria would also have been 
endemic in the East Asian/ISEA homeland of the original Austronesian-speaking populations 
from whom the Polynesians are ultimately descended (Hay et al., 2004). In fact, there is other 
evidence that transit through these malarial regions has shaped the genomes of modern 
Polynesians; there is an unusually high frequency of α-thalassaemia variants in Polynesians and 
particularly amongst East Polynesians (Figure 3.2) (Hill et al., 1985, Flint et al., 1986, Hill et al., 
1987, Hill et al., 1989), especially for populations living in an area which does not have, and has 
probably never had, active malarial transmission (Clark & Kelly, 1993). Thus malarial selection 
could have operated either during the spread of populations through the region of Near Oceania, 









Figure 3.2: Prevalence of α-thalassaemia (α3.7III variant) in various malaria and non-malaria endemic Pacific 
populations 
 
It is important to note that mean serum urate concentrations reported in populations from 
coastal Papua New Guinea, where malaria is endemic, are much lower than those observed in 
Polynesians, and indeed, Micronesians. For instance, male Papuans living on the Madang Coast 
(northern mainland Papua New Guinea) have serum urate levels of 4.8 mg/dL (Hornabrook et 
al., 1975), while males from Kalo village in the lowlands (Central Province, Papua New Guinea) 
were reported to have urate levels of 4.2 mg/dL (Wyatt et al., 1980). Malaria is thought to have 
been present in coastal regions for a substantial period of time – the early habitation (around 
50,000 years ago) of the malaria-free Highland regions of New Guinea (Summerhayes et al., 
2010b) may have been driven by the presence of the malarial parasite in the lowlands. As a 
result of this long exposure to malaria, a wide array of malaria-associated haemoglobinopathies, 
including the globin gene variant (α3.7III) seen in Polynesians, are observed in lowland New 
Guinean populations (Müller et al., 2003). Evidence of substantial genetic admixture between 
the Asian-derived Austronesians and the non-Austronesian original inhabitants of New Guinea is 
only significant in the Admiralty Islands and the Bismarck Archipelago, to the north of the 
mainland of New Guinea, particularly the New Ireland Province (Friedlaender et al., 2007). To 
date, there are only published data on the serum urate levels from mainland New Guinea 
populations. Because of the different genetic background of ancient Near Oceanic and Asian 
derived Austronesian populations, it is conceivable that different adaptive mechanisms 
 
 




developed in response to malaria, explaining the absence of elevated serum urate in these 
populations. 
3.3.4.2 Western diseases as a means of selection 
The introduction of novel diseases and pathogens after European contact had a significant effect 
on the demographics of many Pacific populations (Kirch & Rallu, 2007). Prior to the exploration 
of the Pacific by Europeans, Oceania had long been isolated from most infectious diseases. The 
small-scale nature of most populations but particularly their isolation, protected these islands 
from influenza, measles, mumps, smallpox, tuberculosis, cholera, plague, typhoid, whooping 
cough and venereal disease (Denoon, 1995). These diseases were therefore alien to Pacific 
Islanders, leaving them immunologically naïve, and thus exposure to these diseases had the 
capacity to cause large-scale loss of life.  
While it remains challenging for archaeological and historical demographers to assess the effect 
of the introduction of Western diseases on these island populations for a number of reasons, in 
part because of the lack of regular, systematic censuses on many islands and the uncertainty 
over the initial population sizes (McArthur, 1968), it is clear that introduced diseases did have a 
major impact. Some islands seem to have been more affected than others, but on some islands 
where records are available, it is possible to link epidemic outbreaks of diseases like whooping 
cough, measles and influenza to visits by certain European ships, and many of these epidemics 
caused significant mortality (Denoon, 1995). As previously mentioned, East Polynesia was hit 
particularly hard – much more so than West Polynesia – particularly during the initial 
introduction of these diseases which resulted in losses up to 75% of the population in some 
islands (McArthur, 1968, Harrison et al., 1988). This may go some way to explain some of the 
genetic differences between East and West Polynesia (Phipps-Green et al., 2010, Hill et al., 
1989). Given the role of monosodium urate crystals in enhancing the innate immune response, it 
is possible that genotypes promoting increased urate levels were also positively selected for 
during these periods of massive depopulation. It is also likely, given the presence of 
archaeological evidence for gout in samples that are definitely from a pre-European era, that 










There have been a number of different hypotheses put forward to explain the high rates of 
metabolic disease among Pacific populations. The ‘Thrifty Genotype’ hypothesis, and variants of 
this, has been a common explanatory scenario. The lack of genetic evidence supporting this 
hypothesis, and because it does not fit well with current archaeological understandings 
surrounding the prehistory of the region, means that continuing to apply this hypothesis to the 
Pacific scenario is not helpful in understanding phenotypic variation between populations. 
Houghton’s (1990) proposal that Bergmann’s rule may account for the differences in body mass 
and susceptibility to disease is also unsupported by present archaeological data. 
Raised serum urate levels are seen throughout the Pacific, particularly in Polynesia, Micronesia 
and amongst Taiwanese aborigines. Archaeological evidence suggests that this is not a new 
phenomenon (Buckley, 2011). The multifactorial aetiology of hyperuricaemia indicates that 
there are likely to be a number of contributing factors, including a genetic contribution. The 
localised heightened prevalence of hyperuricaemia and gout in Polynesian and Micronesian 
populations suggests that shared heredity may contribute. However, while potential reasons for 
this may be proposed, it remains difficult to disentangle how, when and why this hypothesised 
genetic contribution arose in these populations.  
Processes of natural selection may have contributed to the phenotype which is observed in 
modern populations – in particular, infectious disease may have played a role in this process of 
selection; however, random genetic drift cannot be discounted. The colonisation process of the 
Pacific with serial founder effects, as well as catastrophic events in the fragile island 
environments, means that there have been ample opportunities for genetic drift. However, at the 
same time, given the high levels of hyperuricaemia and gout seen in populations who likely 
share at least some ancestry with the Polynesians and Micronesians, for instance, the Taiwanese 
aborigines (Chang et al., 1997, Chou & Lai, 1998, Chang et al., 2001), and the Malagasy 
highlanders (Capdevielle et al., 1980), the probability of random genetic drift operating in all of 
these populations to result in the same phenotype seems unlikely. Multiple processes are likely 
to have worked in tandem resulting in the genetic predisposition to hyperuricaemia. 
Ancestry, itself, is not a trivial consideration. Examination of the available published literature 
indicate that elevated serum urate may be a trait shared by populations descended from the 
Austronesian-speaking peoples who departed from South East Asia around 8000 years ago. In 
light of the low serum urate levels seen in coastal populations in mainland Papua New Guinea, it 
would be interesting to investigate the state of serum urate levels among the Lapita-derived, 
Austronesian-speaking populations living in the Bismarck Archipelago, to the north-east of 
 
 




mainland Papua New Guinea: are they inherently hyperuricaemic like Polynesian and 
Micronesian populations, or are there lower urate levels similar to the mainland? 
There is significant scope for further investigations to determine the reasons for elevated serum 
urate, and indeed evolutionary reasons for other metabolic phenotypes, in populations in the 
Pacific region. While there have been efforts to understand prehistoric human migration in this 
region, disease has not been a major focus. The gulf between anthropological studies in the 
Pacific and genetic disease research has meant that genetic predisposition to conditions like 
hyperuricaemia has not been examined from an evolutionary perspective. Further genetic 
studies in Pacific populations are warranted and could assist in testing hypotheses, for example, 
the application of tools for detecting selection to the genomic sequence of genes involved in the 
regulation of urate.  
It is also important to recognise that while the high serum urate levels seen throughout the 
Pacific are a useful marker to use to speculate about the origins of metabolic disorders like gout, 
high urate alone does not lead to disease. Conditions such as gout and type 2 diabetes have an 
auto-inflammatory component, where an inappropriate immune response is mounted and 
inflammation occurs, and as a result, there are likely other immune related genetic variants 
contributing to this susceptibility to disease. This is compatible with models of infectious disease 
contributing selective pressure as is discussed above.  
 
 












4 NLRP3 inflammasome and metabolic disease 
4.1 The NLRP3 inflammasome 
As alluded to in the preceding chapter, the NLRP3 inflammasome constitutes an important part 
of the innate immune response countering malaria infection and has also been implicated in the 
inflammatory processes in gout. This observation underlies the proposal that exposure of 
ancestral Pacific populations to malaria may have resulted in positive selection for genetic 
variants contributing to elevated serum urate levels. Given the high prevalence of metabolic 
diseases among Polynesians, and emerging research implicating the NLRP3 inflammasome in a 
range of auto-inflammatory diseases, this chapter aims to review what is known about the role 
of this type of immune response to these disorders, and to give background into the reasons for 
exploring mitochondrial variation in the Polynesians. 
The immune system in humans consists of two main branches: the innate and acquired immune 
systems. The innate immune system constitutes the first line of defence in the overall immune 
system (Akira et al., 2006). It is able to react to pathogens in a relatively generic way, 
recognising both pathogen-associated molecular patterns (PAMPs) such as microbial cell wall 
components but also damage-associated molecular patterns (DAMPs)(Table 4.1). DAMPs are 
largely endogenous, comprising certain common immune stimulatory molecules present inside 
most cells, but which are not usually exposed in the extracellular matrix where they may be 
encountered by antigen presenting cells such as dendritic cells or macrophages that are 
constantly on the lookout for such distress signals. When there is cellular damage or necrosis 
caused by pathogenesis or other means, these are released and recognised as danger signals. 
Therefore, these DAMPs can contribute not only to pathogen-associated immune responses, but 
also to sterile inflammation and autoimmunity. Notably, unlike the acquired immune system, the 
innate immune response does not confer long-lasting or protective immunity to the host: it is 
purely reactive. It is an ancient system among multicellular organisms protecting against attack 
by microbes, and is the dominant immune system found in not only vertebrates, but 
invertebrates, plants and primitive multicellular organisms (Kimbrell & Beutler, 2001) . 
There are multiple mechanisms for the innate immune response to detect perturbations 
potentially caused by exposure to pathogens. In mammals, humans included, cytokine-mediated 
inflammatory processes seem to be the dominant form of innate immunity.   
 
 





Table 4.1: Common pathogen- and damage-associated molecular patterns which initiate innate immune 
responses 
PAMPs DAMPs 
Microbial cell wall components Extracellular ATP 
i.e. Peptidoglycan, lipopolysaccharide, lipoteichoic acid  Extracellular host DNA (mtDNA and nuclear) 
Flagellin Hyaluronan 
Pathogen RNA (especially double stranded) Monosodium urate crystals 
Pathogen DNA (especially unmethylated CpG motifs) HMGB1  
Toxins e.g. Nigericin, α-toxin  
Parasitic metabolites, e.g. Haemozoin  
 
It is becoming increasingly evident that inflammasomes are an important means of inducing of 
innate immune responses (Martinon et al., 2002). Inflammasomes are a relatively recently 
identified multi-protein complex which consist of caspase 1, a caspase recruitment domain 
(CARD), a pyrin domain and various other components (for instance, nucleotide-binding 
domains) depending on their activator. The NLRP3 inflammasome is one of a number of 
inflammasomes that have been identified, and has been found to respond to a wide range of 
PAMPs and DAMPs.  
 
 
Figure 4.1: Components of the NLRP3 inflammasome. CARD, caspase-recruitment domain; LRRs, leucine-rich 








Specifically, the NLRP3 inflammasome describes a multiprotein oligomer comprising Nod-like 
receptor protein 3, also known as nucleotide-binding domain, leucine rich repeat containing 
family, pyrin domain-containing 3 (NLRP3) protein, caspase-1 and apoptosis-associated speck-
like protein containing a CARD (ASC) (Figure 4.1). Activation requires the NLRP3 protein and 
the ASC protein to come into proximity, a process dependent on other cellular processes. 
NLRP3 inflammasome initiation is dependent on a two-signal activation system, which 
represents an important regulatory check-point to avoid inappropriate activation which would 
damage the host. The first activation signal triggers a signalling pathway which results in the 
stimulation of a protein complex named nuclear factor kappa-light-chain-enhancer of activated 
B cells (NF-κB) via toll-like receptor 4 (TLR4) or toll-like receptor 2 (TLR2), transmembrane 
receptors highly expressed on the exterior of macrophages and dendritic cells, professional 
antigen-presenting cells whose sole job is to patrol the body looking for signs of abnormal 
cellular damage or out-of-place microbial cellular components. NF-κB is a transcription factor 
that is always present in cells in an inactive state, allowing for immune responses to be rapidly 
switched on when necessary. The triggering of signal 1 causes an upregulation of the production 
of NLRP3 protein, however without the second signal, inflammation will not proceed. As well as 
being triggered by foreign pathogenic entities, TLR2 and TLR4 can be stimulated by oxidised low 
density lipoprotein (LDL) (Chávez-Sánchez et al., 2010), a biomarker which is often found in 
elevated levels in individuals with metabolic dysfunction. 
Table 4.2: - Known endogenous triggers of the NLRP3 inflammasome 
 
[1] (Halle et al., 2008); [2] (Martinon et al., 2006); [3] (Vandanmagsar et al., 2011); [4] (Duewell et al., 2010, Rajamäki 
et al., 2010); [5] (Masters et al., 2010); [6] (Martinon et al., 2006); [7] (Wen et al., 2011) 
Metabolic danger signal Disease state References 
Amyloid beta Alzheimer’s disease [1] 
Calcium pyrophosphate dehydrate crystals Pseudogout [2] 
Ceramides Obesity [3] 
Cholesterol crystals Atherosclerosis [4] 
Islet Amyloid Polypeptide Type 2 diabetes progression [5] 
Monosodium urate crystals Gout [6] 
Palmitate Early type 2 diabetes [7] 
 
 




The second activation signal is known to be activated by a number of different danger signals, 
though its precise mechanism is still yet to be elucidated. There are several possibilities which 
are discussed later in the chapter. This second signal causes the co-localisation of the NLRP3 
proteins with the ASC, a process in which mitochondria seem to play a central role (Zhou et al., 
2011, Misawa et al., 2013), instigating the activation of caspase-1, which goes on to proteolyse 
the precursors of pro-inflammatory cytokines interleukin (IL)-1β and IL-18 (Martinon et al., 
2002). IL-1β binds to the IL-1 receptor (IL-1R) and induces the formation of a ternary complex 
with the IL-1R accessory protein, resulting in a downstream signalling cascade involving the 
induction of more proinflammatory cytokines and chemokines and enticement of neutrophils 
and other immune effector cells to the region (Cullinan et al., 1998). This sort of response is 
invaluable when there is a pathogenic stimulus, indeed there is evidence for NLRP3 
inflammasome involvement in the resolution of influenza (Allen et al., 2009) and malaria 
(Kalantari et al., 2014, Gazzinelli et al., 2014) infection. However, given that some of the danger 
signals recognised by the NRLP3 inflammasome are endogenous (Table 4.2), this opens up the 
possibility of auto-inflammatory diseases. 
 
4.2 Links between NLRP3 and metabolic diseases 
The causation of gouty pathology by monosodium urate (MSU) crystals inducing inflammation is 
something long established. As early as 1679, Anton van Leeuwenhoek, one of the pioneers of 
microscopy, described the appearance of crystals from a gouty tophus (McCarty, 1970). By 1859, 
Alfred Baring Garrod had identified these crystals as consisting of a “urate of soda” (Garrod, 
1859). It has been a lot more recently that the specific inflammatory processes stimulated by 
urate have begun to be disentangled. Shi et al. (2003) found that eliminating uric acid in vivo 
inhibits the immune response associated with DAMPs, and Martinon et al. (2006) identified the 
specific involvement of the NLRP3 inflammasome in the inflammatory processes responsible for 
gout (Figure 4.2). 
The NLRP3 inflammasome seems to be unique in that it can detect not only pathogen-associated 
molecular patterns (PAMPs) but also damage-associated molecular patterns (DAMPs) and other 
endogenous danger signals, particularly crystalline structures (Table 4.2). The NLRP3 appears to 
be playing a role in a range of other age-related auto-inflammatory diseases (Schroder et al., 
2010), including obesity-induced insulin resistance, type 2 diabetes and atherosclerosis. This 
should perhaps be unsurprising given the fundamental and highly conserved and closely 
integrated natures of the immune and metabolic systems. Given that many of these conditions 
occur as co-morbidities (Li et al., 2013), it may be that an over-active (or more-easily 
stimulated) immune response of this sort (perhaps as a result of genetic predisposition) may 
 
 




underlie disease – particularly in populations where there appears to be a higher prevalence of 
disease. 
Below, the connections between a number of other metabolic conditions, which also occur at 
high frequency among Pacific peoples (see Chapter 2 regarding prevalence), and the links 




Figure 4.2: The NLRP3 inflammasome recognises monosodium urate crystals and is involved in the 









4.2.1 NLRP3 in Obesity 
With the increasing rates of obesity among human populations worldwide, there has been a 
growing awareness of the accompanying health problems (Figure 4.3) – conditions including 
type 2 diabetes, cardiovascular disease, hepatic steatosis, neurodegeneration and biliary disease 
(Hotamisligil, 2006). Human obesity does not always result in disease, suggesting that there is a 
variable threshold for tolerable fat between individuals that is likely to be determined by 
environmental and genetic variables (Gregor & Hotamisligil, 2011). There is also some variation 
in terms of the total body fat to mass ratios, with populations with different ancestral 
backgrounds being shown to have subtly different body compositions (Lovejoy et al., 1996, 
Swinburn et al., 1999, Després et al., 2000, WHO, 2004) that may in turn affect their 
susceptibility to metabolic disease. The distribution of the fat also contributes variable risk; 
subcutaneous adipose tissue has subtly different cell size (Johnson & Hirsch, 1972), metabolic 
activity (Krotkiewski et al., 1983) and may play a different role in the development of insulin 
resistance (Gastaldelli et al., 2002) compared to abdominal or visceral fat. Indeed, visceral fat 
appears to be more pathogenic (Fujioka et al., 1987, Fox et al., 2007). 
 
 
Figure 4.3: Clustering on metabolic diseases with obesity. The mechanisms behind the diseases on the right 
with obesity are less well understood than those on the left.  (modified from Hotamisligil 2006). 
Obesity is considered a risk factor for various other metabolic conditions. It may be that the low-
grade inflammatory response which accompanies obesity underlies susceptibility to these other 
various metabolic diseases (Lumeng & Saltiel, 2011). The definition of this inflammatory state 
falls outside that of classical inflammation as defined by redness, swelling, heat and pain (the 
standard self-limited response to infection or injury), however the inflammation associated with 
obesity is chronic, arising in specialised cells such as adipocytes that are triggered by metabolic 
factors (for instance, the consumption of excess calories – pro-inflammatory cytokine levels 
have been found to fluctuate several hours after the consumption of food (Blackburn et al., 2006, 
Manning et al., 2008, Gregor & Hotamisligil, 2011)). The earliest studies detecting inflammation 
 
 




in obesity (in a murine model) found increased levels of the pro-inflammatory cytokine TNF-α in 
adipose tissue (Hotamisligil et al., 1995), however since this finding a plethora of other 
cytokines have been detected including those with associated with NLRP3 inflammasome 
activity (Vandanmagsar et al., 2011). Adipose tissue is not the only affected tissue, with the liver 
(Cai et al., 2005), muscle (Saghizadeh et al., 1996, Fink et al., 2013) and pancreas (Maedler et al., 
2002) also being subject to inflammation in presence of obesity. This chronic inflammatory 
response affects insulin resistance by interfering with insulin signalling in peripheral tissues. 
This may contribute to the development of type 2 diabetes.  
Vandanmagsar et al. (2011)  found that in mice, mRNA expression of Il1b and Nlrp3 in visceral 
adipose tissue correlated with body weight and adiposity. Moreover calorie restriction an d 
weight loss in humans resulted in decreased expression of these genes, which was accompanied 
by lower glycaemic levels and improved insulin sensitivity. Nlrp3-/- mice on a high fat diet had 
enhanced insulin sensitivity compared to wild-type mice, which suggests that the NLRP3 
inflammasome is likely contributing to obesity-induced insulin resistance.  
 
Figure 4.4: Activation of NLRP3 inflammasome in obesity. TLRs and NLRs can be activated by a variety of 
dietary factors and DAMPs in response to obesity-induced metabolic stress 
 
 




There are a number of possible triggers for the NLRP3 inflammasome in obesity (Figure 4.4). 
The first trigger may be stimulated by saturated fatty acids such as palmitate, which have been 
shown to be able to induce inflammation via TLR4 (Shi et al., 2006, Davis et al., 2008, Milanski et 
al., 2009). Holland et al. (2011) found this TLR4-mediated insulin-resistance requires the 
biosynthesis of ceramides, which is compatible with research undertaken by Vandanmagsar et 
al. (2011) indicating that ceramides are able to stimulate the NLRP3 response (which therefore 
may constitute the second required signal for inflammasome activation). There may also be 
other factors contributing, considering that obesity is associated with hypoxia (Hosogai et al., 
2007) and adipocyte death (Strissel et al., 2007), which likely also result in the release of pro-
inflammatory markers. It is of note that hyperuricaemia is correlated with obesity, so MSU 
crystals are another potential trigger for the chronic nonspecific inflammation. 
4.2.2 NLRP3 in Type 2 Diabetes 
 
As just discussed, obesity-mediated inflammation often results in impaired insulin sensitivity, a 
state often considered as pre-diabetes. When this is accompanied by the inability to modulate 
insulin levels due to dysfunction of pancreatic islet β-cells, this is considered to be full-blown 
type 2 diabetes (Kahn et al., 2006). Pancreatic β–cells are responsible for releasing insulin to 
modulate glucose levels, so dysfunction can result in hyperglycaemia and complications 
associated with this.  
The role of auto-inflammation in type 2 diabetes pathogenesis is well established and there are 
ample reports of various inflammatory markers associated with the disease (Pickup & Crook, 
1998, Pradhan et al., 2001, Donath & Shoelson, 2011). Given the relatively recent discovery of 
inflammasome complexes in general (Martinon et al., 2002), it is unsurprising that the links 
found between the NLRP3 inflammasome and the pathological process of type 2 diabetes are 
still being uncovered (Wen et al., 2010, Vandanmagsar et al., 2011, Lee et al., 2013)(Figure 4.5). 
Lee et al. (2013) observed up-regulated IL-1β maturation, IL-18 secretion and caspase-1 
cleavage in monocyte-derived macrophages from drug-naïve type 2 diabetes patients, as well as 
increased expression of Nlrp3, Asc and Il1b. Interestingly, treating the cells with a mitochondria-
targeting antioxidant to inhibit mitochondrial ROS production significantly reduced the IL-1β 
and IL-18 production (Lee et al., 2013), indicating that mitochondria may play a central role in 
this inflammasome generation. This is supported by other emerging research that will be 
discussed in more depth later in this chapter (Nakahira et al., 2011, Zhou et al., 2011). 
As mentioned previously in relation to obesity-associated NLRP3 inflammasome activation, 
products of long chain saturated fatty acid metabolism such as palmitate and ceramide have also 
 
 




been found to mediate NLRP3 inflammasome activation (Vandanmagsar et al., 2011, Wen et al., 
2011). The resulting inflammatory response can cause damage to the pancreatic β-cells.  
Further damage to β-cells results from the high glucose concentrations associated with 
hyperglycaemia that stimulate the disassociation of thioredoxin-interacting protein (TXNIP) 
from thioredoxin in a ROS-dependent manner (Zhou et al., 2010). TXNIP is a cytoplasmic protein 
that is able to shuttle into other cellular compartments including the nucleus and the 
mitochondria and plays an important role in maintaining reduced environment in the cell 
(Yoshihara et al., 2013) and regulating apoptosis (Saxena et al., 2010). Current evidence 
suggests that TXNIP can influence the development of type 2 diabetes in a number of ways. 
Firstly, while under normal physiological conditions, TXNIP is usually present in the nucleus of 
the pancreatic β-cells, under conditions of oxidative stress TXNIP shuttles into the mitochondria 
where is able to induce a mitochondrial pathway of apoptosis (Saxena et al., 2010). As well as 
stimulating this apoptosis pathway, when inside the mitochondria, TXNIP can cause 
mitochondrial dysfunction and ROS accumulation in mitochondria (Zhou et al., 2011), 
potentially part of the same inflammation-inducing process resulting in NLRP3 activation. 
Independently of this, TXNIP has also been found to bind directly with NLRP3 (Zhou et al., 
2010). The ultimate result of all of these processes is further damage to β-cells, which then has 
other flow-on inflammatory effects. 
Damage to the β-cells results in the dysregulation of insulin secretion, a process which helps 
modulate blood glucose concentrations. This can result in the aggregation of islet amyloid 
polypeptide (IAPP), a protein usually co-secreted with insulin, in the pancreas during type 2 
diabetes. This can form amyloid deposits, which have also been shown to trigger NLRP3 
inflammasome activation (Masters et al., 2010).  
While there are other inflammatory pathways being stimulated in type 2 diabetes, much of the 
pathology can be linked back to an initial inappropriate NLRP3 inflammasome-mediated 
response to what could be a range of endogenous DAMPs. This is supported by evidence from 
type 2 diabetes drug therapies targeted at dampening NLRP3 activation that have been found to 
reduce hyperglycaemia and improve insulin sensitivity (Ehses et al., 2009). Some of these 
DAMPs which stimulate inflammation may stem from an underlying obese state, but other 










Figure 4.5: NLRP3 activation in type 2 diabetes involves NLRP3 activation in both macrophages and 
pancreatic beta-cells 
 
4.2.3 NLRP3 in Atherosclerosis 
 
Atherosclerosis is a condition wherein arterial walls thicken as a result of invasion and 
accumulation of white blood cells, including macrophages. It is a chronic disease that generally 
remains asymptomatic for such of the sufferers life, however in late phases of disease, rupture of 
atherosclerotic plaques may result in ischemic heart disease and stroke. Like other metabolic 
diseases, progression of disease is a complex and not fully understood process. Literature 
surrounding the development of the inflammatory response is summarised below. 
The accumulation of immune cells is thought to be a result of the flux of LDL cholesterol into the 
endothelial cells of the arterial walls, where it can become oxidised and unable to migrate back 
into the arterial blood flow (Weber & Noels, 2011). Oxidised LDL has pro-inflammatory 
properties and is able to interact with TLR2 and TLR4, which is a priming signal for NLRP3 
inflammasome activation (Chávez-Sánchez et al., 2010). The accumulation of lipids in the 
 
 




vascular endothelium results in recruitment of macrophages to the site. Here they may become 
‘foam cells’ resulting from their altered morphology following the uptake of cholesterol and its 
storage as lipid droplets. Duewell et al. (2010) have found that using microscopy, it is possible to 
detect cholesterol crystals present in the early stages of diet-induced atherosclerotic lesions, 
coinciding with the first appearance of inflammatory cells. Furthermore, Rajamäki et al. (2010) 
have shown that cholesterol crystals stimulate an inflammatory response in human 
macrophages, and that silencing of NLRP3 attenuates cholesterol crystal-induced IL-1β 
secretion. Further studies have confirmed the role of NLRP3 involvement in the secretion of IL-
1β from foam cells using mouse (Usui et al., 2012) and cell-line (Jiang et al., 2012) models. 
Together, this suggests that the NLRP3 inflammasome underpins some of the inflammatory 
responses involved in atherosclerotic cardiovascular disease. 
 
4.2.4 Implications of NLRP3 and its involvement in metabolic diseases 
 
To summarise the above, all of these diseases piggyback on what is essentially the same 
inflammatory process. There may be slightly different triggers, for instance, monosodium urate 
crystals in gout (Martinon et al., 2006) or ceramide crystals in the stimulation of the 
inflammatory processes in obesity (Vandanmagsar et al., 2011), but at the core of it, it is the 
same process. This makes sense, as despite being a complex system with redundancies built in, 
evolution tends not to reinvent the wheel multiple times if it does not have to.  
The high prevalence of disorders that are linked to NLRP3 inflammation, including not only gout 
(Winnard et al., 2012, Gosling et al., 2014), but also type 2 diabetes and obesity in Polynesians 
and other Pacific people (Gosling et al., 2015) may suggest that they may have over-reactive 
NLRP3 inflammatory responses. Atherosclerosis could also be added to this list as it is a major 
contributor to ischemic heart disease, a condition which occurs at a much higher frequency 
among Māori than among New Zealanders of European ancestry (Bramley et al., 2004, Tobias et 
al., 2006). While there are undoubtedly environmental factors contributing to this trend 
including diet (differences in dietary composition appears to affect an individual’s 
immunological profile (Thorburn et al., 2014)), exercise levels and socio-economic class, genetic 
determinants are also likely to be influential. As suggested in previous chapters, immune 
responses have a strong genetic component (Cooke & Hill, 2001) and as such genes involved in 
survival of infectious diseases may be subject to strong selective pressure. There have been 
instances where selection by infectious disease exposure has had the opportunity to shape the 
genomes of the peoples who have since become Polynesians, for instance the proposed malarial 
influence in Chapter 2. 
 
 




There are many components to the NLRP3 inflammasome that may be subject to genetic 
variation, which may downstream contribute to susceptibility to metabolic disease. In terms of 
gout, there has been much focus on identifying the urate transporters contributing to the 
underlying hyperuricaemia (Choi et al., 2010, Reginato et al., 2012, Merriman et al., 2014), 
however there has been minimal success in identifying genetic variation contributing to the 
immune response (Qing et al., 2013a, Qing et al., 2013b). Similarly, with other metabolic 
diseases including atherosclerosis (Lusis, 2012) and type 2 diabetes (Herder & Roden, 2011), 
genetic variation underlying the inflammatory processes have remained elusive. This will no 
doubt be addressed as the complex pathways underlying innate immunity are disentangled over 
the coming years and as more population-specific studies are undertaken, with consideration of 
the unique evolutionary histories of the populations in question. 
Understanding of inflammasome-mediated disease is still the focus of intense study. While it is 
known that the NLRP3 inflammasome requires two distinct triggers for activation and a 
plethora of activating signals have been identified (Figure 4.2), the precise mechanisms by 
which these activators trigger the inflammasome are poorly understood. These known 
activators of NLRP3-mediated inflammation are structurally and chemically diverse which 
means that the mode of activation is probably more complex than the proposed mechanism for 
toll-like receptor activation where direct interaction between the agonist (PAMPs for instance) 
and the receptor appears likely (Tschopp, 2011). Instead it seems probable that a common 
cellular structure or organelle integrates the various activation signals and consequently 
initiates a signaling pathway that leads to inflammasome activation. Tschopp (2011) suggests 
that this could be mitochondria.  
 
4.3 Mitochondria as an integral component of the NLRP3 inflammasome 
4.3.1 What are mitochondria? 
 
Mitochondria are organelles present within cells, usually in large numbers. They comprise a 
double-membrane-bound structure involved in a wide range of cellular processes (Figure 4.6). 
Mitochondria are unique among organelles in humans in that they have their own small circular 
genome, probably a remnant of their origin as a D-proteobacterium, which struck up a symbiotic 
relationship with proto-eukaryotic cells (Andersson et al., 2003). Through the course of 
evolution, they have become indispensible. Of most importance is the role of mitochondria in 
oxidative phosphorylation (OXPHOS). OXPHOS is the primary means of energy production, 
generating somewhere between 30 and 36 ATPs per glucose molecule. OXPHOS is achieved 
 
 




through membrane potential differences, and the shuttling of electrons through the electron 
transport chain.  
It is during this process that the mitochondria can also produce radical oxygen species (ROS) 
including superoxide and hydrogen peroxide, which can lead to mitochondrial dysfunction, 
cellular damage and correspondingly disease when left unchecked. ROS generation also 
constitute an important aspect of cellular signalling, including apoptosis (programmed cell 
death) (Fleury et al., 2002) and inflammasome activation (Tschopp & Schroder, 2010). 
Additionally, mitochondria are involved in calcium homeostasis and the biosynthesis of amino 
acids, lipids, nucleotides and haem (Gattermann et al., 2004, Ajioka et al., 2006). 
It has been becoming increasingly clear that mitochondria play an important role in cellular 
defence and the immune response (Cloonan & Choi, 2013). As already discussed, there are many 
diverse activators of NLRP3-mediated inflammation as evidenced by its role in a range of 
metabolic conditions, and there is some indication that mitochondria are essential players in 
this process. Rather than the NLRP3 molecular complex itself detecting each of the diverse 
activator signals independently, it could instead monitor the activity of the mitochondrion, 




Figure 4.6: The mitochondrial sub-compartments and examples of compartment specific processes 
 
 





Complex interplay between metabolism and innate immune processes appears to underpin the 
multitude of age-related metabolic diseases found in humans. Given that metabolic efficiency 
alters during pathogenic challenge, it is perhaps unsurprising that the innate immune response 
is hardwired to detect such perturbations and respond accordingly. The central role that 
mitochondria play in metabolism thus may act as a bridge linking these two vitally important 
processes together. Indeed, there is evidence to suggest that mitochondrially generated ROS 
(Zhou et al., 2011) and the release of mitochondrial DNA (Nakahira et al., 2011, Shimada et al., 
2012) are important in inflammasome activation. 
 
4.3.2 Proposed mechanisms for a role of mitochondria in NLRP3 inflammasome 
generation 
 
Bearing in mind that this is still very much an area of active research and the details are yet to be 
elucidated, there have been a number of proposed mechanisms for NLRP3 inflammasome 
activation but no real consensus. Proposed mechanisms include potassium efflux (Perregaux & 
Gabel, 1994, Petrilli et al., 2007, Muñoz-Planillo et al., 2013), an increase in intracellular calcium 
and a decrease in cyclic AMP (Lee et al., 2012, Murakami et al., 2012), phagosomal 
destabilisation (Hornung et al., 2008, Dostert et al., 2008), pore-forming actions caused by 
bacteria or host (Pelegrin & Surprenant, 2006, Harder et al., 2009), changes to cell volume 
(Compan et al., 2012), and mitochondrial-associated dysfunction, including the release of 
mitochondrial ROS (Zhou et al., 2011), oxidised mtDNA (Nakahira et al., 2011, Shimada et al., 
2012), the translocation of cardiolipin from the inner to the outer mitochondrial membrane 
(Iyer et al., 2013) or the expression of the mitochondria-associated adapter molecule, 
Mitochondrial Antiviral Signalling protein (MAVS) receptor on the mitochondrial outer 
membrane (Subramanian et al., 2013, Park et al., 2013). There is no reason to believe that any 










Figure 4.7: A role for the mitochondria in NLRP3 inflammasome activation. From (Akira et al., 2013)  
 
The co-localisation of ASC and NLRP3 is vital for the induction of the NLRP3 inflammasome 
(Zhou et al., 2011, Misawa et al., 2013, Subramanian et al., 2013). Recent evidence suggests that 
the ASC is localised on the mitochondria, while the NLRP3 is present on the endoplasmic 
reticulum (Zhou et al., 2011, Misawa et al., 2013)(Figure 4.7). After stimulation with inducers of 
the NLRP3 inflammasome, mitochondria approach the endoplasmic reticulum at the peri-
nuclear margin, resulting in the co-localisation of ASC and NLRP3, and the subsequent activation 
of caspase-1 and the generation of IL-1β. This appears to be mediated by acetylated α-tubulin in 
the form of microtubules (Misawa et al., 2013). This process does not seem to be affected by 
either potassium ion concentrations or by ROS, and seems to result from the inactivation of 
sirtuin 2 (SIRT2), a tubulin deacetylase sensitive to changes in the mitochondrial NAD+ gradient 
(Misawa et al., 2013), though there may also be other deacetylase inhibitors involved (Lee et al., 
2015b). This co-localisation of NLRP3 and ASC was also observed in viral-mediated NLRP3 
inflammasome activation via MAVS, which has been found to optimise this co-localisation 
process (Park et al., 2013, Subramanian et al., 2013).  
It is unclear what triggers the co-localisation of the mitochondrion to the endoplasmic reticulum 
during the induction of the NLRP3 inflammasome. While Misawa et al. (2013) suggest that it 
 
 




may be fluctuation of NAD+ concentrations which inactivate SIRT2, it may equally be the 
mitochondrial-derived ROS (Zhou et al., 2011) or some other yet unidentified stimulus. 
Certainly, mitochondrial dysfunction and the blockade of mitophagy lead to an accumulation of 
ROS that go onto stimulate NLRP3 inflammasome initiation (Zhou et al., 2011).  
 
4.3.3 Mitophagy and mitochondrial biogenesis 
 
Mitophagy and mitochondrial biogenesis are two inter-related processes, and describe the 
degradation and the generation of mitochondria, respectively. These processes are essential to 
maintaining homeostasis. Mitophagy occurs via a process known as autophagy, wherein the 
mitochondrion becomes encapsulated by a double-membrane structure known as an 
autophagosome and is subsequently broken down and its components recycled by the cell 
(Youle & Narendra, 2011). This process is preceded by mitochondrial fission, which divides the 
mitochondria into smaller, more manageable units for encapsulation (Twig et al., 2008). 
Mitophagy is important for regulating mitochondria, in particular the disposal of those that have 
become dysfunctional, which may make the cell susceptible to inappropriate auto-inflammatory 
responses. There is evidence suggesting that alterations in mitophagy efficiency might 
contribute to pathology. OMM kinase PINK1 (Valente et al., 2004) and PARKIN (Kitada et al., 
1998), genes associated with autosomal recessive Parkinson’s disease, encode proteins which 
mediate a signalling pathway inducing mitophagy in mammalian cells (Youle & Narendra, 2011). 
If cellular mitophagy processes breakdown and dysfunctional mitochondria are not being taken 
out of circulation, susceptibility to inappropriate NLRP3 inflammasome activation may ensue 
(Nakahira et al., 2011, Lazarou, 2015). Mitophagy has been found to negatively correlate with 
inflammation (Nakahira et al., 2011).  
Mitochondrial biogenesis is equally important in maintaining normal homeostasis as if 
dysfunctional mitochondria are not replaced once they are taken out of circulation there may be 
energy imbalance. Peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-
1α; encoded by the gene PPARGC1A) seems to be involved in this process of biogenesis by 
modulating the transcriptional activity of nuclear-encoded mitochondrial genes (Scarpulla, 
2011). Factors like exercise (Wright et al., 2007) and aging (Viña et al., 2009) have been found to 
affect PPARGC1A expression. Sahin et al. (2011) found that impaired mitochondrial biogenesis 
contributed to metabolic dysfunction. Interestingly, genetic variants in PPARGC1A have 
previously been associated with type 2 diabetes risk, insulin resistance and altered lipid profiles 
(Ek et al., 2001, Hara et al., 2002, Muller et al., 2003, Barroso et al., 2003). While the mechanism 
 
 




behind this remains unclear, genetic variants in PPARGC1A may be contributing to a reduction in 
mitochondrial turnover, contributing to a susceptibility to inflammation.  
Consistent with the observation that PPARGC1A expression decreases with age (Viña et al., 
2009), it has been subsequently found that the shortening of telomeres is accompanied by a 
down-regulation of PPARGC1A (Sahin et al., 2011). This may also be interpreted as reduced 
turnover of mitochondria, which in turn may result in the accumulation of dysfunctional 
mitochondria and contribute to age-related metabolic disease. Conditions such as gout, type 2 
diabetes and ischemic heart disease all increase in prevalence with advanced age. Given that 
telomeres shorten with age (Hastie et al., 1990), these phenomena may be inter-related. This 
down-regulation in mitochondrial biogenesis with age is probably a normal part of the aging 
process, and possibly explains why there is an increased risk of complex disease with age 
(Fosslien, 2001, Petersen et al., 2003, Puddu et al., 2005, Lin & Beal, 2006).  
 
4.3.4 Mitochondrial genetic variation 
 
Much of the above, including OXPHOS (and the generation of ROS through this process) and 
mitochondrial biogenesis and autophagy, may be directly affected by mitochondrial genetic 
variation. Mitochondria are encoded by DNA contained not only within the nuclear genome but 
also in an accessory genome contained within the mitochondria themselves. Each 
mitochondrion possesses multiple copies of its own circular genome consisting of around 16.5 
kB of DNA encoding 13 subunits of oxidative phosphorylation and 24 RNA components of the 
mitochondrial translational apparatus (2 rRNAs and 22 tRNAs) (Figure 4.8). The mitochondrial 
genome is reductionist, characterised by tight packaging of genetic material with a lack of 
intronic DNA – intergenic sequences are either absent or limited to a few bases. In some cases, 
genes overlap (e.g. MT-ATP8/MT-ATP6 and MT-ND4L/MTND4). Recently, there has also been the 
identification of additional short open reading frames that can be translated into peptides 
(humanin and MOTS-c) with important biological functions (Guo et al., 2003, Lee et al., 2015a). 
An additional 1500 genes are encoded by the nuclear genome – including all those that encode 
proteins responsible for mtDNA replication and repair, as well as all the proteins responsible for 
transcription and translation - which means that communication between the organelle and the 
nucleus is vital for coordinating mitochondrial biogenesis. Imbalances in this process likely lead 









Figure 4.8: a) a human mitochondrial genome consisting of 37 mitochondrial genes. Encoded genes include 
seven subunits of complex I (ND1, 2, 3, 4, 4L, 5 and 6), one subunit of complex III (cytochrome b; Cyt b), three 
subsunits of complex IV (Cyt c oxidase (COX) I, II and III), two subunits of complex V (ATP6 and ATP8, labelled 
A6 and A8 on diagram), two rRNAs (12S and 16S) and 22 tRNAs. Also shown are the origins of replication of 
the heavy strand and the light strand (OH and OL, respectively), and their respective promoter regions (HSP 
and LSP) ; b) oxidative phosphorylation complexes, showing the location of the mitochondrially encoded 









It has been proposed that mitochondrial dysfunction, and alteration to mitochondrial genes, are 
key contributors to metabolic disease and may account for the differences in prevalence 
observed between populations (Wallace, 2013). The mitochondrial genome, for the most part, 
does not undergo recombination and is primarily transmitted through the maternal line (White 
et al., 2008). This strict pattern of inheritance means that the major mechanism of change to the 
genome sequence is the accumulation of sequential mutations over generations, which results in 
the emergence of phylogenetically new lineages. Changes to the genome sequence are tempered 
by the need to maintain the function of mitochondrial genes, thus the sequence evolutionary 
rate is generally slow enough to be of use in disentangling past human migrations (Cann et al., 
1987). Despite this slow accumulation of nucleotide changes, the rate of mitochondrial genome 
evolution still far outpaces the nuclear genome (Brown et al., 1979), which suggests that it might 
provide some plasticity when encountering new environments or adverse conditions (Ruiz-
Pesini & Wallace, 2006). There has been some evidence to suggest disparity in metabolic rates 
between mitochondrial haplogroups, which might be related to adaptation to new environments 
encountered by populations as they moved out of Africa (Mishmar et al., 2003, Ruiz-Pesini et al., 
2004).  
 
Mitochondrial genetic diversity has been the focus of a number of studies in the Pacific. These 
have largely emerged from the perspective of disentangling population histories and settlement 
of the region (Redd et al., 1995, Lum & Cann, 2000, Trejaut et al., 2005, Kayser et al., 2006, 
Pierson et al., 2006, Soares et al., 2011, Delfin et al., 2012, Duggan & Stoneking, 2013, Duggan et 
al., 2014, van Oven et al., 2014), but may also be relevant when considering disease 
epidemiology in the region given the role of the mitochondria in innate immunity. These studies 
have found that the range of mtDNA macrohaplogroups found in the Pacific, Polynesians in 
particular, are relatively limited compared to other geographic areas. This, in part, is likely due 
to the colonisation processes and the relative geographic isolation of island groups in this 
locality. There is a distinct cline as one moves east across the Pacific, with B4a1a1 lineages (also 
known as the ‘Polynesian motif’), and derived sublineages, reaching frequencies of up to 96% in 
some Polynesian populations (Figure 4.9)(Kayser, 2010). Recent studies of whole mitochondrial 
genomes (as opposed to control region sequences, like many of the studies mentioned above) 
from the Pacific have shown that there is more diversity within the B4a1a1 haplogroup than 









Figure 4.9: Mitochondrial haplogroup variation in the Pacific based on control region genotyping (Kayser 
2010), note that the B4a1a1a lineage here has been downgraded to a B4a1a1 on the basis of the 16247G site 
which characterised this lineage has been found to be a mutational hotspot which as limited utility as a 
phylogenetic marker (Duggan & Stoneking, 2013). 
4.4 Conclusion 
 
Underlying the high rates of metabolic disease in Polynesian and other Pacific people there is a 
common immune pathway, the NLRP3 inflammasome. Given the shared ancestry of these 
populations, it may be that there is a shared genetic predisposition to an overactive NLRP3 
immune response that may have developed in response to pathogen exposure prior to or during 
the settlement process. Studies of mitochondrial genetic variation among Polynesian 
populations have revealed a high frequency of haplogroups belonging the B4-lineage.  
Given that mitochondria are emerging as a key player in innate immune responses, particularly 
their apparent involvement in the co-localisation of NLRP3 and ASC during the induction of 
NLRP3 inflammasome activation, mitochondrial genetic variation may influence the 
susceptibility to metabolic disease. This variation may be in the mitochondrial genome itself, or 
 
 




within mitochondrial genes embedded in the nuclear genome responsible aspects of 
mitochondrial function, for instance mitochondrial biogenesis.  
In the following two chapters, mitochondrial genetics and their potential impact on metabolic 
disease is going to be explored. Firstly, the role of the variation in the 16.5 kb mitochondrial 
genome itself and potential associations with disease among Polynesians will be investigated 
(Chapter 5). This will be followed up by a chapter looking at whether there may be differences in 
mtDNA copy number between those possessing metabolic diseases and those without, and 
exploring potential mechanisms for this difference (Chapter 6). There will be a more in depth 


















5 Mitochondrial variation as a potential determinant for 
disease susceptibility in the Pacific 
 
5.1 Introduction 
As discussed in the previous chapter, mitochondrial genetic diversity has been the focus of a 
number of studies in the Pacific. What has been established in the past two decades of research 
is that there is relatively more mitochondrial variation in Near Oceania where there is a long 
history of human occupation. Present are lineages which were introduced by the earliest 
colonists who arrived in the region at least 49,000 years ago (Summerhayes et al., 2010b), 
including M27, M28, M29, P and Q haplogroups (Kayser et al., 2006, Friedlaender et al., 2007, 
Kayser et al., 2008, Duggan et al., 2014), but there are also more recent Asian-derived lineages 
which were likely introduced to the region with the expansion of Austronesian-speaking 
colonists. Within Remote Oceania, Polynesia in particular, the range of mtDNA 
macrohaplogroups is relatively limited, with the B4a1a1 lineage (also known as the ‘Polynesian 
motif’) (Melton et al., 1995, Redd et al., 1995, Kayser et al., 2006, Duggan et al., 2014), and 
derived sub-lineages, being ubiquitous. This distribution of mitochondrial genetic variation may 
be significant in terms of susceptibility to complex metabolic diseases. The mitochondrial 
genome is a functionally important entity and as such, this variation may be having a phenotypic 
effect.  
There are a number of ways that mitochondrial genetic variation may affect susceptibility to 
metabolic disease. As discussed in the previous chapter, metabolism and immunity are 
inextricably intertwined, and mitochondria appear to play an integral role in the stimulation of 
the NLRP3 inflammasome, an important component of innate immunity. There is also the direct 
role that mitochondria play in the generation of ATP and cellular energetics that may contribute; 
with metabolic diseases being fundamentally a result of compromised metabolic function. 
Additionally, there is increasing evidence to suggest that heteroplasmy among mitochondrial 
populations within an individual may contribute to susceptibility to metabolic disease. Lastly, 
there is evidence for cross-talk between the mitochondrial and nuclear genomes, and it seems 
possible that variation in mtDNA may influence this inter-genome communication. Impaired 
communication between these genomes is also likely to effect organismal fitness. These are all 








5.1.1 Mitochondrial variation and energetics 
Mitochondria play a vital role in energy production, so it is unsurprising that changes to the 
mtDNA sequence have been hypothesised to alter mitochondrial efficiency. As previously 
discussed in Chapter 4, the mitochondrial genome encodes 13 polypeptides involved in OXPHOS, 
therefore non-synonymous changes to nucleotide sequence may affect the structure of the 
subunits and ultimately the enzyme kinetics. Human mtDNA is variable and approximately one-
third of sequence variants found in the general population may be functionally important 
(Wallace et al., 2010). As mentioned in Chapter 4, some of the variation that has arisen in the 
mitochondrial genome may be related to changing energy demands arising from altered 
environmental exposures (Mishmar et al., 2003, Ruiz-Pesini et al., 2004). 
All manner of environments – tropical, temperate, glacial, high altitude, desert, coastal - have 
been inhabited by humans since the departure of human populations from Africa some 60,000 
years ago, each environment possessing unique energetic demands, offering varying food 
sources, and with differing pathogen loads. The mitochondrial genome has been found to evolve 
much more rapidly than the nuclear genome (Brown et al., 1979), which may facilitate adaptive 
mitochondrial-nuclear co-evolution based on changing environmental demands (Levin et al., 
2014). The idea that the mitochondrial genome is adaptive has major repercussions when it 
comes to the mitochondrial molecular clock and estimations of lineage divergence. If the rapidly 
changing mitochondrial genome, as Wallace (2013) suggests, is allowing for a certain degree of 
metabolic plasticity, it may be that certain sequence changes, in combination with modern diets 
and lifestyles are having an adverse effect on health.  
This perspective remains contentious (Soares et al., 2009). There has been much debate over 
whether mtDNA is adaptive, and whether the observed variation is purely an artefact of the 
rapid dispersal of modern humans out of Africa and the population expansions that followed. 
This may have conflated what would otherwise be rare private mutations occurring at non-
synonymous loci, as there may not been sufficient time for purifying selection to occur and 
remove all of these variants (Ingman & Gyllensten, 2007, Soares et al., 2009). However, 
emerging evidence for differences in the rate of nuclear genome evolution between populations 
resulting from different environmental stimuli, for instance UV exposure in Europeans (Harris, 
2015), suggests that changes in environment may increase the rate of evolution. As such, the 
varying environments faced by anatomically modern humans as they departed Africa, or even 
within Africa itself, may have also provided selective pressures on the mitochondrial genome 










Figure 5.1: Cybrid: Cells depleted of mitochondria are merged with enucleated cells. The resulting cells have a 
common nucleus but differ in mtDNA 
In support of some of these energetic differences resulting from variation in mtDNA sequence 
suggested by Mishmar et al. (2003), Ruiz-Pesini et al. (2004) and others, is evidence coming out 
of “cybrid” studies. A “cybrid” is a term that describes a cytoplasmic hybrid (Figure 5.1). This 
method is currently the best tool to dissociate the action of mitochondrial genomes from that of 
the nuclear genes. At present, it is impossible to genetically engineer or transform the 
mitochondrial genome in vivo or in vitro. Because the nuclear genome encodes a further 70 gene 
products involved in OXPHOS, as well as a number of mitochondrial regulatory elements, 
population-specific changes to the nuclear genome could mask the effect of mitochondrial 
variants. Gómez-Durán et al. (2010) were able to demonstrate that there were differences in 
mtDNA and mtRNA levels, mitochondrial protein synthesis, cytochrome oxidase activity and 
amount, normalised oxygen consumption, mitochondrial inner membrane potential and growth 
capacity between cybrids containing mitochondrial haplogroup H compared to haplogroup Uk. 
Furthermore, Mueller et al. (2012) were able to show that cells containing mitochondria 
belonging to haplogroup T had a higher growth rate than those belonging to haplogroup H, 
though the normalised activity rate of the OXPHOS enzymes in the respective mitochondria did 
not differ significantly. The haplogroup T cells were also found to be less susceptible to oxidative 
stress (Mueller et al., 2012). 
Lin et al. (2012) prepared cybrids containing mtDNA from ethnically-Chinese Taiwanese. Cybrid 








was found to have a significantly lower oxygen consumption rate and higher mitochondrial 
membrane potential compared to F1a, B5, D4a, D5a, and N9a cybrids, however they were more 
susceptible to induced oxidative stress (Lin et al., 2012). This may be significant because of links 
between metabolic syndromes such as atherosclerosis, diabetes and hypertension and oxidative 
stress (Roberts & Sindhu, 2009). 
 
5.1.2 Mitochondrial genetic variation and immunity 
As discussed in the previous chapter, in addition to being a key player in metabolism, the 
mitochondrion also plays a vital role in the development of inflammation and the clearance of 
pathogens, being the largest producer of highly toxic radical oxygen species (ROS) in the cell. 
Indeed, there are data which suggest that not only NLRP3-mediated inflammation (as discussed 
in Chapter 4) but also retinoic acid inducible genes (RIG-1)-like receptor (RLR) and Toll-like 
receptor (TLR) signalling pathways are inextricably linked to mitochondrial function (Cloonan & 
Choi, 2013). These pathways all play an important role in innate immunity.  
Cybrid studies have shown that mtDNA variation can affect the expression of nuclear genes 
involved in the innate immune response, particularly inflammatory and complement pathways 
(Kenney et al., 2014a, Kenney et al., 2014b). This could mean that mitochondrial variants are 
subject to selection mediated by exposure to infectious diseases. While most of the studies 
discussed above regarding adaptive mitochondrial genomes (e.g. Mishmar et al., 2003 and Ruiz-
Pesini et al., 2004) suggest climatic stimuli contribute to selection, this could very well transfer 
over to different pathogenic exposures. There have been several studies that have shown that 
common mitochondrial variants can influence the likelihood of survival following acute sepsis 
(Baudouin et al., 2005, Jiménez-Sousa et al., 2015). Infectious disease has been shown to have a 
profound selective effect on the nuclear genome (Kwiatkowski, 2005). There is no reason to 
believe that the mitochondrial genome could not be similarly affected. If mitochondrial genomes 
have been subject to selection on the basis of phenotypic differences in immune function, this 
may also translate to susceptibility to auto-inflammatory and metabolic disease.  
 
5.1.3 Mitochondrial-Nuclear Genome Cross-talk/Interaction 
While variation in the mitochondrial genome may be having a direct effect on metabolism, as 
well as influencing the expression of genes involved in innate immunity, the cybrid studies 
discussed earlier show that the mitochondrial genome is having a more broad effect on gene 
expression in the cell. There is increasing evidence to suggest that the mitochondria can act as 








mitochondrial function being encoded by the nuclear genome rather than by the mitochondria 
itself (Lopez et al., 2000), inter-genome communication is essential for mitochondrial function, 
and indeed, the optimal functioning of the cell as a whole. The cell needs to know when to 
manufacture the protein subunits, which then need to be exported through  the cytosol to the 
mitochondria, and because cells usually contain a high number of mitochondria, the cell also 
needs to get the products to the right mitochondrion. Signalling occurs in a number of ways.  
Specific variants may induce compensatory signals between the nuclear and mitochondrial 
genomes and contribute to enhanced fitness in younger individuals that deteriorates with age, 
contributing to age-related disease. While there is little evidence for this in humans thus far, a 
study of Drosophila found that an amino acid change in the ATP6 protein of the electron 
transport system complex V in OXPHOS resulted in metabolic compensatory mechanisms within 
several metabolic pathways, which broke down as the individuals aged. The flies with the 
mutations were found to have enhanced fertility rates at a younger age but a shorter life 
expectancy with phenotypic defects that appeared with age (Ballard et al., 2007, Ballard & 
Melvin, 2011). While fruit flies clearly possess some significant differences in metabolic 
demands compared to humans, there may be a similar compensatory effect in humans where 
mtDNA mutations that enable an increase in performance in early life, contribute to disease in 
aged individuals (Ballard & Pichaud, 2014). An example of this may be mitochondrial 
haplogroup V, which appears to be overrepresented in some studies of endurance athletes 
(Nogales-Gadea et al., 2011), and also in individuals who suffer type 2 diabetes (Soini et al., 
2012) and diabetes-related renal failure (Achilli et al., 2011). 
As well as encoding thirteen subunits of oxidative phosphorylation, the mitochondrial genome 
also encodes in excess of 2000 noncoding RNAs (Mercer et al., 2011, Rackham et al., 2011) and 
also a number of small peptides (Guo et al., 2003, Lee et al., 2015a). These mitochondrial 
products may be affecting nuclear gene expression, and variation within these noncoding RNAs 
might influence the intergenomic cross-talk which must occur for normal cellular function. 
Additionally, this year, there has been the discovery of a short open reading frame encoding a 
small peptide, MOTS-c, which has been implicated in having a role in maintaining metabolic 
homeostasis (Lee et al., 2015a). This is not the first of such molecules to be discovered with 
humanin previously being identified and implicated in Alzheimer’s disease (Guo et al., 2003). 
There have been further open-reading frames proposed (Faure et al., 2011), as well as the 
potential for functional anti-sense tRNAs (Seligmann, 2012), which may complicate the picture 
further should they be robust to rigorous testing. It is clear that the full complexity of the 








5.1.4 Mitochondrial heteroplasmy 
Although each individual is generally characterised by a single mtDNA type, each individual 
actually possesses a population of mitochondrial genomes, and there may be multiple mtDNA 
types present. This is described by the term ‘heteroplasmy’. Originally, heteroplasmy was 
thought to be quite rare in healthy individuals (Monnat & Loeb, 1985, Monnat & Reay, 1986), 
though it had been detected in those with mitochondrial disease (Holt et al., 1990, Shoffner et al., 
1990, Boulet et al., 1992), however many non-disease related heteroplasmies have since been 
identified (Comas et al., 1995, Jazin et al., 1996, Elliott et al., 2008, Irwin et al., 2009). Advances 
in sequencing technology have lead to the ability to sequence mitochondrial genomes at higher 
resolution, thus allowing the detection of low-level heteroplasmy (Li et al., 2010, Sosa et al., 
2012).  
Mitochondrial heteroplasmy can be inherited – this is likely the basis of the divergence of 
different mitochondrial haplogroups – or it can develop in an individual over the course of their 
life. As discussed previously in Chapter 4, the inheritance of mtDNA is quite different from that 
of nuclear DNA. The mitochondrial genome does not undergo recombination and is solely 
transmitted through the maternal line. This continuity in maternal mtDNA transmission is 
amplified with mitochondria passing through an extreme bottleneck during postnatal 
folliculogenesis, reducing the variation in the mitochondria passed on to the next generation 
(Wai et al., 2008) (though it is perhaps notable that there is a correlation between advanced 
maternal age and an increase in heteroplasmies present in oocytes (Rebolledo-Jaramillo et al., 
2014)). This process effectively limits the number of private mutations that may get passed onto 
the next generation and provides some stability in the mtDNA sequence. However, in somatic 
tissues, as a result of the relatively high turnover of mitochondria (even in post-mitotic cells), 
mtDNA is constantly going through replication, and thus there is plenty opportunity for small 
errors in DNA replication to occur during the lifetime of the individual and for changes to the 
nucleotide sequence to occur.  
Assisting this process may be the existence of hypervariable sites that are hotspots of mutation 
(Stoneking, 2000); this is supported by a study that found three heteroplasmies occurring at the 
same position in two different individuals who belonged to not only different mitochondrial 
haplogroups but also different populations (Li et al., 2010). It is probable that these 
heteroplasmies were independent events, but it is highly improbable for them to occur at the 
same positions if mutations are random throughout the genome, suggesting that some positions 
are more variable than others. If these changes to the sequence are not overtly pathogenic, these 
may then get passed onto more mitochondria as further mitochondrial biogenesis occurs. 








mtDNA accumulate, there can be pathogenic effects (Stewart & Chinnery, 2015)(Figure 5.2). 
There is increasing evidence to suggest that many mitochondriopathies are a result of changes 
that occur during the life of the individual rather than inherited at birth, which may account for 
susceptibility to age-related disease in some (Ozawa, 1995, Bender et al., 2006, Li et al., 2015). 
As previously mentioned, mitochondrial heteroplasmy has been implicated in disease. While 
being prevalent in the human population, mitochondrial heteroplasmy has been found to be 
overrepresented in disease-associated sites and specifically, heteroplasmies at non-synonymous 
and tRNA loci have been found to be highly pathogenic (Ye et al., 2014). In vitro studies of 
heteroplasmic mutations using cybrid cell lines (Koga et al., 1995), and studies using single cells 
isolated from tissue biopsy samples (Boulet et al., 1992), have shown that the proportion of 
mutated mtDNA must exceed a critical threshold level (~ 60-80%) before phenotypic changes 
can be detected using laboratory techniques. The threshold is likely to vary from tissue to tissue 
and mutation to mutation (Stewart & Chinnery, 2015). These differences in precise thresholds 
may contribute to clinical heterogeneity of mitochondrial disease caused by the same variants. 
The precise reasons for high levels of heteroplasmy causing pathogenesis are not entirely 
understood, though it may be that it contributes to poor signalling between the mitochondrial 
and nuclear genomes. As previously discussed, this intergenome communication is vital for 
maintaining homeostasis, and perturbations to this cross-talk are thought to contribute to 
pathology (Horan & Cooper, 2014). 
Given the pre-existing literature surrounding mitochondrial heteroplasmy and its potential 
pathogenicity, it may be worth exploring mitochondrial heteroplasmy in the context of gout and 
other metabolic traits among Polynesians.  
 
Figure 5.2: mtDNA heteroplasmy threshold – the cell can usually tolerate a high threshold of heteroplasmic 
mtDNA. For pathogenic variants, there seems to be a threshold of >80% before phenotypic effects are 









5.1.6 Previous studies looking at mitochondrial variation and metabolic disease 
Some of the earlier disease studies investigated the role of individual mtDNA SNPs rather than 
SNPs as a collective haplotype (Poulton et al., 1998, Poulton et al., 2002, Saxena et al., 2006). 
Such studies have yielded inconsistent results depending on the cohort used in the investigation. 
In genetically diverse populations with many different mitochondrial haplotypes, identification 
of variants associating with metabolic traits has largely been unsuccessful. For example, Saxena 
et al. (2006) studied mitochondrial variants in a cohort of 6,608 ‘white’ subjects recruited from 
Scandinavia, Poland and North America. With participants in such studies being pooled across 
wide geographic areas with diverse population histories and with much mitochondrial diversity, 
SNPs associated with disease are likely to be masked by this inherent heterogeneity. Where less 
genetically diverse populations have been used, for instance Poulton et al. (1998), there is less 
background noise so variants associated with disease can be detected more easily. In this case, 
Poulton et al. (1998) were able to identify an association between metabolic disease and the 
T16189C variant in a cohort of 251 English men, predominantly of Anglo-Saxon-derived 
ancestry.  
Evidence can be conflicting between studies. For instance, the European mtDNA haplogroup J 
has been associated increased risk of type 2 diabetes in populations of European descent 
(Mohlke et al., 2005, Crispim et al., 2006). Conversely, there have also been connections between 
this haplogroup and longevity (De Benedictis et al., 1999, Rose et al., 2001). This may suggest 
that there is some interaction with nuclear DNA variants or environmental factors – or indeed, 
that the associations are spurious – as metabolic conditions such as type 2 diabetes are not 
usually correlated with longevity. Likewise, A3243G, a locus which is thought to contribute to 
susceptibility to type 2 diabetes and insulin resistance, is underrepresented among Europeans 
belonging to mitochondrial haplogroup J (Pierron et al., 2008), which is interesting given the 
apparent susceptibility of people belonging to this haplogroup to diabetes. This may be because 
additional mutations to the haplotype increase the stress elicited by the molecule, which results 
in negative selection against this at the embryo or germ line stages (Pierron et al., 2008).  
Exploring the effect of mitochondrial haplotypes as a whole and their association with obesity 
and other metabolic traits may offer insight into disease susceptible lineages. Because the 
mitochondrial genome does not recombine at an appreciable frequency and is subject to strong 
purifying selection, certain variants are often inherited together. This approach has also yielded 
variable results. A study of 2000 Danish participants was unable to find any association between 
mitochondrial haplogroup and type 2 diabetes (Li et al., 2014), while Liou et al. (2012) found 








associated with type 2 diabetes while D4 derived lineages had a protective effect. This particular 
finding is interesting in light of the predominance of B4-derived lineages among Pacific 
populations. 
5.1.7 Whole mitochondrial genome sequencing versus control region genotyping 
The first complete mitochondrial genome was sequenced in 1981 (Anderson et al., 1981). Most 
early studies of mitochondria focused on the control region, a non-coding region of the 
mitochondrial genome that has been found to be a hotspot for variation (Aquadro & Greenberg, 
1983). The non-coding nature of the region has allowed it to accumulate more mutations than 
the coding regions, though this variation is still constrained by the origin of replication of one of 
the strands and the origin of transcription for both strands being present in this region. Because 
of the variable nature of this region, it was soon realised that it was possible to identify 
population-based variation, which had had a lot of utility in disentangling past human 
migrations (Cann et al., 1987). Additional to this, restriction fragment length polymorphism 
(RFLP) analysis was employed to identify other features of the mitochondrial genome that 
varied from population to population. An example of this is the 9 base pair deletion that is one of 
the defining features of the B macrohaplogroup (Redd et al., 1995).  
With the advent of massively parallel high throughput sequencing technology, in particular next 
generation sequencing technologies, it has been possible to sequence whole mitochondrial 
genomes relatively cheaply en masse. Prior to this, whole mitochondrial genome sequencing was 
costly and involved either primer-walking around the mitochondrial genome or shotgun 
sequencing methods with the use of molecular cloning (Burger et al., 2007), which was a time 
consuming and costly process. The capillary sequencing technology requires the use of only a 
single template in each sequencing reaction, and the readout is a consensus of the reaction 
within the samples. In contrast, next generation sequencing allows for the reading of many 
different molecules in a single sequencing run with the ‘sequencing by synthesis’ approach, 
where barcoded DNA libraries are dispersed on a plate, and emulsion PCR is carried out. This 
allows not only many molecules to be sequenced at once, but many individuals, as unique 
barcodes can be ligated to the DNA template enzymatically, allowing hundreds of individuals to 
be genotyped in a single sequencing operation. The ability to sequence whole mitochondrial 
genomes has a lot of utility, not only in contributing to our understanding of past human 










There are two separate hypotheses tested in this chapter. 
1)  Mitochondrial genetic variation may be contributing to differences in energetics, which 
may underlie the high prevalence of obesity among Polynesian populations. Here, BMI is 
used as a proxy for energy metabolism, being a phenotype controlled through energy 
homeostasis. 
2) Mitochondrial genetic variation may be contributing to differences in immune response, 
which may contribute to the high prevalence of metabolic disease in Polynesians. Gout is 
used as a proxy for immune function, being an auto-inflammatory condition resulting 
from the activation of the NLRP3 inflammasome. 
Given the mitochondrial diversity, or lack thereof, and the widespread occurrence of high BMI 
and gout among Pacific people, mitochondrial haplotype may be contributing to susceptibility to 
metabolic disease or high BMI. To address this, mtDNA sequencing of a cohort of Polynesians 
has been undertaken to test for over-representation of certain haplogroups and other 
mitochondrial variation.  
 
5.2 Methods 
5.2.1 Sample selection 
The samples for this study were selected from a pre-existing cohort that was recruited from 
2006 to 2013 for the study of metabolic diseases. These participants were recruited from 
throughout New Zealand; those with gout were predominantly recruited from rheumatology 
clinics, workplaces and community focal points from Auckland, Bay of Plenty, Wellington, 
Christchurch and Dunedin, while controls with no self-reported history of gout were sampled 
from workplaces and community focal points in Auckland. Ethical approval for the collection of 
the samples and subsequent analysis was obtained from the NZ Multi-Region Ethics Committee 
(MREC 05/10/130). Written consent was acquired from all subjects for collection of blood 
samples for DNA extraction and biochemical measurements. Alongside the informed consent, 
participants were asked to complete a questionnaire focusing on lifestyle factors and ancestry. 
As of 2015, this cohort comprised 2359 individuals who self-declare some portion of Polynesian 
ancestry, with varying amounts of admixture, predominantly with Europeans. 
A subset of this cohort was selected with the criterion of an adjusted BMI calculation for 








body fat percentage Polynesian populations possess. This adjustment involves the following 
equation:  
𝐵𝑜𝑑𝑦 𝑓𝑎𝑡 𝑖𝑛 𝑘𝑔 (𝑓𝑜𝑟 𝑚𝑎𝑙𝑒𝑠) =  −30.56 + 1.817 × 𝐵𝑀𝐼 
The value that comes out gives a comparable body fat mass to European BMI calculations. For 
the East Polynesian cohort (comprised of NZ Māori, Cook Islanders and Tahitians living in NZ), 
112 individuals with an adjusted BMI of greater than 33 and 118 individuals with an adjusted 
BMI less than 30 were selected for sequencing. For the West Polynesian cohort (comprised of 
Samoans, Tongans, Tokelauans, Niueans and Tuvaluans), 110 individuals with an adjusted BMI 
of greater than 33 and 105 individuals with an adjusted BMI of less than 31 were selected for 
genotyping. Other metabolic characteristics for the samples chosen can be viewed in Table 5.1. 
All individuals chosen were male, 40 years of age or greater and had self-reported at least 50% 
Polynesian ancestry, specifically with a Polynesian maternal grandmother. Individuals with 
greater proportions of Polynesian ancestry were targeted (assessed by looking at the number of 
self-declared Polynesian grandparents) during sample selection to try to mitigate the effect of 
non-Polynesian admixture. 
Table 5.1: Mean metabolic characteristics of the 445 Polynesian men whose mitochondrial genomes were 
sequenced. 
Variable WP EP Combined 
 High BMI Low BMI High BMI Low BMI High BMI Low BMI 
n 110 106 113 121 223 227 
Age 50.7±0.8 53.3±0.8 54.0±0.9 55.8±0.9 52.2±0.6 54.5±0.7 
% Polynesian Ancestry 0.97±0.01 0.96±0.01 0.93±0.01 0.97±0.01 0.95±0.01 0.97±0.01 
Adjusted BMI* 45.4±1.0 24.6±0.4 44.4±1.1 22.5±0.5 44.8±0.8 23.4±0.2 
BMI (kg/m2) 41.8±0.6 30.3±0.3 41.3±0.6 29.2±0.3 41.5±0.43 29.7±0.18 
Triglycerides (mmol/L) 2.59±0.17 2.08±0.13 2.70±0.19 2.26±0.21 2.64±0.13  2.17±0.12 
HDL (mmol/L) 0.95±0.03 1.08±0.03 1.02±0.04 1.19±0.04 0.98±0.02 1.13±0.02 
Serum Urate (mmol/L) 0.43±0.01 0.42±0.01 0.44±0.01 0.41±0.01 0.44±0.01 0.42±0.01 
 
5.2.2 Amplification of mitochondrial genome 
Where the quality of the extracted DNA allowed, the complete mitochondrial genome was PCR 
amplified in two overlapping fragments of 8511 bp (LR_1) and 8735 bp (LR_2) (Clarke et al., 
2014). Long range PCR was undertaken using two long range products: Roche’s Expand Long 
Range dNTPack and the following reagent concentrations: 1x Long Range Buffer, 0.4 µM of each 
primer, 0.4 µM of each dNTP, 3% (v/v) DMSO (dimethyl sulfoxide) and 2 units of enzyme; and 5 
Prime PCR Extender System with the following reagent concentrations: 1x Tuning Buffer, 0.4 µm 
of each primer, 0.5 µM of each dNTP, 1 unit of enzyme. 3 µL of DNA extract was added for a total 
reaction mix of 30 µL. The 5 Prime PCR Extender System product was used on difficult to 








consisted of an initial denaturation period of 92°C for 2 minutes, followed by 10 cycles of 92°C 
for 10 seconds, 55°C for 10 seconds and 68°C for 8 minutes and 30 seconds. This was followed 
by 20 cycles of 90°C for 10 seconds, 55°C for 15 seconds 68°C for 8 minutes and 30 seconds, 
with an increase 20 seconds at 68°C each cycle. The cycling ended with a final extension at 68°C 
for 7 minutes. The conditions for the 5 Prime PCR expander system reactions consisted of an 
initial denaturation period of 93°C for 3 minutes, followed by 10 cycles of 93°C for 15 seconds, 
55°C for 30 seconds and 68°C for 8 minutes. This was followed by 20 cycles of 93°C for 15 
seconds, 55°C for 30 seconds and 68°C for 8 minutes, with an increase of 20 seconds at 68°C 
each cycle. The cycling ended with a final extension step 68°C for 10 minutes. PCR products 
were visualised under UV on SYBR Safe (Invitrogen) stained 2% agarose gels. The samples that 
could not be successfully amplified in two fragments were amplified in three or four fragments 
with primer pairs LR_1a, LR_1a, LR_2a and LR_2b. 
Products were purified using the AMPure XP Kit (Beckman Coulter) and solid-phase reversible 
immobilisation (SPRI) technology. A PicoGreen quantification assay was used to determine the 
quantity of each PCR product to be pooled for fragmentation. 
5.2.3 Fragmentation  
PCR products from each individual were pooled in equimolar ratios, and 1 µg of DNA was 
fragmented by sonication using a PicoRuptor sonicator. A total of 12 samples could be sonicated 
at once for 8 cycles of 15 seconds on and 45 seconds off. Sonication was carried out in order to 
reduce the size of the fragments to less than 1000 base pairs.  
 
5.2.4 Barcoding and library preparation for 454 Sequencing  
Barcoding involved end-repair, the ligation of hairpin shaped barcodes, a fill-in step and 
subsequent restriction digest to cleave the hairpin, an approach known as parallel-tagged 
sequencing as described by Meyer et al. (2008). The barcoded DNA was subsequently library 
prepped for sequencing and sequenced on a GS FLX sequencer by the University of Otago High-
Throughput Sequencing Unit as described by Clarke et al. (2014). Raw data processing also 
followed the pipeline presented by Clarke et al. (2014). 
 
5.2.5 Library preparation for Illumina MiSeq Sequencing 
An overview of the laboratory methods, beginning with the DNA extracts and ending with the 









Figure 5.3: a summary of the laboratory methods required in prepping whole mt genomes  for sequencing, 
starred steps indicated enzymatic reactions 
DNA extracts 
LR PCRs* 
Sonicated into 200-300bp 
fragments using the PicoRuptor 
DNA concentration quantified 
using a VIKTOR plate reader 
Long range fragments pooled in 
equimolar amounts for each 
individual 
DNA end repair* (T4 DNA 
polymerase, T4 PNK) 
A-tailing of DNA* using Klenow-Exo 
Ligation of Illumina compatible P5 
and P7 adapters* (T4 ligase)  
Indexing of DNA libraries via PCR 
extension primers* (dual indexing)  
DNA concentration quantified 
using a VIKTOR plate reader 
Libraries pooled in equimolar 
amounts 
Sent to NZGL for 










The protocol and adapter sequences used in library preparation were adapted from the 
published protocols by Meyer & Kircher (2010) and Kircher et al. (2012). Library preparation 
involved end-repair steps (blunt-ending and 3’ adenylation), ligation and the addition of index 
sequences using PCR. Each enzymatic step was followed by an AMPure purification as described 
earlier. The blunt-ending of the DNA fragments used the following reagent concentrations: 1x 
Buffer Tango, 100 µM of each dNTP, 1 mM ATP, 0.5 U/µL T4 polynucleotide kinase and 0.1 U/µL 
T4 polymerase. The total reaction volume was 40 µL, including 250 ng of template DNA, which 
was incubated in a thermocycler for 15 minutes at 12°C followed by 15 minutes at 25°C. Sticky 
ends were added to the DNA by A-tailing in an attempt to circumvent the problem of inefficient 
blunt ligation which was faced in the previous library preparation process for 454 sequencing. 
This reaction consisted of 1x NEBuffer 2, 0.1 mM dATP and 1 unit of Klenow fragment, and was 
incubated in a thermocycler for 30 minutes at 37°C. 
 
Modified custom Solexa-compatible adapters (modified from (Meyer & Kircher, 2010) with an 
additional T added to reflect the A-tailed template) were next ligated to the DNA in a reaction 
with the following reagent concentrations: 1x T4 ligase buffer, 0.125 U/µL T4 ligase. The 
reaction was incubated for 1 hour at 22°C in a thermocycler. The adapter-ligated DNA template 
had dual-indexes added using a PCR step (Kircher et al., 2012), with 20 cycles of denaturation, 
annealing and extension. This PCR consisted of the entirety of the adapter-ligated DNA, 1x Kapa 
HiFi buffer, 0.3 µM of each primer, 0.3 µM of each nucleotide and 1 unit of Kapa HiFi Hot Start 
enzyme, in a volume of 50 µL. This step enriches the sample for template that had successfully 
ligated adapters, as well as giving each sample a unique combination of barcodes. 
The barcoded libraries were then quantified using a PicoGreen quantification assay, prior to 
pooling in equimolar ratios. The pooled library was sent to New Zealand Genomic Limited 
(NZGL) for sequencing on an Illumina MiSeq Sequencing Platform using a 2x 250bp reagent kit. 
 
5.2.6  TaqMan Genotyping of A6905G 
TaqMan assays are a quick and easy way of genotyping a single locus very rapidly. Here, 
TaqMan genotyping was used to follow up a variant that was associated with BMI in the 
sequencing data produced above. A custom TaqMan probe was designed for the 6905G variant 
using the Applied Biosystems web tool. A total of 1946 individuals who had Polynesian ancestry 
were genotyped using a Lightcycler 480 Real-Time PCR System. Of these, 446 had previously 
had their whole mitochondrial genomes sequenced, and thus were removed from subsequent 








excluded from further analysis on the grounds of them being unlikely to have a Polynesian 
mitochondrial genome. 
The data were then downloaded and statistical analyses were performed to test for associations 
with metabolic traits. Logistic regressions were performed in R Studio, as described later. 
 
5.2.7 Bioinformatics processing of MiSeq Sequence Data 
5.2.7.1 Raw data processing 
The raw sequencing files were run through the pipeline described below. This pipeline was put 
together and is curated by James Boocock. 
Sequence reads in the FASTQ format were aligned to the human reference genome 
(GRCH37/hg19) using the maximal exact matches (MEM) command of the Burrow’s Wheeler 
Aligner (BWA) (v0.7.13) (Li, 2013). The full reference was chosen for alignment to reduce the 
impact of nuclear mitochondrial insertions (NUMTs). NUMTs that map to the mitochondrial 
reference (rCRS) (Andrews et al., 1999), but included in other sequences within the human 
reference genome (as many as 755 mitochondrial insertions into the nuclear genome have been 
detected in the build 37 of the Human Reference Genome (Ramos et al., 2011), some of which 
are close to whole mitochondrial genomes in length), will have a reduced mapping quality as a 
consequence of having multiple possible locations to map. This reduces the probability that 
NUMTs present in the reference genome will impact on downstream analyses. PCR duplicates 
were removed from the resulting BAM files using Picard’s MarkDuplicates (v1.114) 
(http://broadinstitute.github.io/picard/). Read groups were added using Picard’s 
AddOrReplaceGroups, and reads mapping to the mitochondrial reference sequence were 
extracted. Local realignment was performed using the Genome Analysis Toolkit’s (GATK v 3.4.0) 
(McKenna et al., 2010) IndelRealigner with a set of mitochondrial insertions and deletions 
(INDELS) annotated in HmtDB (Rubino et al., 2012) and MITOMAP (Brandon et al., 2005). These 
realigned BAM files were then sorted and indexed using SAMtools (v0.1.19) (Li et al., 2009). All 
the above steps were run with GNU parallel (Tange, 2011) (a shell tool for executing jobs in 
parallel) improving the run-time of each step significantly. Coverage plots were created using 
the R programming language (v3.2.0) with the package ggplot2 (v1.0.1)(Hadley, 2009). 
5.2.7.2 Variant calling and filtering 
Homoplasmic single nucleotide polymorphisms (SNPs) and insertions and deletions (INDELs) 
were identified using the GATK HaplotypeCaller (v3.4.0) (DePristo et al., 2011) with the ‘-ploidy’ 








within a single cell, usually only one dominant lineage is inherited. To simplify downstream 
association analyses the resulting variant call format (VCF) file was split into one containing 
only bi-allelic SNPs and INDELs, and one containing all other SNPs and INDELs. For the 
homoplasmic analyses only the former was considered. Both these files were filtered at the 
sample level to remove any SNP having a depth (DP) < 10, genotype quality (GQ) < 30, mapping 
quality (MQ) < 30, and a Phred scaled P-value for a Fisher’s exact test for strand bias 
(FisherStrand) > 60. Furthermore, we calculated the number of bases that support the non-
called allele, if this fraction was greater than 10% it was considered a putative heteroplasmic 
variant and was removed from this homoplasmic analysis.  
 
To identify heteroplasmic variants, we used the GATK HaplotypeCaller (v3.4.0) with the ‘-ploidy’ 
option set to 2. A variant was considered a candidate heteroplasmic variant, if at least two 
samples had heterozygote calls and the fraction of total bases supporting each of the alleles was 
greater than 10%. The 10% threshold was chosen to ensure that low frequency sequencing 
errors that are present when sequencing with the Illumina MiSeq were not identified as 
heteroplasmies. This VCF files was filtered for DP < 10, GQ < 30, MQ < 30, and FisherStrand > 60. 
In addition to the HaplotypeCaller, another variant caller freebayes (0.9.21) (Garrison & Marth, 
2012) with the same set of filters was used to identify heteroplasmic variants. For downstream 
analysis, only variants present in both files were considered. 
 
Annovar was used to annotate the gene(s) associated with each variant in the VCF file (Wang et 
al., 2010). This was done to facilitate burden analyses of genes . 
 
5.2.7.3 Haplogroup assignment. 
The VCF containing only bi-allelic SNPs and INDELS was converted to the Haplogrep (.hsd) 
format file using a locally developed python script 
(https://github.com/smilefreak/ancient_dna_pipeline/blob/master/python_scripts/vcf_to_fasta
.py). The web-interface to Haplogrep, which utilises Phylotree version 16, was used to assign 
haplogroups to each sample. Haplogrep is a web-based application that assists with the 
assignment of haplogroup calls (Kloss-Brandstätter et al., 2011). The haplogroups are 
determined using a periodically updated database of worldwide mitochondrial genotypic 
variation named Phylotree (van Oven & Kayser, 2009). The software determines the ten most 
likely haplogroups matches based on the SNPs present in the input samples and shows why it 
has grouped the samples into these groups by compiling a list of the expected SNPs and any 








private mutations, which are defined as variants observed in the sample but which are not 
associated with the haplogroup assignment, and global private mutations, which are mutations 
that have not previously been seen in Phylotree and thus, that the programmers have decided 
are likely the result of “inconsistent alignments, phantom mutations or point heteroplasmies”, 
but which might represent real, novel SNPs. Sometimes these haplogroup calls need to be 
adjusted by eye because of discrepancies in how insertions and deletions are called, however 
this software is useful for grouping samples in a phylogenetic manner as it is able to rapidly 
compare the SNPs in each uploaded sample with known haplogroups and give the most 
probable match. 
5.2.8 Statistical analyses 
Statistical analysis was carried out in R-studio. Regression analysis was used to investigate 
relationships between mitochondrial variation and various phenotypic traits in this study. For 
binary variables, for instance gout status or stratified BMI (the grouping of individuals into two 
groups based on having BMI greater than or less than 34 kg/m2), logistic regression was used. 
For continuous variables, such as the concentration of various biochemical markers in blood, a 
standard linear regression was performed. The main focus was gout status and BMI so as to test 
the two main hypotheses investigated in this chapter. The relationships of other metabolic 
markers (such as triglycerides, HDL levels and urate) were also explored because these have not 
been examined in relation to mitochondrial variation in Pacific people previously. In each test, 
age, East or West Polynesian ancestry and percentage Polynesian ancestry (as calculated on the 
basis of self-declared Polynesian grandparentage) were adjusted for. Accounting for degree of 
Polynesian ancestry is important because admixture may confound associations. 
Associations between both haplogroup variation and individual SNP variants and various 
phenotypes were performed. For testing for associations with haplogroups, only those 
haplogroups previously identified in Phylotree possessing greater than 10 individuals were 
utilised. For associations between individual mitochondrial variants, there was a main focus on 
variants that occurred at a frequency greater than 0.05. For these common variants, linear and 
logistic regressions were undertaken (as described above). There was no adjustment for 
multiple testing such as a Bonferroni Correction performed for the reason that most of the 
variants were in linkage disequilibrium, which made determining the absolute number of 
independent tests challenging. 
5.2.8.1 Heteroplasmies 
When examining the common SNP variant data (MAF > 0.05), it was noticed that some variants 








be highly variable. The region was visually inspected using the Broad Institute’s Integrated 
Genomics Viewer (IGV) (Thorvaldsdóttir et al., 2013) and multiple haplotypes were possessed 
by some individuals. This led to this region to be explored more in depth. 
Variant calling was redone using the GATK HaplotypeCaller (v3.4.0)(DePristo et al., 2011) with 
the ‘-ploidy’ option set to 2, to produce diploid SNP calls. From individuals who had greater than 
30 unique reads mapping in the region of interest, an allelic fraction was produced by dividing 
the number of reads mapping to alternate alleles by the total number of reads mapping at each 
variable position in this 16050-16189 mitochondrial region.  
i.e.: 𝐴𝑙𝑙𝑒𝑙𝑖𝑐 𝑓𝑟𝑎𝑐𝑡𝑖𝑜𝑛 =  𝑛 𝑎𝑙𝑡𝑒𝑟𝑛𝑎𝑡𝑒 𝑎𝑙𝑙𝑒𝑙𝑒 𝑟𝑒𝑎𝑑𝑠 𝑎𝑡 𝑝𝑜𝑠𝑖𝑡𝑖𝑜𝑛𝑛 𝑜𝑓 𝑟𝑒𝑎𝑑𝑠 𝑚𝑎𝑝𝑝𝑖𝑛𝑔 𝑡𝑜 𝑝𝑜𝑠𝑖𝑡𝑖𝑜𝑛  
An allelic fraction threshold of 0.10 was used to subset the data into two groups, which 
represented those who possessed heteroplasmy at these positions at an appreciable frequency 
and those who did not. These groups were then statistically analysed using logistic regression to 
test for association with gout, adjusting for age, East versus West Polynesian ancestry and the 
proportion of self-declared Polynesian grandparentage. 
Further statistical tests were undertaken to explore potential relationships between allelic 
fractions (as a measure of the amount of heteroplasmy in an individual) and among those 
possessing mtDNA haplogroup B lineages. 
5.2.8.2 SKAT test for burden of mtDNA variants 
Testing for associations between rare variants and disease is complicated by the nature of the 
variants being uncommon, which severely limits statistical power. Instead, a sequence kernel 
association test (SKAT) can be performed. This tests the association between genetic variants 
(common and rare) in a region and a continuous or discrete trait, allowing for the detection of a 
burden of variants rather than association between individual variants on their own (Wu et al., 
2011). It does this by aggregating the individual score test statistics of SNPs in a SNP set and 
calculates SNP-set level P-values. SKAT tests were performed looking at the association of 
variants in mitochondrial genic regions and the dichotomous traits of gout status and stratified 
BMI. Age, East versus West Polynesian ancestry and percentage of self-declared Polynesian 
grandparental ancestry were adjusted for in these tests. 
5.2.8.3 Testing for Associations with Maternal Grandparental Ancestry 
Because there was a high concordance between self-reported maternal grandparental ancestry 
and haplogroup calling from the sequencing data (99.6% concordance), in addition to statistical 
analyses between the sequencing data and various phenotypes described above, further testing 








disease status among those with three grandparents of Polynesian ancestry and one 
grandparent of European ancestry from the extended cohort described earlier that had not had 
mtDNA sequenced. This test was undertaken to try and detect any differences in inferred 
mitochondrial lineage and disease – with 96% of the participants belonging to the same 
mitochondrial macrohaplogroup, there are difficulties in assessing whether these individuals 
may all possess a predisposition to disease from possessing a mitochondrial lineage belonging to 
this haplogroup. 
5.3 Results 
5.3.1 454 Sequencing results 
Sequencing was initially carried out in 4 sequencing runs on the 454 Junior Sequencer. 
Unfortunately, the quality of the sequence was not good enough to analyse. Many reads were not 
properly barcoded and despite efforts in the lab to reduce this loss of reads by increasing 
ligation times and reducing the number of individuals included in a run, there were still a 
significant proportion of reads which lacked barcodes making it impossible to assign them to an 
individual. As a result of this reduction of usable data, there were substantial numbers of 
individuals missing sequence coverage (Table 5.2). To re-run samples was going to be 
prohibitively expensive, so ultimately this approach was abandoned in favour of resequencing 
the same individuals on the Illumina MiSeq Platform.  












Run 1 130 138871 77401 (56%) 48% 
Run 2 112 95658 62604 (65%) 88% 
Run 3 116 135067 20888 (15%) 24% 
Run 4 117 161454 17527 (11%) 10% 
TOTAL 475*   41%* 
*NB. Some individuals were run on multiple runs in an attempt to improve their coverage. There were a total of 451 
unique individual run across the four runs. 
 
The problem with the approach taken here was the adherence to the PTS barcoding protocol 
(Meyer et al., 2008), wherein the samples are barcoded prior to library preparation for 
sequencing. This meant that if the barcoding process was inefficient and there was abundant 
unbarcoded DNA still present, this got carried through to the library preparation point and to 
sequencing. This would not necessarily have been such a big problem if the number of reads 
returned by the GS FLX Junior sequencer were reaching the levels that are returned from the 








however the relatively modest number of reads (albeit longer reads) returned by the GS FLX 
Junior did not compensate for this loss of usable reads. It is also of note that Roche are 
discontinuing their 454 sequencing platform in 2016. 
5.3.2  MiSeq Sequencing 
Of the 446 individuals sequenced, four had slightly less than 100% coverage, though these all 
had coverage above 92%. On average, the coverage was 774 r 344 times, allowing for good 
confidence in base calls. The standard deviations for coverage were rather large because of the 
overlapping regions of the long range PCR products used, meaning that overlap regions had 
much higher coverage than the rest of the mitochondrial genome. Individuals who possessed 
less than 100% coverage were excluded from further analysis. 
5.3.3 Haplogroups 
There were 23 different haplogroups identified using the Haplogrep software. These 
haplogroups predominantly belonged to Asian-derived B4 lineages, though there were also a 
minority of people belonging to the M28a, M28b, Q1 and P1d lineages, which originated in Near 
Oceania (Table 5.3). Two individuals possessed European-derived mitochondrial haplogroups. 
These two individuals were excluded from subsequent analysis. 
When comparing the mitochondrial sequences within the sample, it was possible to define novel 
haplogroups that had not previously been identified (Table 5.4) and to expand on previously 
described lineages. These new haplogroups were defined by the presence of new SNPs in four or 
more individuals who claimed ancestry from different island groups (to reduce the chance that 
these individuals were closely maternally related). Because the number of individuals belong to 
new lineages was limited, these were not incorporated into subsequent statistical analyses 








Table 5.3: Haplogroups from the genotyped samples split into the various high and low BMI cohorts, including 
novel haplogroups that are indicated an asterisk (these are described further in Table 5.4) 
  
















n = 219 n = 223 n = 109 n = 104 n = 110 n = 119 n = 442 
R 
 
211 (96.3%) 215 (96.4%) 102 (93.6%) 102 (98.1%) 109 (99.1%) 116 (95.0%) 426 (96.4%) 
 
B4a1a1 65 (29.7%) 55 (24.7%) 50 (45.9%) 40 (38.5%) 15 (13.6%) 15 (12.6%) 120 (27.1%) 
 
B4a1a1a 27 (12.3%) 22 (9.9%) 22 (20.2%) 22 (21.2%) 5 (4.5%) … 49 (11.1%) 
 
B4a1a1a1 … 1 (0.4%) … 1 (1.0%) … … 1 (0.2%) 
 
B4a1a1a1c* 1 (0.5%) 4 (1.8%) 1 (0.9%) 4 (3.8%) … … 5 (1.1%) 
 
B4a1a1a8 2 (0.9%) 9 (4.0%) 2 (1.8%) 7 (6.7%) … 2 (1.7%) 11 (2.5%) 
 
B4a1a1a9 1 (0.5%) 1 (0.4%) 1 (0.9%) 1 (1.0%) … … 2 (0.5%) 
 
B4a1a1a11 … 2 (0.9%) … 2 (1.9%) … … 2 (0.5%) 
 
B4a1a1a11a 1 (0.5%) 2 (0.9%) 1 (0.9%) 2 (1.9%) … … 3 (0.7%) 
 
B4a1a1a13 1 (0.5%) … 1 (0.9%) … … … 1 (0.2%) 
 
B4a1a1a14* 3 (1.4%) 7 (3.1%) … 3 (2.9%) 3 (2.7%) 4 (3.4%) 10 (2.3%) 
 
B4a1a1a15* 4 (1.8%) 5 (2.2%) … … 4 (3.6%) 5 (4.2%) 9 (2.0%) 
 
B4a1a1a16* 1 (0.5%) 3 (1.3%) 1 (0.9%) 3 (2.9%) … … 4 (0.9%) 
 
B4a1a1a17* 2 (0.9%) 6 (2.7%) 1 (0.9%) … 1 (0.9%) 6 (5.0%) 8 (1.8%) 
 
B4a1a1c 29 (13.2%) 24 (10.8%) 1 (0.9%) … 28 (25.5%) 24 (20.2%) 53 (12.0%) 
 
B4a1a1h … 1 (0.4%) … … … 1 (0.8%) 1 (0.2%) 
 
B4a1a1k 2 (0.9%) 1 (0.4%) 2 (1.8%) 1 (1.0%) … … 3 (0.7%) 
 
B4a1a1m 44 (20.1%) 40 (17.9%) 7 (6.4%) 6 (5.8%) 37 (33.6%) 34 (28.6%) 84 (19.0%) 
 
B4a1a1n 7 (3.2%) 2 (0.9%) 1 (0.9%) … 6 (5.5%) 2 (1.7%) 9 (2.0%) 
 
B4a1a1r* 4 (1.8%) 10 (4.5%) 2 (1.8%) 1 (1.0%) 2 (1.8%) 9 (7.6%) 14 (3.2%) 
 
B4a1a1x … 1 (0.4%) … 1 (1.0%) … … 1 (0.2%) 
 
B4a1a1z* 5 (2.3%) 4 (1.8%) 1 (0.9%) … 4 (3.6%) 4 (3.4%) 9 (2.0%) 
 
B4a1a1aa* 3 (1.4%) 3 (1.3%) 3 (2.8%) 2 (1.9%) … 1 (0.8%) 6 (1.4%) 
 
B4a1a1ab* 4 (1.8%) 5 (2.2%) 1 (0.9%) 2 (1.9%) 3 (2.7%) 3 (2.5%) 9 (2.0%) 
 
B4a1a1ac* 3 (1.4%) 4 (1.8%) 2 (1.8%) 1 (1.0%) 1 (0.9%) 3 (2.5%) 7 (1.6%) 
 
B4b1a2 … 2 (0.9%) … 2 (1.9%) … … 2 (0.5%) 
 
P1d 2 (0.9%) 1 (0.4%) 2 (1.8%) 1 (1.0%) … … 3 (0.7%) 
M 
 
8 (3.7%) 8 (3.6%) 7 (6.4%) 2 (1.9%) 1 (0.9%) 6 (5.0%) 16(3.6%) 
 
M28a 2 (0.9%) 2 (0.9%) 2 (1.8%) 2 (1.9%) … … 4 (0.9%) 
 
M28b 1 (0.5%) … 1 (0.9%) … … … 1 (0.2%) 
 










Table 5.4: Description of haplogroups belonging to B macrohaplogroup with defining polymorphisms, 
including the new lineages and where they occur. New lineages had to be present on more than one island 
group to be defined as a novel haplogroup and are indicated by an asterisk. 
Haplogroup n Polynesian populations Polymorphisms 
B4a1a1 120 NZ Māori, Samoa, Tonga, Cook Island Māori, 
Pukapuka, Tokelau, Niue, Tahiti  
A14022G 
B4a1a1a 49 Niue, Samoa, Tonga, NZ Māori, Cook Island 
Māori,  
A6905G 
B4a1a1a1 1 Samoa A13479G 
B4a1a1a1c* 5 Samoa, Tonga T152C, G12940A 
B4a1a1a8 11 Niue, Samoa, Tonga, Cook Island Māori G6261A, A235G, T12468C1 
B4a1a1a9 2 Samoa G2706A, A16163G 
B4a1a1a11 2 Samoa, Tonga C13943T 
B4a1a1a11a 3 Samoa T10966C 
B4a1a1a13 1 Samoa A4093G 
B4a1a1a14* 10 Niue, NZ Māori, Cook Island Māori, Samoa T3398C, G16384A 
B4a1a1a15* 9 NZ Māori, Cook Island Māori G9145A, A16051G 
B4a1a1a16* 4 Samoa, Tonga G13759A 









B4a1a1k 3 Samoa, Tonga A16399G 
B4a1a1m 84 NZ Māori, Cook Island Māori, Pukapuka, Samoa, 
Tonga, Niue 
C151T, A1692G, T2416C 
B4a1a1n  9 Tonga, Cook Island Māori, NZ Māori G8572A 
B4a1a1r2 14 NZ Māori, Cook Island Māori, Samoa T16126C 
B4a1a1x 1 Tokelau A15924G 
B4a1a1z* 9 NZ Māori, Cook Island Māori, Tonga T4314C 
B4a1a1aa* 6 Niue, Samoa, Cook Island Māori T414G 
B4a1a1ab* 9 Samoa, NZ Māori, Cook Island Māori T16092C 
B4a1a1ac* 7 Samoa, Niue, Cook Island Māori, Pukapuka C13692T 
B4b1a2 2 Tonga, Tuvalu C16067T (plus those normal 
for B4b1a2) 
1) Bold text indicates additional defining SNPs for the lineage 
2) B4a1a1r, defined by variants T16126C and C3909T, is a previously described lineage, however those in our cohort 
are missing one of the defining polymorphisms (C3909T). For this reason, we propose that individuals, who possess 
this C3909T variant, should belong to a new lineage named B4a1a1r1, making B4a1a1r defined solely on the presence 








There was a difference in the distribution of certain haplogroups between East and West 
Polynesia, in particular when it came to the proportion of certain lineages in each population 
(Table 5.3). A breakdown of the haplogroup frequencies in various island populations is 
included in the Appendix 3 (Table 8.2). The B4a1a1c lineage, for instance, was common among 
East Polynesians, with 98% of those who belonged to this haplogroup coming from the Cook 
Islands or New Zealand (a single Tongan belonged to this lineage). Likewise, the B4a1a1a 
lineage and derived sub-lineages were less common in East Polynesia than West Polynesia, with 
71% of those belonging to this lineage and sub-lineages coming from West Polynesia. In this 
way, the mitochondrial genome is able to show differences in population structure between 
what are often considered homogeneous populations and may be indicative of differences in 
nuclear genome variation also.  
Table 5.3 shows no obvious signs of trends in haplogroup frequency contributing to high or low 
BMI status. Statistical analysis is carried out in an upcoming section. In Appendix 3, Table 8.1, 
the haplogroups are broken into gout status compared to healthy controls. Likewise there were 
few obvious trends between haplogroup and gout, although among the East Polynesians the 
lineage B4a1a1m was appreciably higher among individuals with gout than controls under 
visual inspection (48 versus 11). This proved statistically nominally significant when a Fisher’s 
Exact test was utilised (OR 2.17 [1.01-5.05], P = 0.04). This statistical association was not 
evident in the combined East and West Polynesian dataset. No other haplogroup appeared 
overly inflated in either gout cases or healthy controls. 
5.3.4 Non-synonymous and synonymous variants 
As with most mitochondrial polymorphisms, most of the variants detected were transitions. 
There was also one lineage-defining transversion at position T414G, present in six individuals. 
Many of the more ancient lineage-defining mutations were synonymous rather than non-
synonymous changes (Table 5.5). This is not unexpected because of the highly conserved nature 
of the mitochondrial genes. Most of the non-synonymous changes were relatively rare and 










Table 5.5: Variants contributing to haplogroup calls and their context.  
Variant Lineage defining? Coding/noncoding? Syn/Non-syn Frequency within sample 
8261 9bp del B Noncoding 
 
0.961 
T16217C B4 HVR 
 
0.961 
C16261T B4a HVR 
 
0.957 
C9123A B4a MT-ATP6 Syn 0.957 
T5465C B4a MT-ND5 Syn 0.957 
T10238C B4a1 MT-ND3 Syn 0.957 
T146C! B4a1a HVR 
 
0.957 
T6719C B4a1a MT-CO1 Syn 0.957 
A15746G B4a1a MT-CYB Non-syn 0.957 
C12239T B4a1a MT-TS2 (tRNA) 
 
0.957 
14022G B4a1a1 MT-ND5 Syn 0.957 
(A16247G) B4a1a1 HVR 
 
0.840 
A6905G B4a1a1a MT-CO1 Syn 0.235 
A13479G B4a1a1a1 MT-ND5 Syn 0.013 
C13943T B4a1a1a11 MT-ND5 Non-syn 0.011 
T10966C B4a1a1a11a MT-ND4 Syn 0.007 
A4093G B4a1a1a13 MT-ND1 Non-syn 0.02 
G16384A B4a1a1a14* HVR 
 
0.022 
T3398C1 B4a1a1a14* MT-ND1 Non-syn 0.022 
G16051G B4a1a1a15* HVR 
 
0.02 
G9145A B4a1a1a15* MT-ATP6 Non-syn 0.02 
G13759A B4a1a1a16* MT-ND5 Non-syn 0.009 
A14587G B4a1a1a17* MT-ND6 Syn 0.018 
T152C B4a1a1a1c* HVR 
 
0.011 
G12940A B4a1a1a1c* MT-ND5 Non-syn 0.011 
A235G B4a1a1a8 HVR 
 
0.025 
G6261A B4a1a1a8 MT-CO1 Non-syn 0.025 
T12468C B4a1a1a8 MT-ND5 Syn 0.025 
G2706A B4a1a1a9 MT-RNR2 
 
0.004 
G4769A B4a1a1c MT-ND2 Syn 0.119 
C1185T  B4a1a1c MT-RNR1 
 
0.119 
T318C B4a1a1h HVR 
 
0.002 
T10031C B4a1a1h MT-TG (tRNA) 
 
0.002 
A16399G B4a1a1k HVR 
 
0.007 
C151T B4a1a1m HVR 
 
0.197 
A1692G B4a1a1m MT-RNR1 
 
0.197 
T2416C B4a1a1m MT-RNR2 
 
0.197 
G8572A B4a1a1n MT-ATP8/MT-ATP6 Syn/Non-syn 0.02 
T16126C B4a1a1r** HVR 
 
0.031 
T4314C2  B4a1a1z* MT-TI (tRNA) 
 
0.02 
T414G B4a1a1aa* HVR 
 
0.013 
T16092C B4a1a1ab* HVR 
 
0.02 
C13692T B4a1a1ac* MT-ND5 Syn 0.016 
* Designates the novel lineages identified in this study 
1) Previously been found to be associated with Gestational Diabetes Mellitus and a few other disorders (Jaksch et al., 1996, Chen et 
al., 2000, Tang et al., 2010)  
2) Previously reported as a possible hypertension factor (Zhu et al., 2009) 
 
5.3.5 Associations between mitochondrial haplogroup and BMI and gout 
Logistic regression was used to test for associations between mitochondrial haplogroup and 
BMI. BMI was transformed into a binomial factor by splitting into two groups – in this study, 
‘high BMI’ is defined as BMI greater than 34 kg/m2, while ‘low BMI’ is less than 34 kg/m2. This 
cut-off is used in part because of the high proportion of high BMI individuals among Pacific 








(Swinburn et al., 1999) and others. Because relatively few individuals belonged to certain 
haplogroups (Table 5.3), haplogroups with less than ten individuals were excluded from the 
statistical analysis. From the haplogroups where there were sufficient numbers of individuals, it 
was only possible to detect a statistical association by logistic regression with B4a1a1a8 (OR 
0.18 [0.03-0.72], P = 0.03), which appeared to have a protective effect against BMI (Table 5.6). 
This haplogroup was relatively rare, with only 11 individuals possessing it. No other 
associations were detected for any of the other haplogroups. This lack of detected association 
between mitochondrial haplogroup and BMI held true when the data were divided into East and 
West Polynesian groups, though very few mitochondrial haplogroups possessed enough 
individuals once stratified into sub-populations. 
Gout was also tested for association with haplogroup. There were no associations (Table 5.6). 
The association detected in the raw data tables with the B4a1a1m lineage and gout risk among 
East Polynesians (OR 2.17 [1.01-5.05], P = 0.04), was not supported in this analysis. Further 
traits were tested including urate, HDL cholesterol and triglycerides, and also yielded no 
associations. These are reported in Appendix 3, Table 8.3. 
Table 5.6: Logistic regression predicting stratified BMI and gout from haplogroup, adjusted for age, East 
versus West Polynesian ancestry and proportion of self-declared Polynesian grandparents 








All B4a1a1+16126 13 0.46 (0.11-1.57) 0.23 1.04 (0.21-2.84) 0.60 
(n = 396) B4a1a1a 78 0.70 (0.40-1.23) 0.22 1.00 (0.43-1.58) 0.55 
 B4a1a1a8 11 0.18 (0.03-0.72) 0.03* 0.99 (31-9.03) 0.74 
 B4a1a1c 53 1.46 (0.72-2.99) 0.30 0.95 (0.34-1.62) 0.45 
 B4a1a1m 83 1.18 (0.66-2.11) 0.59 1.05 (0.59-2.37) 0.65 
 Q1 11 0.83 (0.22-2.96) 0.77 1.12 (0.15-2.19) 0.35 
EP B4a1a1a 27 0.94 (0.36-2.44) 0.89 1.04 (0.29-2.13) 0.62 
(n = 188) B4a1a1c 52 1.19 (0.52-2.70) 0.68 1.00 (0.38-2.11) 0.81 
 B4a1a1m 59 1.16 (0.53-2.56) 0.70 0.99 (0.80-4.88) 0.14 
WP B4a1a1a 51 0.57 (0.28-1.15) 0.12 1.04 (0.38-2.21) 0.82 









5.3.6 Associations between individual mitochondrial variants and BMI 
Further analysis was undertaken with individual variants, including SNPs and small insertions 
and deletions which had a minor allele frequency of greater than 0.05. While the SNPs define the 
haplogroups in an additive manner, by looking at the SNPs in isolation of the haplogroup call, it 
can increase the number of individuals in some of the groups that get stratified further as more 
peripheral haplogroups are called. Additionally, some SNP variants are not used in the 
assignment of haplogroups because they are considered too variable and switch backwards and 
forwards too rapidly to be reliable phylogenetic markers. Such variants may confer risk to 
disease.  
Most of the mitochondrial variants are biallelic, so present as either the same as the revised 
Cambridge Reference Sequence at the position or as a single alternate allele, however there 
were two positions (302 and 16179) where it was possible to detect multiple different alleles. At 
position 302, there is a variable length insertion, while at position 16179, there is a variable 
length deletion. Both of these positions are located close by extended tracts of consecutive 
cytosine bases. Below, the results for statistical analyses of both simple bi-alleleic variants and 
these poly-allelic variants are reported. 
5.3.6.1 Bi-allelic variants 
Here, BMI was tested in a stratified manner, splitting the cohort into the high and low BMI 
groups previously described. The only mitochondrial SNP that was found to associate with 
stratified BMI was A6905G (Table 5.7), which appeared to be having a protective effect against 
high BMI (OR 0.57 [0.35-0.90], P = 0.02)(Figure 5.4A). Because the 6905G variant is more 
common among West Polynesians, the association was also tested among West Polynesians 
alone, which also yielded statistically significant results (OR 0.42 [0.23-0.79], P = 0.007)(Table 
5.7).  
However, when the sample size was increased to 1811 individuals using TaqMan SNP 
genotyping, of which 1019 remained after removing the individuals who had already been 
genotyped via whole mitochondrial genome sequencing, and those who did not declare a 
Polynesian maternal grandmother. Most unusually, the direction of the effect switched in this 
replication cohort (Figure 5.4B), with the 6905G allele appearing to contribute a 39% greater 
risk of high BMI than the reference A allele (OR 1.39 [1.00-1.94], P = 0.05)(Table 5.8). Again, the 
association was driven by West Polynesians, where the 6905G allele appeared to be contributing 
risk of obesity (OR 1.83 [1.16-2.95], P = 0.01), in particular West Polynesian men (OR 2.54 [1.45-
4.56], P = 0.001). 









































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 5.4: Box plot showing differences in BMI based on variation at mtDNA position 6905. A) Individuals  
possessing the 6905G variants have on average a lower BMI in the 442 Polynesian men sequenced in this 
study; B) Testing in a larger cohort (1019 Polynesians) lead to the trend switching direction.  
 
To ensure that the alleles had been correctly coded in the results of the TaqMan assay, a Pearson 
correlation test was performed between the whole mitochondrial genome data and the TaqMan 
genotyping data for the 440 individuals who overlapped between datasets. There was a 
correlation of 0.97 (P < 2.2 x 10-1 6), indicating that only one individual was incorrectly 
genotyped. Furthermore, using the TaqMan data for these 440 individuals, the original result 
(and its direction of effect) was replicated. This either suggests that there is something 
fundamentally different about the make-up of the sample sets (which seems unlikely), or that 
the conflicting findings are a random statistic sampling effect. 
When the data from both the genotyping and the whole mitochondrial genome groups were 
merged, there was no longer a statistically significant association between the 6905G and 








Table 5.8: Logistic regression predicting stratified BMI (High BMI > 34, low BMI < 34) by 6905G. Results have 
been adjusted for sex, age, East versus West Polynesian ancestry and grandparental ancestry as covariates. 
Analysis only includes individuals who self-reported Polynesian maternal ancestry (so who should therefore 
possess Polynesian mitochondrial lineages).  




 OR (CI) P 
Discovery      
All 442 219/223 0.20/0.28 0.57 (0.35-0.90) 0.02* 
EP 213 102/111 0.20/0.22 0.95 (0.48-1.90) 0.89 
WP 229 119/110 0.20/0.35 0.42 (0.23-0.79) 0.007* 
Replication      
All  1019 484/535 0.22/0.15 1.39 (1.00-1.94) 0.05* 
Males 529 248/282 0.30/0.15 1.98 (1.27-3.13) 0.003* 
Females 490 236/253 0.16/0.16 0.88 (0.53-1.44) 0.60 
EP 747 317/430 0.12/0.11 1.11 (0.70-1.76) 0.65 
Males 284 105/179 0.10/0.09 1.16 (0.50-2.60) 0.72 
Females 392 177/215 0.10/0.08 0.83 (0.43-1.57) 0.57 
WP 353 208/145 0.41/0.28 1.83 (1.16-2.95) 0.01* 
Males 252 147/105 0.45/0.25 2.54 (1.45-4.56) 0.001* 
Females 101 61/40 0.33/0.38 0.89 (0.37-2.12) 0.78 
Merged      
All 1449 696/753 0.22/0.19 1.04 (0.80-1.36) 0.76 
Males 954 457/497 0.25/0.20 1.14 (0.83-1.57) 0.41 
EP 899 390/509 0.12/0.12 0.93 (0.60-1.41) 0.72 
Males 505 211/294 0.11/0.08 1.04 (0.59-1.82) 0.89 
WP 550 306/244 0.36/0.34 1.08 (0.76-1.54) 0.66 
Males 449 246/203 0.37/0.34 1.15 (0.78-1.60) 0.49 
 
5.3.6.2 Poly-allelic variants 
Logistic regression analysis showed that the CAA variant at position 16179 appeared to have a 
protective effect against high BMI (OR 0.48 [0.30-0.77], P = 0.002)(Table 5.9). This remained 
consistent when splitting the cohort into East and West Polynesian sub-populations (OR 0.37 
[0.18-0.75], P = 0.008; OR 0.52 (0.27-1.01), P = 0.05, respectively).  
None of the variants at postion 302 showed association with BMI status until split into 
subpopulations, where two of the non-reference alleles appeared to contribute to risk of high 
BMI in East Polynesians (ACC variant: 2.40 [1.03-5.90], P = 0.05; AC variant: 2.80 [1.15-7.19], P = 
0.02).   
 
 





5.3.7 Associations between individual mitochondrial variants and Gout 
5.3.7.1 Bi-allelic variants 
When the mitochondrial variants with a MAF > 0.05 were tested for association with gout, the 
variant A16183C was found to be associated with nearly four-fold higher disease risk (OR 3.80 
[1.86-7.83], P = 0.0002) (Table 5.10). When East and West Polynesian subgroupings were 
analysed separately, this association was maintained, though the effect appeared to be greater 
among West Polynesians (EP: OR 4.15 [1.43-12.93], P = 0.01; WP: OR 4.73 [1.67-13.63], P = 
0.003).  
There were also population-specific SNPs detected (Table 5.10). Among East Polynesians, 
A1692G and T2416C were found to contribute risk to gout. These SNPs are found in linkage 
disequilibrium, thus had the same effect size (OR 2.14 [1.05-4.66], P = 0.04). The C151T SNP that 
these variants are in linkage disequilibrium with (making up the mitochondrial haplogroup 
B4a1a1m) was also trending towards a significant association in the same direction (OR 1.86 
[0.93-3.97], P = 0.09). These SNPs are less common among West Polynesians, and this same 
trend was not detected. However, among West Polynesians, the variant T16189C was found to 
contribute to risk to gout (OR 3.92 [1.13-13.40], P = 0.03). This was not detected among East 
Polynesians. 
5.3.7.2 Poly-allelic variants 
Logistic regression analysis of the poly-allelic variants found no association with gout status for 
variation at position 302, however one of the variants (the CA variant of the deletion at position 
16179) was found to contribute to gout risk (OR 2.70 [1.17-7.32], P = 0.03)(Table 5.9). Given 
that this variant is physically close to the biallelic variant 16183C, it seems likely that these 
variants are in linkage disequilibrium and the same effect is being detected in both tests. This 
was confirmed using a Pearson Correlation test, which found a correlation of 0.81 between the 
two variants (P < 2.2 x 10-16). The variant did not retain significance when the combined 
Polynesian group was split into East and West Polynesian subgroups. 
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5.3.8 Associations between individual mitochondrial variants and other metabolic 
markers 
Other metabolic markers were tested for association with mitochondrial variants (Table 5.11). 
Results for East and West Polynesian sub-populations are included in the Tables 8.4 and 8.5 in 
Appendix 3. Interestingly, the two variants that appeared to be associated with urate levels 
albeit with miniscule effect sizes (variants C1185T: β-coefficient 0.03, P = 0.05; A4769G: β-
coefficient -0.03, P = 0.04) are those that define the B4a1a1c lineage. The effect of the A4769G 
variant is flipped because the variant defining the B4a1a1c lineage is a reversion to the ancestral 
A allele. Based on this analysis, people possessing these SNPs have a slight tendency toward 
higher serum urate levels. Because this lineage primarily presents among East Polynesians, 
association was also tested for among this subset of individuals, the association did not hold and 
the direction of the effect changed, appearing to reduce urate levels (C1185T: β-coefficient -0.02, 
P = 0.23; A4679G: β-coefficient 0.02, P = 0.27). This indicates that this finding is not likely to be a 
real effect, particularly when problems associated with multiple testing (which have not been 
corrected for in this analysis) are considered.  
 
Table 5.11: The results for linear regressions predicting various metabolic markers by mitochondrial 
variants. These have been adjusted by age, East versus West Polynesian ancestry and proportion of 

















C151T -0.36 (0.22) 0.11 0.08 (0.04) 0.07 0.00 0.99 
310T/TC 0.60 (0.35) 0.08 -0.03 (0.07) 0.61 0.00 (0.02) 0.84 
C1185T 0.09 (0.27) 0.75 0.00 (0.05) 0.94 0.03 (0.02) 0.05* 
A1692G -0.32 (0.23) 0.16 0.07 (0.04) 0.10 0.01 (0.01) 0.69 
T2416C -0.33 (0.23) 0.14 0.07 (0.04) 0.11 0.01 (0.01) 0.69 
A4769G -0.09 (0.27) 0.75 0.02 (0.05) 0.74 -0.03 (0.02) 0.04* 
T5465C -0.55 (0.41) 0.18 0.01 (0.08) 0.86 0.02 (0.02) 0.46 
T6719C -0.55 (0.41) 0.18 0.01 (0.08) 0.86 0.02 (0.02) 0.46 
A6905G 0.25 (0.21) 0.25 -0.03 (0.04) 0.49 0.00 (0.01) 0.69 
G9123A -0.55 (0.41) 0.18 0.01 (0.08) 0.86 0.02 (0.02) 0.46 
T10238C -0.55 (0.41) 0.18 0.01 (0.08) 0.86 0.02 (0.02) 0.46 
C12239T -0.62 (0.40) 0.12 0.03 (0.08) 0.74 0.01 (0.02) 0.75 
A14022G -0.55 (0.41) 0.18 0.01 (0.08) 0.86 0.02 (0.02) 0.46 
A15746G -0.55 (0.41) 0.18 0.01 (0.08) 0.66 0.02 (0.02) 0.46 
A16183C -0.12 (0.34) 0.73 -0.01 (0.07) 0.89 0.02 (0.02) 0.24 
T16189C -0.46 (0.41) 0.26 0.00 (0.08) 0.95 0.02 (0.02) 0.48 
T16217C -0.45 (0.42) 0.29 -0.01 (0.08) 0.87 0.02 (0.02) 0.53 
A16247G -0.44 (0.24) 0.07 0.01 (0.05) 0.81 0.00 (0.01) 0.98 









All SNPs that were identified as being associated with a disease phenotype were visually 
checked using the Integrated Genomics Viewer (IGV) (Thorvaldsdóttir et al., 2013). By doing 
this, it was possible to see that in some places, there are multiple haplotypes present (Figure 
5.5). The region where the variants that were found to associate with gout (i.e. 16179CA and 
16183C) was found to be particularly complex, with some individuals possessing multiple 
haplotypes in this region. This heteroplasmy seems to be exclusive to those who possess 
mitochondrial genomes belonging to the B macrohaplogroup in this dataset. There are three 
main haplotypes detectable (Figure 5.5): 
1) A single base pair deletion at position 16179 in linkage disequilibrium with 16183C; 
2) A two base pair deletion at the same position that co-occurs with the reference A alleles 
at positions 16182 and 16183 (as opposed to the derived C alleles); 
3) No deletion at position 16179 in these individuals belonging to the B macrohaplogroup 
is usually associated with the presence of the alternate C allele at positions 16182 and 
16183.  
Most people possess variable levels of these three different co-existing haplotypes. In contrast, 
individuals with Q1, P1d or M28-derived mtDNA appear to be homoplasmic at these positions 
(Figure 5.5c). Statistical analysis for eleven detected heteroplasmic positions in hypervariable 
region I (HVR1) from positions 16051 to 16189 was undertaken to determine whether 
possessing heteroplasmy in this region contributed risk to developing gout (Table 5.12). 
Heteroplasmic variants from 16179 to 16182 (which are likely in linkage disequilibrium) were 
all found to be significantly associated with gout, contributing an around three-fold higher risk 
of gout (i.e. at positions 16179 and 16180: OR 3.28 [1.32-8.05], P= 0.009; at position 16181: OR 
3.87 [1.96-7.64], P = 0.00009; at position 16182: OR 3.43 [1.43-8.18], P = 0.05). Position 16183 
was not significantly associated but had an odds ratio that was trending in the same direction 
(OR 2.24 [0.80-5.87], P = 0.11). 
None of the upstream heteroplasmic positions were found to be associated with gout. These 
other variants all occurred at low frequency compared to the heteroplasmic variants from 
16179 to 16183, which as previously mentioned were only observed among those individuals 
possessing a mitochondrial genome belonging to the B macrohaplogroup. 
When only individuals belonging to the B-derived lineages were statistically analysed (n= 399: 
308 gout cases, 91 controls), this association between variants at 16179 and 16183 became 
difficult to test. This was because heteroplasmy in this region is almost ubiquitous. At only two 








(OR 6.28 [2.52-16.60] P = 0.0001 and OR 19.50 [2.68-396.62], P = 0.01, respectively). It was not 
possible to determine whether or not the degree of heteroplasmy may be affecting the risk to 
gout with the dataset presented here, as once filtering for those with adequate read depth (i.e.. 
more than 30 reads mapping to the region), there were too few gout-free control individuals to 
do perform reliable statistical analysis. 
 
 
Figure 5.5: Screenshots from IGV showing different proportions of calls at position 16182 (and the 
surrounding region). 5.5a & b belong the B4 derived lineages, while 5.5c belongs to haplogroup Q1. The 
heteroplasmic indels at this position appear to occur almost exclusively in B4 related lineages. In 5.5a & b, it 
is possible to see linked variants. A 2 bp deletion at position 16180 always occurs with the reference A allele, 
a 1bp deletion at position 16180 almost always co-occurs with a C at positon 16183, while no deletion at this 


















Table 5.12: The results for logistic regressions predicting gout status by allelic fraction of presence of 
heteroplasmy at positions within HVR1. Results adjusted for age, East versus West Polynesian ancestry and 







OR (95% CI) P 
16051 A/G 0.02/0.05 0.38 (0.10-1.43) 0.14 
16092 T/C 0.02/0.02 1.34 (0.31-9.17) 0.72 
16126 T/C 0.03/0.04 0.79 (0.25-3.02) 0.71 
16129 G/A 0.04/0.06 0.72 (0.27-2.10) 0.51 
16144 T/C 0.02/0.04 0.59 (0.17-2.31) 0.41 
16148 C/T 0.03/0.06 0.52 (0.19-1.58) 0.22 
16179 CAAA/C/CAA/CA 0.96/0.91 3.28 (1.32-8.05) 0.009* 
16180 A/G 0.96/0.91 3.28 (1.32-8.05) 0.009* 
16181 AAAC/GAAC 0.94/0.84 3.86 (1.96-7.64) 0.00009* 
16182 A/C 0.96/0.91 3.43 (1.43-8.18) 0.005* 
16183 A/C/AGC/ACCC 0.96/0.93 2.24 (0.80-5.87) 0.11 
 
 
5.3.10 Mitochondrial rare variants and phenotypic variation? 
Rare variants are difficult to test for because they are by nature uncommon. SKAT tests were 
undertaken to test for an over representation of common and rare variants in mitochondrial 
genic regions. Table 5.13 shows that no statistically significant associations (as indicated by a P 
value less than 0.05) were detected in this cohort between a burden of variants in any 









Table 5.13: The results of a SKAT test for a burden of rare variants in genic regions contributing to stratified 
BMI and gout, adjusted for age, East versus West Polynesian ancestry and percentage of Polynesian ancestry 











ATP6 19 19 0.89 0.55 
ATP6/ATP8 intersect 5 5 0.11 0.90 
ATP8 1 1 0.50 0.59 
COX1 31 29 0.32 0.80 
COX2 12 12 0.78 0.77 
COX3 17 17 0.63 0.33 
CYTB 38 32 0.92 0.50 
ND1 16 15 0.55 0.30 
ND2 18 18 0.57 0.65 
ND3 6 6 0.81 0.34 
ND4 20 18 0.50 0.64 
ND4L 2 1 0.55 0.20 
ND5 38 35 0.37 0.45 
ND6 9 9 0.32 0.37 
RNR1 13 11 0.92 0.50 
RNR2 12 11 0.83 0.69 
tRNA-Ala 2 1 0.87 0.40 
tRNA-Asn 1 1 0.45 0.63 
tRNA-Asp 1 1 0.34 0.08 
tRNA-Cys 2 2 0.32 0.78 
tRNA-Gln 1 1 0.43 0.63 
tRNA-Glu 1 1 0.37 0.72 
tRNA-Gly 1 1 0.30 0.07 
tRNA-His 1 1 0.34 0.61 
tRNA-Ile 1 1 0.59 0.25 
tRNA-Lys 3 3 0.10 0.29 
tRNA-Met 2 2 0.79 0.65 
tRNA-Phe 1 1 0.32 0.49 
tRNA-Ser 2 2 0.97 0.20 
tRNA-Thr 2 2 0.31 0.18 
tRNA-Thy 1 1 0.82 0.36 
 
5.3.11 Maternal grandparentage and disease? 
Because 96% of the cohort sequenced here belong to the B4 macrohaplogroup that has been 
previously suggested to be susceptible to disease, it is difficult to determine whether this lineage 
may in itself be more susceptible to disease – though the heteroplasmy results are certainly 
suggestive of this. Because there was a high concordance (99.6%) between self -declared 
maternal grandparentage and mitochondrial haplogroup, and because 96% of the Polynesians 
sequenced here belong to B4-derived sublineages, it may be assumed that most of those 
declaring Polynesian maternal grandparental ancestry belong to a B4-derived mitochondrial 
lineage, while those who claim to have a maternal grandmother of European ancestry are likely 
to possess a European-derived mitochondrial genome. On the basis of these assumptions, 
individuals with three self-declared Polynesian grandparents (so as to compare individuals with 








effect arising from having a Polynesian or a European maternal grandmother. Unfortunately, few 
people met these criteria (only 224 out of the total 2359 people with Polynesian ancestry for 
whom there is phenotypic data for) meaning there is very little power to detect associations. 
Table 5.14 shows the results of the statistical tests. A statistically significant association between 
maternal grandparental ancestry and gout was found only with no adjustment for sex, mainly 
because the number of males possessing a European maternal grandmother and three 
Polynesian grandparents was very small in this sample (12 men). Having a maternal 
grandmother of European ancestry appeared to confer a protective effect against gout 
(unadjusted OR 2.24 (1.07-4.97), P = 0.02). Individuals with a Polynesian maternal grandmother 
were twice as likely to have gout than those with a grandmother of European ancestry. This 
effect remained consistent after adjusting for sex, age and East versus West Polynesian ancestry, 
however the significant result did not remain. As mentioned earlier, this is likely an artefact of 
the small sample size, in particular, the limited number of men with European maternal 
grandmothers. This may suggest that Polynesian individuals possessing a Polynesian 
mitochondrial genome are more likely to have gout than those possessing a European 
mitochondrial genome. 
For testing BMI, the cohort was stratified into two groups, for high and low (BMI greater or less 
than 34 kg/m2). There was no significant association detected between maternal grandparental 
ancestry and BMI.  
Table 5.14: The relationship between gout status and stratified BMI and having a maternal grandmother of 
Polynesian or European ancestry (as a proxy of Polynesian- versus European- derived mitochondrial 
lineages) in 224 Polynesians with three grandparents of Polynesian ancestry and one of European ancestry. 
Presented here are the results of logistic regressions. The adjusted results have been adjusted for sex (where 
appropriate), age and East versus West Polynesian ancestry. For BMI, the case/control status refers to 
individuals with a BMI > 34 as a case, and individuals with a BMI < 34 as a control. 
  Polynesian European Unadjusted Adjusted 
 n Case/Control Case/Control OR (95% CI) P OR (95% CI) P 
Gout        
All  224 91/96 11/26 2.24 (1.07-4.97) 0.02* 1.69 (0.67-4.46) 0.27 
Males 121 74/35 8/4 1.05 (0.27-3.60) 0.93 1.54 (0.37-5.68) 0.52 
Females 103 16/61 3/22 2.04 (0.61-9.35) 0.29 1.97 (0.52-9.89) 0.36 
BMI        
All  224 86/87 19/15 0.78 (0.37-1.63) 0.51 0.79 (0.37-1.67) 0.54 
Males 121 52/52 6/6 1.00 (0.29-3.39) 1.00 1.09 (0.31-3.77) 0.89 









5.4.1 Mitochondrial variation and implications for settlement history 
As previously discussed in Chapter 2, understanding population history is important in 
understanding the prevalence of chronic metabolic disease. The high prevalence of metabolic 
disease among Pacific peoples is undoubtedly due to a combination of environmental and 
genetic factors. As was discussed earlier in the chapter, mitochondria have been found to play an 
important role in the immune system and variation in mtDNA may contribute to immune 
function. For this reason, undertaking a study assessing mitochondrial variation among 
Polynesians and its potential associations with disease may help disentangle reasons for the 
high frequency of conditions such as gout. 
When this study was designed, it was prior to the recent update of Phylotree and the reported 
variation within Polynesia was restricted to a handful of whole mitochondrial genomes – several 
Samoans (Pierson et al., 2006), twenty whole mitochondrial genomes from New Zealand Māori 
(Benton et al., 2012), and a single ancient whole mitochondrial genome from an ancient Māori 
(Knapp et al., 2012). All other studies had focussed on short control region fragments. As such, 
the degree of variation within the cohort was not anticipated. The 2014 update of Phylotree to 
Build 16 saw at least an additional 30 descendent lineages of the B4a1a1 sub-lineage added onto 
the phylogenetic tree. These were primarily identified from the mtDNA of Solomon Islanders, 
Tuvaluans and Cook Islanders sequenced by Duggan et al. (2014). The sequencing effort 
described here is the largest to date for Polynesia exclusively and thus identified previously 
undetected variation. 
The haplogroups identified in this study belong predominantly to sub-lineages of the previously 
described ‘Polynesian motif’, B4a1a1 (Figure 5.6). Geography has an effect on the frequency of 
the haplogroups among the various sub-populations (Figure 5.7), but this is unsurprising given 
the rapid mode of colonisation and putative founder effects. The variation fits into a wider 
Pacific-wide pattern, where moving east from Papua New Guinea, through the Solomon Islands 
and beyond sees a reduction in the frequency of non-B related lineages. Because of the recent 
nature of this colonisation, with West Polynesia being settled only 3000 years ago (Burley et al., 
2012), and East Polynesia less than 1000 years ago (Wilmshurst et al., 2011), and with West 
Polynesia being a putative source of these East Polynesian colonists, the similarities seen in the 
lineages in each region with different proportions of the respective lineages in each population 
are somewhat surprising (Appendix 3, Table 8.2). One particularly striking difference in 
haplogroup frequency is B4a1a1c, which presented in 22.7% of the East Polynesian cohort 








differences in frequency, with this lineage being more common among New Zealand Māori than 
Cook Island Māori), compared to 0.03% of the West Polynesian cohort (only one individual – a 
Tongan). Similarly, the lineage B4a1a1m occurs at a frequency of 31% in this East Polynesian 
cohort compared to 6.1% among West Polynesians. In other datasets, the B4a1a1c lineage has 
been proven to be rare in West Polynesian populations, with Duggan et al. (2014) reporting a 
frequency of 4% and 2% in Niue and Futuna respectively. The B4a1a1m lineage is less rare, 
though it still occurs at modest frequencies in West Polynesians, Fijians (Duggan et al., 2014) 




Figure 5.6: A tree showing the divergence of the groups. Note that most of the variation occurs at the very tips 









Figure 5.7: Frequency of mtDNA haplogroups between Pacific populations (data from this study, also Delfin et 
al. (2012): Solomons data, Duggan et al. (2014): New Britain, Bougainville, Fiji, and some additional Tongan, 
Samoan and Cook Island data, Kim et al. (2012): Hawaiian data, and some unpublished data from the Society, 
Tuamotu, Gambier, Austral and Marquesas archipelagos 
This may have some interesting implications regarding the settlement of the region. The 
coalescence time for the B4a1a1c haplogroup has recently been calculated at 4.94 kya (95% 
HPD: 2.02-8.28) (Rieux et al., 2014). This estimate clearly long predates the settlement of East 
Polynesia, and indeed, West Polynesia, which may indicate problems with the calibration of the 
molecular dating. The ultra low frequency of the B4a1a1c haplogroup among modern West 
Polynesians may raise some questions about the putative homeland of this lineage. This lineage 
is clearly very rare outside of East Polynesia, something indisputable given the large number of 
non-Polynesian Oceanic populations which have undergone mitochondrial sequencing (Delfin et 
al., 2012, Duggan et al., 2014). However, there are a few conspicuous gaps in sampling within the 
region, with no data from Micronesia, New Caledonia or Vanuatu being available to date.  
As well as giving insight to settlement history, these differences in mitochondrial lineage 
frequencies may indicate differences in population structure that may well have an impact on 
the differences in frequency of disease between island groups. Even if the mitochondrial 
haplogroups and genetic variation themselves seem mostly to be having only a subtle effect on 
phenotype, they may be themselves associated with nuclear variation that contributes to subtle 
differences in disease susceptibility. There have been indications from studies of nuclear 








and that these variants may be contributing different degrees of risk or protection against the 
development of disease (Phipps-Green et al., 2010). Table 5.1 shows that there are subtle 
differences in mean BMI and HDL cholesterol levels between groups. 
Another factor regarding population stratification that needs considering is the amount of 
European admixture that has occurred since European contact, as this will undoubtedly have an 
effect on population structure. Among the sub-populations in this study, there are differences in 
the amount of admixture. For instance, NZ Māori have a higher proportion of admixture 
compared to Tongans, fully unsurprising considering the histories of these localities and the 
relative numbers of people of European ancestry living in each country respectively. While there 
was a high concordance (99.6%) in the self-reported maternal grandparental ancestry among 
those who were sequenced with only two of the 447 men whose mtDNA was sequenced 
belonging to European-derived mitochondrial lineages, there is still likely genome-wide scale 
European admixture introduced.  
There is a possibility that this admixture in itself may be introducing a tendency towards 
disease, potentially interrupting mito-nuclear coevolution that has developed over the 
generations since each population diverged (Osada & Akashi, 2012). There is some evidence to 
suggest that the influence of a specific mitochondrial haplotype may be dependent on the 
autosomal background (Dunbar et al., 1995), thus this admixture and the disruption of 
mitochondrial-nuclear crosstalk pathways may contribute to pathology (Gershoni et al., 2014). 
5.4.2 B4a1a1-derived lineages and disease susceptibility? 
The observed diversity among the B4a1a1-derived lineages, and paradoxically, this lack of 
diversity, with few non-B derived lineages present, makes it difficult to assess the role of the 
mitochondrial genome in contributing to BMI and other metabolic traits in Polynesians. There 
were not enough non-B lineages present in order to test whether metabolic conditions were 
overrepresented among those possessing mitochondrial genomes belonging to B lineages, as 
96% of the individuals genotyped were found to possess B4-derived lineages. As noted 
previously, the B4 haplotype has been previously found to be associated with type 2 diabetes in 
a more genetically diverse Asian population from Taiwan (Wang et al., 2009, Liou et al., 2012), 
and a number of the variants which define the lineage, including T16189C (Poulton et al., 2002, 
Liou et al., 2007, Park et al., 2008), C16261T and T16519C (Weng et al., 2013) have found to be 
associated with metabolic conditions (type 2 diabetes, abdominal obesity and hypertension 
respectively).  
As with many association-type studies, the evidence supporting association with T16189C is 








different ancestral groups (Gill-Randall et al., 2001, Chinnery et al., 2005, Zhong et al., 2014). In 
their study, Zhong et al. (2014) concede that the B macrohaplogroup does seem to have a 
propensity towards type 2 diabetes (which holds up to statistical significance prior to correcting 
for multiple testing), which may be associated with other mitochondrial variants. Given the 
almost homogeneous inheritance of the B4-related lineages in our cohort, we simply do not have 
the power to detect this association. In other words, the modest success in detecting mtDNA 
differences within the Polynesian mitochondrial lineages that explain differential susceptibility 
to disease may be in part because the predominant lineage in Polynesia is inherently more 
susceptible to disease than other lineages (or the lineage may be equally be marking nuclear 
variation which has this effect). 
This is supported by the crude analysis of self-reported maternal grandparentage, which shows 
that individuals who had three Polynesian grandparents (so who would have similar levels of 
European ancestry and thus European-derived nuclear DNA) with a Polynesian maternal 
grandmother (and therefore likely a Polynesian mitochondrial genome) are more susceptible to 
gout than those with a maternal grandmother of European ancestry (unadjusted OR 2.24 (1.07-
4.97), P = 0.02). This result should be considered tentatively because of the small sample size, 
however it hints to potential differences in the propensity toward developing auto-inflammatory 
disease on the basis of mitochondrial lineage. This result is supported by the indication that the 
presence of heteroplasmy in the region 16179-16183 is associated with gout (e.g. at position 
16179: OR 5.08 [1.74-14.14], P = 0.002). Given that this heteroplasmy is ubiquitous among those 
belonging to B4 derived lineages, this may be interpreted as this lineage being particularly prone 
to gout compared to M28, P1d and Q1 lineages who typically do not possess heteroplasmic 
sequences at this position, though once again, there are sample size issues which will be 
discussed further later.  
The high prevalence of metabolic disease in Polynesia and other Oceanic populations, in 
combination with the high incidence of derivations of the B4 haplotype make a compelling 
argument for the susceptibility of this lineage to adiposity and metabolic problems. Indeed, it 
was difficult to select samples with a ‘low BMI’ to make up a control group – particularly for the 
West Polynesian cohort. Table 1 shows that even once the adjusted BMI was calculated, taking 
into consideration the differing body fat to mass ratio of Polynesians (Swinburn et al., 1999), the 
mean adjusted BMI was close to being in the overweight range. This could be a result of a genetic 
propensity to higher BMI driven in part by mitochondrial background, though environmental 








5.4.3 A6905G and BMI? 
There was only one SNP among those with an allele frequency of greater than 0.05, which was 
found to associate with BMI among the Polynesian whole mitochondrial genomes genotyped in 
this project (Figure 5.4). The A6905G variant is relatively common with an allele frequency of 
0.24 and defines the B4a1a1a lineage and its corresponding sub-lineages. The derived allele 
appeared to be having a protective effect against obesity, with those possessing it having (on 
average) a lower BMI than those without. Interestingly, this lineage is more common among 
West Polynesians, who generally have a higher BMI than East Polynesians (Table 5.1).  
As discussed in the results section, this association did not hold out after further genotyping in a 
larger Polynesian cohort – in fact, the replication cohort showed an altered direction of effect, 
with the 6905G variant seeming to contribute a 40% higher risk of having a BMI exceeding 34 
kg/m2 (OR 1.39 [1.00-1.94], P = 0.05). Again, this effect was driven by West Polynesians, who 
had a higher allele frequency of the variant, and the effect appeared to be stronger in West 
Polynesian men. Because of this apparent complete switch in direction of the effect of the allele 
in a slightly different cohort, and the flattening of the result when the original cohort was added 
to the analysis, it may be that the variant has no real effect on BMI and what was detected here 
was a statistical anomaly arising from small datasets. The association is likely underpowered, as 
it is unlikely that any real major differences exist between the cohort chosen for whole genome 
sequencing and those in the replication cohort. Problems with replication of phenotype-
genotype associations are a well-documented phenomenon, colloquially known as ‘Winner’s 
Curse’, where associations with a disease phenotype may be identified in a small, underpowered 
cohort and not replicated in a larger cohort (Chanock et al., 2007). 
 
5.4.4  Association of mitochondrial SNPs with gout 
Only one variant was found to associate with gout in both East and West Polynesian populations. 
Those possessing the 16183C variant have a four-fold higher risk of gout than those with the A 
variant (OR 4.11 [1.99-862], P = 0.0001). The 16183C variant did not appear to be having a role 
in modulating urate levels (Table 5.11) suggesting that it was somehow involved in 
inflammatory processes contributing to the gout phenotype. Given the putative role of the 
mitochondria in NLRP3 inflammasome generation (Akira et al., 2013), genetic variation within 
the mitochondrial genome could be contributing to this. Closer inspection of the variant showed 
while the variant was bi-allelic, it was also present within a heteroplasmic region, which makes 
it difficult to assess what is causing the increase in gout risk – the variant itself, or the 
heteroplasmy. Those who were heteroplasmic at the 16183 position, were also found to have a 
similarly high risk of gout (5.54 [1.87-15.73], P = 0.001), which is probably due to the same 








The A16183C variant is present within hypervariable region I (HVR1), thus is considered non-
coding. The site is considered highly variable and is not used as a lineage-defining marker. It has 
not been previously associated with metabolic disease but was found over-represented among 
Caucasian melanoma patients (Ebner et al., 2011). This may indicate that the region may 
influence immune responses, as cancers are known to manipulate the immune system to avoid 
destruction. A transition at this position would contribute to a poly-cytosine (poly-C) tract, 
something previously suggested to contribute to defective mtDNA replication, which may affect 
mtDNA copy number and susceptibility to disease (Liou et al., 2010). mtDNA copy number and 
its effect on gout is explored in the next chapter.  
A second variant found to trend with risk of gout, though among West Polynesians exclusively, 
was at position T16189C (OR 3.92 [1.13-13.40], P = 0.03), which also contributes to the 
generation of a poly-C tract. It is of note that this variant is very close by the 16183 variant, and 
as will be discussed later, these variants appear to be at least partly in linkage. This 16189C 
variant has, as discussed earlier, previously been associated with metabolic disease including 
type 2 diabetes and obesity in a number of populations (Poulton et al., 2002, Liou et al., 2007, 
Park et al., 2008) (though this has not necessarily been consistently replicable (Gill-Randall et 
al., 2001, Chinnery et al., 2005, Zhong et al., 2014)). This would be the first such association in 
gout, largely because mitochondrial variation has not previously been explored in relation to 
this disease. If the poly-C tract is somehow affecting copy number, this may have implications 
when it comes to mitochondrial biogenesis and mitochondrial function, and resulting in 
impaired mitochondrial turnover, something which has been found to be pro-inflammatory 
(Nakahira et al., 2011). 
Among East Polynesians, it was possible to detect further association between a number of 
linked SNPs and risk of gout. Variants C151T, A1692G and T2416C are those that define the 
mitochondrial haplogroup B4a1a1m, which is not uncommon among East Polynesians (in this 
dataset, it was present at a frequency of 31% in East Polynesia making it the most common 
single lineage). Of the East Polynesians belonging to this haplogroup, 81.4% of them had gout 
(though this is skewed by an imbalance of gout versus control patients in this cohort). In the 
whole haplogroup analysis, this haplogroup did not appear to be associated with gout (OR 0.99, 
P = 0.14; Table 5.6), while the analyses of 1692G and 2416C in East Polynesians showed a two-
fold higher risk of gout among those with these variants (OR 2.14 [1.05-4.66], P = 0.04) which is 
intriguing, but may point to some problems with using the whole haplogroup in analysis rather 








These variants are located in the hypervariable region (C151T), and in the 16S rRNA gene 
(A1692G and T2416C). It is not clear how such variants may contribute to disease, but the 
presence of variants within the 16S rRNA gene may result in subtle differences in the secondary 
structure of these ribosomal subunits, which may have flow on effects to pathology. Genetic 
variation in 16S rRNA has previously been observed in Alzheimer’s and Parkinson’s disease 
(Shoffner et al., 1993, Tanaka et al., 2010), mitochondrial encephalomyopathy, lactic acidosis, 
and stroke like episode (MELAS) (Hsieh et al., 2001) and myopathy (Coulbault et al., 2007), so it 
is not unreasonable to consider that such variation may play a role in auto-inflammatory 
diseases like gout. 
5.4.5 Heteroplasmy and disease 
It was possible to detect what appeared to be a lineage specific heteroplasmic region, where 
there were three main haplotypes. This variation occurs in a region which has previously been 
identified as being highly variable, with length heteroplasmy from positions 16184-16193 
having been detected in association with the SNP variant 16189C (Bendall & Sykes, 1995), a 
variant which is near universal in our cohort (allele frequency 0.95). The presence of this 
heteroplasmy appeared to associate strongly with gout risk when including other haplogroups 
in the analysis, conferring up to a three-fold higher risk of gout (e.g. at position 16179: OR 3.28 
[1.32-8.05], P = 0.009; at position 16181: OR 3.87 [1.96-7.64], P = 0.00009; at position 16182: 
OR 3.43 [1.43-8.18], P = 0.05).  
The previously mentioned 16189C variant contributes to a poly-C tract between 16184 and 
16193, and there is accumulating evidence that homo-nucleotide tracts such as this may induce 
polymerase slippage – something that has certainly been observed in vitro, but which may also 
be occurring in vivo (Verscheure et al., 2015). The 16189C variant is prevalent among those 
possessing a mitochondrial genome belonging to the B macrohaplogroup, however what is 
interesting is this variant itself was not consistently found to be associated with gout risk – 
though it was trending in the right direction (for all Polynesians: OR 1.99 [0.77-4.87], P = 0.14; 
for West Polynesians: OR 3.92 [1.13-13.40], P = 0.03). It is also in linkage disequilibrium with 
variants indicative of the heteroplasmy – a Pearson correlation of 0.81 was calculated between 
the 16189C variant and the 16183C variant (P < 2.2 x 10-1 6). The heteroplasmy may be a direct 
result of the variant.  
Consistent with the observation that 16189C is associated with length variation heteroplasmies, 
the heteroplasmic variants observed in this data appear to alter the length of a poly-C tract in 
HVR1, close by the origin of replication. This extension of the poly-C tract may further amplify 








Alterations to poly-C tracts have previously been linked to cancer (Ha et al., 2002). If replication 
is slowed down, this may reduce the rate of mitochondrial biogenesis, an important cellular 
process that has been previously shown to reduce inappropriate auto-inflammatory stimulation 
(Nakahira et al., 2011). 
The near universal nature of the heteroplasmy among those possessing B-derived mtDNA, made 
it difficult to conclude that the heteroplasmy itself was contributing to susceptibility to gout, or 
whether it was possessing a B-derived mitochondrial genome more generally. What is clear is 
that those with heteroplasmy at these positions (who all happen to belong to the B 
macrohaplogroup) are three times more susceptible to developing gout rather than those who 
do not have the heteroplasmy. Those belonging to B lineages who did not have gout had less 
diversity in the heteroplasmic haplotypes (i.e. they were less likely to have all three of the three 
main haplotypes in this region) – though this is purely observational and something that has not 
been quantified as it is difficult to quantify the precise proportions of these haplotypes using the 
crude quantificative measures of heteroplasmy that were applied here (which only tested 
whether the presence of heteroplasmy, not the amount of heteroplasmy, was correlated with 
gout). The statistically significant associations seen when analysing only individuals possessing 
a B mitochondrial lineage (i.e. at position 16181 [AAAC>GAAC]: OR 6.288 [2.52-16.60], P = 
0.0001; position 16182 [A>C]: OR 19.50 [2.68-396.62], P = 0.01) may be detecting this potential 
difference. Further analysis looking at the proportions of haplotypes would be something 
worthwhile doing.  
 
5.4.6 Concluding remarks 
This study is a testament to how whole mitochondrial DNA sequencing is required in order to 
assess not only disease associations within a population but also when considering phylogenetic 
questions. This was the first mitochondrial project of its scale among Polynesians, and it was 
possible to detect novel variation, some of which was region specific. While an in depth 
phylogenetic study was not carried out here, it was possible to detect differences in 
mitochondrial lineages between East and West Polynesia, which may relate to the settlement 
processes of the region. Furthermore, variants associating with both BMI and gout were 
detected, which supports the multifaceted role of mitochondria, even if was not immediately 
obvious what functional effect the variants were having. The modest size of the dataset (in terms 
of medical genetic studies) means that there are certainly some limitations, and that follow-up 
work is necessary to confirm these associations – in particular, the heteroplasmic findings. This 
in itself  comes with complications given sampling constraints, and when the effect may be more 

















6 Mitochondrial Copy Number Variation & Metabolic disease 
6.1 Introduction 
6.1.1 Why mitochondrial DNA copy number? 
 
As established in the previous chapter, it was not possible to detect a clear relationship between 
mitochondrial DNA haplogroup and disease in the genotyped individuals. What was found was 
an indication that those belonging to the B macrohaplogroup may be more susceptible to gout, 
and that heteroplasmies in the poly-cytosine (poly-C) tract in hyper-variable region I (HVR1) 
may contribute to this. The putative mechanism involved polymerase slippage that may slow 
mtDNA replication, and ultimately mtDNA copy number and mitochondrial biogenesis. Altered 
mtDNA copy number has been implicated in a range of human diseases, including certain 
cancers (Lee et al., 2005, Wu et al., 2005, Wang et al., 2006), type 2 diabetes (Wong et al., 2009), 
neurodegenerative conditions (Baron et al., 2007, Coskun et al., 2012), and aging (Cree et al., 
2008, Mengel-From et al., 2014, van Leeuwen et al., 2014). 
Lee et al. (1998) were the first to detect a lower mtDNA content in peripheral blood 
mononuclear cells (PBMCs) in patients with type 2 diabetes compared to healthy controls. In 
their admittedly small cohort of 55 type 2 diabetes patients and 29 age- and sex-matched 
controls, they found a 35% lower amount of mtDNA in individuals with type 2 diabetes 
compared to healthy controls using slot blot analysis (Lee et al., 1998), a DNA quantification 
method that is less sensitive than quantitative PCR (qPCR) methods (Bosio et al., 2004). This 
corresponds well with the finding that reduced mtDNA content associates with earlier age of 
type 2 diabetes onset, though this result only held in patients without diabetes complications 
(Wong et al., 2009). 
Lower mtDNA levels were reported in peripheral blood of offspring of diabetes patients (Song et 
al., 2001), which was thought to predispose the offspring to developing metabolic disease 
themselves. Given the hereditary component of metabolic diseases like type 2 diabetes, this 
assumption was not unreasonable. The result was brought into question when Singh et al. 
(2007) were unable to replicate the findings in a larger cohort. In contrast to these findings of 
reduced mtDNA copy number, Weng et al. (2008) found progressive increases of mtDNA copy 









Given the commonalities in the inflammatory processes underlying type 2 diabetes and gout, 
differences in copy number may be associated with gout. This chapter explores mtDNA copy 
number variation in individuals with gout and healthy controls. 
As previously discussed in Chapter 4, the mitochondria, and thereby mtDNA content, is usually 
stringently regulated. Mitochondria are far from static entities and through ongoing processes of 
fission, fusion, and motility, their shapes and sizes are constantly changing (Youle & van der 
Bliek, 2012). As such, the arrangement of the mtDNA within the mitochondrion is very pertinent 
when considering this fluidity of mitochondrial morphology, and indeed, questions of mtDNA 
copy number variation. Unlike most illustrations in biology textbooks, mtDNA is not a free-
floating entity within the mitochondrial matrix. Rather it has been shown that mtDNA is protein-
coated and packaged into bacterial-like nucleoid structures that are attached firmly at regular 
intervals to the inner membrane of the mitochondrion (Chen & Butow, 2005)(Figure 6.1). The 
number of mtDNA molecules within each of these nucleoids is debated, with a recent study 
suggesting an average of 1.4 copies (Kukat et al., 2011). If mtDNA copy number within these 
nucleoids gets too high, the structure becomes enlarged and corresponds with defective 
transcription (Ylikallio et al., 2010). These nucleoids provide some important organisation to 
mitochondria, in particular, ensuring that during the frequent fusion and fission events that 
occur between mitochondria during normal homeostasis, sufficient mtDNA and proteins 
involved in transcription and DNA replication are retained in each mitochondrial unit (Clay 
Montier et al., 2009). 
 
Figure 6.1: mtDNA is packaged into nucleoid structures which are anchored onto the inner surface of the 
inner mitochondrial membrane. These nucleoids contain sometimes multiple copies of mtDNA as well as 
enzymes which are involved in transcription and replication, for instance mitochondrial transcription factor 
A (TFAM), DNA polymerase gamma (POLG), human mitochondrial helicase (Twinkle), mitochondrial single-








Mitochondria, and thereby mtDNA, are present in different amounts in different tissues, 
depending on their respective energy requirements. Spermatozoa contain around five 
mitochondria (San Gabriel et al., 2012), while oocytes may contain more than 500,000 (Reynier 
et al., 2001). Not all cells require mitochondria or mtDNA – erythrocytes do not possess 
mitochondria at all, while eosinophils and neutrophils can eject their mtDNA into the 
extracellular environment as an anti-microbial defense and remain viable (Brinkmann et al., 
2004, Yousefi et al., 2008, Yousefi et al., 2009). In any given tissue, normal mtDNA copy number 
is a range rather than a set figure, and in apparently healthy individuals, the amount of mtDNA 
can vary significantly; Stringer et al. (2013) found in their study of mtDNA copy number in 
statin-induced myopathy, that the calculated mtDNA:nuclear DNA ratios varied from 753–7762 
among their control cohort. Additional to this normal variation, there is also a general reduction 
in copy number with age, with lower amounts of mtDNA among the elderly. This reduction in 
mtDNA is not necessarily accompanied with a reduction of fitness and increased pathology (Cree 
et al., 2008, Mengel-From et al., 2014, van Leeuwen et al., 2014). However, altered mtDNA levels 
have been detected in various pathologies so there clearly are some consequences of extreme 
amounts of mtDNA. Reduced mtDNA copy number may contribute to pathology when other 
genetic and environmental conditions are met. Alternatively, the pathological conditions 
themselves may be influencing mtDNA copy number by some other mechanism. 
 
6.1.2 Regulation of mtDNA copy number 
 
As previously mentioned, mitochondrial mass affects the number of mitochondria, and thereby 
mtDNA copy number. Regulation of mitochondrial mass is something which is not entirely 
understood, though it is affected by factors like mitochondrial stress and metabolism. 
Mitochondrial mass is governed largely by the co-dependent processes of biogenesis and 
mitophagy, as well as the on-going fission and fusion of mitochondria. Fission and fusion occur 
frequently and may allow for the rescuing of damaged mitochondrion by co-localising damaged 
portions, before undergoing fission, allowing all of the damaged components to be located in a 
single unit to be broken down via autophagy (Youle & van der Bliek, 2012). 
Nitric oxide, PGC1α (encoded by the gene PPARGC1A, as discussed in Chapter 4), nuclear 
receptor co-repressor-1 (NCOR1) and their co-activators have been implicated as regulators of 
mtDNA copy number through their effects on mitochondrial biogenesis (Shokolenko & Alexeyev, 
2015). A study carried out in Saccharomyces cerevisiae yeast strains by Zhang & Singh (2014) 








diverse functions, though 55% were involved in mitochondrial protein biosynthesis. Of the 
human orthologs of these genes identified by Zhang & Singh (2014), 47 of them, when deleted 
from the genome, resulted in the depletion of mtDNA in human cell lines, and eight (MRPL3, 
MRPS12, MRPS14, MSH3, POLG, PPOX and AFG3L2) had previously been identified as being 
associated with mitochondrial disease in humans. There have been other genes identified 
associating with mtDNA depletion syndromes (Nogueira et al., 2014), which suggests that there 
are a wide range of nuclear genes which contribute to maintaining mtDNA copy number. 
Genome-wide linkage analysis of quantitative trait loci has also indicated that males and females 
may have subtly different genetic mechanisms controlling mtDNA copy number, though mtDNA 
levels among males and females does not differ significantly (López et al., 2012). 
A decrease in mtDNA copy number may also represent mitochondria stress or dysfunction. 
There is increasing evidence to suggest that mitochondria play an essential role in the 
generation of the NLRP3 inflammasome response that is important in innate immunity, and that 
this immune response plays a key role in auto-inflammatory diseases including type 2 diabetes 
and gout. 
There has been some indication that there is some heritability of mtDNA copy number. López et 
al. (2012) calculated that genetic heritability of mtDNA levels was 0.33 r 0.09 (p = 1.8 x 10-5). 
Interestingly, there is some indication that mtDNA variation may affect mtDNA copy number, 
with Liou et al. (2010) suggesting that the variant 16189C is associated with a reduction in 
mtDNA copy number. Their study cohort consisted of 837 healthy Taiwanese adults (of Han 
Chinese ancestry). Given that this variant is one of those that define the B macrohaplogroup and 
the high frequency of B-derived haplogroups in Polynesia, it may be that Polynesians possess 
lower copies of mtDNA, which may put them at higher risk of developing metabolic disease such 
as type 2 diabetes. Liou et al. (2010) suggest that the mechanism in play here may be something 
to do the with Poly-C tract which is caused by the variant 16189C affecting the association of 
proteins involved in the replication of DNA at this position in the mitochondrial D-loop. Given 
that it was possible to find variants in this region which associated with gout among 
Polynesians, most of whom belong to this haplogroup, this may potentially contribute to a 
susceptibility to reduced mtDNA levels. Because a high proportion of Polynesians belong to the 
B mitochondrial haplogroup, it is unlikely to be possible to detect differences in mtDNA copy 
number associated with differences in mtDNA sequence variation, however given that mtDNA 
copy number regulation is not fully understood, there may be other mechanisms at play and 
perturbations in mtDNA copy may be contributing to, or possibly resulting from, susceptibility 








6.1.3 Purpose of this chapter 
 
Given the indication that mitochondrial mass and mtDNA copy number may influence other 
metabolic diseases, mtDNA copy number was assessed in individuals with gout compared to 
healthy controls to determine whether there is an association with disease.  
 
6.2 Methods 
Two main approaches were used to assess the effect of mtDNA copy number on gout and 
metabolic disease. Gout will be primarily focussed on in the analysis, as the cohorts used in this 
study were collected for the primary purpose of exploring the genetics of gout and 
hyperuricaemia.  
6.2.1 Sample selection 
 
The in silico portion of the analyses presented here utilises two next generation sequencing 
(NGS) datasets which have been produced by the Merriman laboratory throughout their on-
going studies of the genetics of gout. These data have been produced from DNA from the pre-
existing cohort of individuals with gout and healthy controls who have been recruited for the 
study of metabolic disease (described previously in Chapter 5). To date, genetic samples from 
2359 individuals of Polynesian ancestry have been collected. To take full advantage of this study 
cohort, whole genome sequencing was undertaken to identify possible Polynesian-specific 
genetic variation. For this purpose, the Merriman laboratory have sequenced 82 low coverage 
genomes, of which 75 belong to people of Māori and Pacific ancestry. The participants 
sequenced were chosen on the basis of their urate levels – both gout cases and asymptomatic 
hyperuricaemic controls were selected for sequencing, everyone having high serum urate levels.  
The second NGS resource is the recently produced Urate Locus Resequencing dataset, which 
comprises 374 people of Māori and Pacific ancestry (excluding individuals who also have whole 
genome data and those with significant European ancestry), again, chosen largely for belonging 
to various extremes of gout/hyperuricaemia and normouricaemia. The gout cases comprised 
151 participants with the highest serum urate measures (average 0.55 mmolL-1), additional to 
the requirement that their gout fulfilled the 1977 American Rheumatology Association 
preliminary classification criteria for gout by clinical examination (Wallace et al., 1977), while 
the control group consisted of 222 participants who had self-reported no history of gouty 
arthritis and who had low serum urate levels (average 0.33 mmolL-1). The Resequencing dataset 








associated with other metabolic traits such as BMI and renal disease from throughout the 
genome.  
The quantitative PCR (qPCR) used to validate the in silico findings utilised a subset of samples 
from the same cohort of 2359 individuals. These comprise Māori and Pacific participants with 
gout and healthy controls. This expanded cohort has lower on average percentage of Polynesian 
ancestry (based on self-declared grandparental ancestry), with the mean proportion of 
Polynesian ancestry among these individuals being 0.82, compared to 0.89 and 0.92 for the 
Whole Genome and the Urate Locus Resequencing groups respectively (Table 6.1).  
Table 6.1 comprises the mean metabolic characteristics of each of these datasets used in testing. 
Some of these characteristics differ between groups, in particular between the Whole Genome 
and Resequencing cohorts compared to the qPCR validation cohort. 588 individuals were tested 
with qPCR including 128 who had previously been sequenced in the Whole Genome or 
Resequencing, and 460 additional individuals. The table below reports only individuals whose 
results passed the quality control thresholds (described in the qPCR methods section) and 
whose data were analysed further. 
Table 6.1: Mean metabolic characteristics of the cohorts tested 
 Whole Genome Cohort 
(n=75) 
Resequencing Cohort 















Males/Females 30/2 43/0 133/18 99/123 207/36 129/112 
Age 45.4 44.2 47.4 44.9 50.2 40.9 
BMI (kg/m2) 36.7 34.9 37.5 32.3 36.1 33.0 
Triglycerides (mmol/L) 2.35 2.44 2.54 1.87 2.47 1.98 
HDL (mmol/L) 1.07 0.99 1.09 1.26 0.96 1.16 
Serum Urate (mmol/L) 0.49 0.45 0.55 0.33 0.42 0.38 
%Polynesian Ancestry 0.91 0.87 0.90 0.93 0.85 0.79 
 
6.2.2 In silico testing 
 
The process of preparing DNA for whole genome sequencing involves the fragmentation of 
genomic DNA through a process such as sonication into short fragments, followed by the ligation 
of sequencing adapters, similar to what was previously described in Chapter 5 for the 
sequencing of the whole mitochondrial genomes (the only difference being that the whole 
mitochondrial genome sequencing involved prior amplification of the mtDNA). Because there is 








relative number of reads mapping to various parts of the genome after sequencing represents 
the relative amounts of DNA.  
The whole genome data had previously undergone raw data processing (again, similar to what 
was described previously for the whole mitochondrial genomes), which meant that .bam files 
that contain aligned reads could be utilised to calculate how many reads map to various loci 
within the genome. The Samtools count function (Li et al., 2009) was used to count the reads 
localised to each of the mitochondrial genome and to chromosome 2 (Figure 6.2). A ratio of the 
reads mapping was generated for each individual by dividing the total number of reads mapping 
to the mitochondrial genome by the reads mapping to chromosome 2. This gives a relative 
mtDNA copy number per individual. 
These data were then imported into R Studio and statistically analysed. Logistic regression was 
used to test for an association between the relative amount of mtDNA and gout status. This was 
adjusted for sex, age, East versus West Polynesian ancestry and percentage of Polynesian 




Figure 6.2: How ratios were produced from the NGS sequence data. The number of reads mapping to the 
mitochondrial genome calculated by Samtools was divided by the number of reads mapping to nuclear 









This was repeated for other chromosomes to make sure the trend was consistent. The relative 
mtDNA amount was highly reproducible when using the reads mapping to other chromosomal 
regions. For instance, a Spearman correlation of 1.00 (P < 2.2 x 10-1 6) was calculated when 
testing for a correlation between the ratio produced from the reads mapping to Chromosome 2 
compared to a ratio of mitochondrial reads produced from the reads mapping to Chromosome 
12.  
When a statistically significant association was found, validation was sought using the second 
dataset – the Urate Locus Resequencing Cohort. This dataset was produced in a slightly different 
manner than that of the whole genome data. After the ligation of sequencing adapters, a 
hybridisation method was used to enrich the DNA for certain parts of the nuclear genome 
(mostly loci thought to be involved in urate control). This hybridisation was not 100% efficient 
in enriching only for reads mapping to regions of interest, and some DNA from other parts of the 
genome also got sequenced. Because of the way this dataset was produced, with certain parts of 
the genome being actively targeted, the mitochondrial reads in this dataset were off-target 
reads. So as to produce similar ratios as those produced from the whole genome data, it was 
necessary to extract reads mapping to regions of the genome that had not been enriched in the 
sequencing approach. Bedtools (Quinlan & Hall, 2010) was used to pull out the off-target reads 
mapping to chromosomal regions. After these regions were extracted, the same process of 
counting reads mapping the mitochondrial and chromosome 2 regions using Samtools was 
employed, and the ratio of reads was determined. Again, a logistic regression in R Studio was 
used to determine whether the same trends were detectable. This again was adjusted for sex, 
age, East versus West Polynesian ancestry and percentage of self-reported Polynesian 
grandparents. 
6.2.3 Validation using Quantitative PCR 
 
To validate the findings from the in silico analyses of the pre-existing datasets, experimental 
validation was required. Quantitative PCR (qPCR) is an accepted method for confirming 
suspected copy number variable regions (D’haene et al., 2010). Here, a TaqMan copy number 
assay was used to quantify the relative amounts of mitochondrial to nuclear DNA in Polynesian 
gout cases and controls using dual hybridisation probes. The probes used target a portion of the 
MT-ATP8 gene (Applied Biosystems, catalogue no. 433118, assay ID Hs02596863_g1) and the 
standard nuclear RNase P reference assay (Applied Biosystems catalogue no. 4403328). The 
mitochondrial probe was designed by Applied Biosystems for the purposes of gene expression 








scientist from Applied Biosystems, it was decided that this probe would likely work for the 
purposes of testing the amount of mtDNA present. 
TaqMan copy number assays are single tube assays, which allow the detection of the relative 
amount of both the mitochondrial target and the standard reference. The assay consists of 
primers and assay probes which anneal to the specific sequences targeted by the primers. The 
TaqMan copy number assay uses fluorescence resonance energy transfer (FRET) probes, which 
have a fluorescent dye attached at one end and a quencher dye at the other. When the probe is 
intact, the proximity of the quencher to the reporter dye causes the signal to be undetectable.  
During the course of PCR, the Taq polymerase cleaves the fluorescent dye off the probe, thereby 
dissociating it from the quencher, allowing the signal to be detected by the Lightcycler 
instrument (Figure 6.3). Because the two probes have different dyes attached [Fam and Vic 
respectively] the LightCycler can detect the relative amount of template DNA present based on 
the relative fluorescence for each dye after each PCR cycle. Duplex qPCR is preferable for this 
type of assay, as it means that there is less chance for detected differences between target and 
reference fluorescence to be due to differences in starting template volume. 
 









6.2.3.1 Testing of samples  
 
The qPCR setup involved 16-20 ng of genomic DNA pipetted in 2 μL volumes in triplicate onto a 
384 well plate, containing both gout cases and non-gout controls, allowing 128 samples to be 
run simultaneously. Cases and controls were plated together, spaced across the plate (Figure 
6.4), in order to minimise any instrument-introduced bias and batch effects which could lead to 
inconsistencies in the fluorescence contributing to misleading results. Five plates were done in 
total. The first plate replicated samples from the Whole Genome and Resequencing Cohorts in 
order to validate the in silico analytical approach. The following four plates consisted of samples 
blindly plated from pre-existing boxes of DNA from gout cases and healthy controls. As such 
some of the individuals within these plates were replicates from the Whole Genome and 
Resequencing groups, though the overlap was minimal. 
 
Figure 6.4: 384 well plate set-up. Samples were plated in triplicate, alternating between cases and controls 
(purple and blue sections) across the plate to reduce instrument-related biases 
Very subtle differences in the amount of DNA was detectable by the qPCR (as evidenced by large 
standard deviation values between PCR replicates), which meant that manual single-channelled 
pipetting of samples was necessary as plating samples using a multichannel pipette was not 
precise enough. The DNA was dried (i.e. the plate was left covered but not sealed overnight in 
order for the liquid portion to evaporate) in order to reduce any inconsistencies that might arise 
from subtle differences in reaction volume. The total volume for each individual reaction was 10 








mix. The plates were centrifuged prior to being placed into the Lightcycler 480 Real-Time PCR 
System. The cycling conditions involved a 10 minute incubation at 95°C to activate the hot-start 
AmpliTaq Gold DNA polymerase, followed by 40 cycles of a 15 second incubation at 95°C 
followed by a 60 second incubation at 60°C. At the end of each cycle, the instrument recorded 
the fluorescence.  
The Lightcycler software maps this fluorescence data against the number of cycles, allowing for 
the calculation of Ct (threshold cycle). Ct is the intersection between an amplification curve and a 
threshold line. The threshold line usually used in the analysis of qPCR is at the  very beginning of 
the exponential increase phase of the PCR reaction. In this study, the Ct values used are those 
calculated by the Lightcycler software using the Second Derivative Maximum for absolute 
quantification (Rebrikov & Trofimov, 2006). The Second Derivative Maximum is automatically 
calculated by the computer, and is the point at which the rate of change of fluorescence is fastest. 
This usually occurs in the cycle where the sample fluorescence can first be distinguished from 
background fluorescence. The relative amount of mtDNA was ascertained by calculating ΔCt 
using the following equation: 
Δ𝐶𝑡 = 𝐶𝑡(𝑚𝑡𝐷𝑁𝐴) − 𝐶𝑡(𝑅𝑁𝑎𝑠𝑒 𝑃) 
For samples with a standard deviation of ΔCt values of the three replicates greater than 0.4, 
where an outlier replicate could be detected, this was removed. If the standard deviation of the 
ΔCt remained above 0.4, the sample was excluded completely from further analysis. These data 
were exported to R Studio for statistical analysis. Linear and logistic regressions were conducted 
to test for association between ΔCt (i.e. relative amount of mtDNA) and various covariates 
including gout status, age, sex and ethnicity.  
It should be noted that there is also a ΔΔCt method, which was not employed in this study as the 
reference assay was not working at optimum efficiency as is shown below in the results section.  
6.2.3.2 Standard Curve to test Primer Efficiency 
 
In qPCR, standard curves are used to test the efficiency of the primers. This is particularly 
important when using relative quantification qPCR methods. Primer efficiency indicates 
whether there is 100% doubling of the target DNA per cycle during the exponential phase of the 
PCR reaction. Generally, an efficiency between 90 and 110% is considered acceptable. Primer 
efficiency is important as a sample amplified under low and high efficiency conditions affects the 
Ct values for the sample and affects repeatability. To assess PCR efficiency, a standard curve is 








a range of concentrations. The standard curve comprised a 1:5 dilution series that covered 5 
logs to ensure the accurate calculation of the efficiency of the probes. The resulting Ct values 
were plotted against the log of the concentration of the DNA, and the slope was calculated. The 
efficiency of the primers is calculated using the following equation:  
𝐸 = 10−
1
𝑠𝑙𝑜𝑝𝑒 − 1 
As discussed in the results section below, there were some issues with primer efficiency. A range 
of different conditions were tested in an attempt to optimise the reaction, including trialling 
different concentrations of mitochondrial probe. Standard curves from assays containing 1x, 
0.5x, 0.25x and 0.125x mitochondrial probes were produced. 
6.3  Results 
6.3.1  In silico testing 
An association between gout and mitochondrial DNA copy number was detected in the Whole 
Genome Sequencing cohort, which was replicated in the Urate Resequencing cohort (Table 6.2). 
The data show that lower ratios of mtDNA:chromosome 2 (i.e. the relative amount of mtDNA) 
are seen in patients with gout compared to controls without gout (Figure 6.5). 
Figure 6.5 shows significant overlap between the relative amounts of mtDNA in participants 
with gout versus healthy controls, however, on average, the ratios are lower in those with gout. 
This is reinforced by the statistically significant association calculated when a logistic regression 
is performed, despite the relatively small numbers of individuals in the study.  
 
Table 6.2: Results from logistic regression testing association between gout status, ratio of mtDNA: chr2 
reads, sex, age and grandparental ancestry in two cohorts 
Cohort n Estimate (SE) Pr (>|z|) 
In Silico whole genome sequencing 72 -391.66 (134.36) 0.004* * 










Figure 6.5: Box plots showing the difference in ratio of mtDNA to nuclear DNA among NZ Māori and Pacific 
gout cases and controls. A) Shows the ratio differences in the whole genome dataset, while B) shows the ratio 
differences in the resequencing cohort. 
 
6.3.2 Quantitative PCR 
6.3.2.1 qPCR of samples 
 
Firstly, a plate replicating samples from the Whole Genome and Resequencing cohorts was run 
to validate the in silico approach. Of the 75 Sequencing cohort individuals, 64 of them had a 
standard deviation of the Ct replicates below 0.4. The remaining 11 individuals were excluded 
from the analysis. When a Spearman Correlation was performed, testing for similarity between 
the in silico results for the Sequencing Cohort with the qPCR results, a correlation of -0.58 (P = 
5.67 x 10-7) was found ( Figure 6.6a). The correlation coefficient is negative because of the way 
in the ΔCt values were calculated (i.e. subtracting the Ct for the mitochondrial probe from the Ct 
for the reference probe) – because the mtDNA is relatively more abundant than the reference 
RNase P DNA, the more negative the ΔCt, the more mtDNA is present. Similarly, for the 
Resequencing cohort, 65 individuals were run, of which 58 individuals remained after filtering. 
A Spearman Correlation of -0.81 (P = 1.21 x 10-14) was found between the qPCR results and the 
results obtained from the NGS data ( Figure 6.6b). 
The significant correlations between the in silico data and from those obtained through the qPCR 
show that the differences that were observed in the NGS data were replicable real differences.  









 Figure 6.6: plot showing correlation between the experimental and the in silico results for A) The Whole 
Genome Cohort; and B)the Urate Resequencing Cohort. Note that the more negative the ΔCt value, the higher 
the mtDNA copy number 
Because the qPCR data correlated well with the in silico data, further samples were assayed to 
increase the sample size to allow for testing further associations. A further 480 individuals were 
assayed using qPCR. After filtering to a standard deviation of less than 0.4, and removing 
individuals who had been assayed multiple times (choosing the ΔCt value with the lowest 
standard deviation between technical replicates), 484 individuals remained. Statistical analyses 
were carried out for these individuals, regressing gout status against the ΔCt value calculated, 
and adjusting for various parameters (sex, age, ethnicity, qPCR batch and percentage of self -
declared Polynesian grandparentage) (Table 6.3). A significant association was found between 
gout status and ΔCt  (OR 1.33 (1.03-1.75), P = 0.03). This means that per ΔCt  unit increase, people 
have a 33% higher chance of having gout, and given that a higher ΔCt value reflects the individual 
possessing less mtDNA, this amounts to individuals with gout possessing less mtDNA, on 
average (Figure 6.7a).  
When the cohort was divided on the basis of ancestry (East versus West Polynesian), it was 
found that the trend was stronger among East Polynesians than West Polynesians (Figure 6.7b-
c). This was reflected in the results of the statistical models (Table 6.3), where a statistically 
significant association between reduced mtDNA and gout was found among the East Polynesians 
(OR 1.44 (1.03-2.03), P = 0.03), but not the West Polynesians (OR 1.25 (0.79-2.02), P = 0.34), 
though the odds ratio was still trending in the same direction for the West Polynesians. 
The same trend was significant among males where an increase in ΔCt was associated with gout 
risk (OR 1.50 (1.09-2.10), P = 0.01), but not females (OR 0.98 (0.58-1.66), P = 0.95). This is 
possibly in part because of the low number of female gout cases. 








When the asymptomatic hyperuricaemic individuals (those possessing serum urate levels above 
0.42 mmolL-1) in the cohort were used as controls to test for the association of gout with ΔCt, not 
only was a statistically significant association was detected between reduced mtDNA copy 
number and gout, but there was also a stronger effect size detected, where for each unit increase 
of ΔCt, there was a two-fold higher risk of gout (OR 2.14 (1.22-3.90), P = 0.01)(Figure 6.7d). This 
indicates that the mechanism is likely something immunological rather than resulting from an 




Figure 6.7: Box plots showing the differences in dCt values between gout cases and healthy controls from: a) 
484 Polynesians; b) 261 East Polynesians; c) 223 West Polynesians; d) 167 Hyperuricaemics. Note that a more 
negative dCt relates to more mitochondrial DNA  
A B 








Table 6.3: Results from logistic regression testing association between gout status, ΔCt from qPCR. Adjusted 
results include sex, age, ethnicity, qPCR batch and percentage self-declared Polynesian grandparental 
ancestry as covariates.  
Samples n Gout/Controls OR (95% CI) Pr (>|z|) 
All Polynesians 484 243/241 1.33 (1.03-1.75) 0.03* 
East Polynesians 261 138/123 1.44 (1.03-2.03) 0.03* 
West Polynesians 223 105/118 1.25 (0.79-2.02) 0.34 
Males 336 207/129 1.50 (1.09-2.10) 0.01* 
Females 148 36/112 0.98 (0.58-1.66) 0.95 
Hyperuricaemics 167 109/58 2.14 (1.22-3.90) 0.01* 
 
6.3.2.2 Standard Curve to test Primer Efficiency 
Standard curves were generated to test the efficiency of the probe sets used in the quantification 
of mtDNA (Figure 6.8). Unfortunately, the standard curve was not run at the beginning of the 
experimentation. It was assumed that because the probes were predesigned by Applied 
Biosystems and had therefore been tested extensively for specificity and efficiency, that running 
a standard curve was not immediately important, which in hindsight was a mistake.  
The PCR efficiency from a standard curve produced from a 1:5 dilution series (Figure 6.5) was 
100% and 160% for the mitochondrial probe and the reference probe respectively. Ideally, 
efficiency should be 100%, though a range of 90-110% is generally accepted. Clearly, the 
efficiency of the reference probe falls outside this range. A high efficiency calculation is usually 
indicative of some kind of inhibition inside the PCR reaction, rather than the reaction being extra 
efficient (it is impossible for the DNA to more than double per cycle, so “high” efficiency actually 
indicates a problem with the assay) – in this case this may result from the huge disparity 
between the mitochondrial and nuclear target, with the mitochondrial reaction out-competing 
the reference and causing a reduction in efficiency. 
As such, further experiments were carried out with reduced concentrations of mitochondrial 
probe. A standard curve produced with 0.25x mitochondrial probe and 1x reference yielded the 
best results, with 93% and 114% reaction efficiency respectively (see appended material). This 
did not ablate the problem as this falls outside the accepted 90-110% range. Likewise, when the 
probes were run in single-plex, the mitochondrial probe did not have efficiency falling within 










Figure 6.8: Standard curve assessing assay efficiency, efficiency calculated for mtDNA probe 99.8%; efficiency 
of the RNase P probe 159.4% 
This has implications for the assays that were carried out and means that relative quantification 
using the ΔΔCt method could not be undertaken as the mitochondrial DNA is being amplified at a 
different rate than the nuclear DNA. Despite this, the data from the assay should still show 
differences in copy number between samples. The concentration of DNA in samples used in the 
assay were normalised to around 8 ng/PL, thus the relative amounts of starting material should 
be around the same. The systemic problem of the different priming efficiencies may in fact 
amplify the differences in mtDNA between samples, so if more mtDNA is present in a given 
sample, there may be slightly more inhibition of the reference assay compared to those with less 
mtDNA. However, despite these problems, there was a strong correlation between the qPCR 
results and the in silico results (Spearman rank correlations of -0.58 (P = 5.67 x 10- 7) and -0.81 
(P = 1.21 x 10-14) for the Whole Genome and Resequencing data respectively) which suggests 










6.4.1 In silico testing methods 
 
There have been a number of methods published recently regarding the extraction of mtDNA 
copy number from NGS data (Chu et al., 2012, D'Erchia et al., 2015, Ding et al., 2015, Fragouli et 
al., 2015). D'Erchia et al. (2015) even published a study which looked at the amount of mtDNA 
using off-target reads, much in the manner which was done in this thesis, with the data from the 
Urate Resequencing Cohort. Given that three of these methodologies have been published this 
year (2015), there has clearly been a global trend in maximising what information can be 
obtained from NGS datasets. In line with this are emerging tools for investigating nuclear 
genome copy number variation, by examining regions where there are higher proportions of 
reads mapping (Zhao et al., 2013). In effect, the approach taken in this thesis is a crude version 
of this. 
Use of relative mapping coverage to calculate “mtDNA copy number” , much in the manner of 
Ding et al. (2015) for the Whole Genome and Resequencing data was undertaken and a range of 
55-411 and 21-308 copies of mtDNA was calculated for each dataset. However, because of the 
low coverage nature of the whole genome data (1-3x mean coverage), and the low proportion of 
off-target reads in the Resequencing data, it is unclear how reliable these assignments are. It was 
decided that using the ratios of mitochondrial to nuclear reads, which in effect communicate the 
same information but do not assume to make absolute calls, was the best approach.  
 
6.4.2 qPCR Issues 
 
The issue with the qPCR and the differences in the efficiency of the primers is not a trivial 
matter. It does raise concerns surrounding the data produced from the assay presented here. 
However, given the correlation with the Whole Genome Sequencing and the Urate Resequencing 
cohorts (-0.60 and -0.81 respectively), the differences seen between copy number among gout 
cases and controls are consistent with the trends detected in these datasets, and thus are robust. 
This is a significant, novel finding which may elucidate processes surrounding the disease 
development.  
A number of strategies to improve the assay have been undertaken, including reducing the 
amount of mitochondrial probe which appears to be significantly outcompeting the nuclear 








success in improving the assay, which will have to be repeated prior to the publication of these 
results. Due to time constraints, it was not possible to optimise the experiment prior to writing 
up this thesis. 
Numerous studies using qPCR to assess mitochondrial copy number that have been carried out 
in the literature use SYBR Green assays rather than TaqMan assays (e.g. (Amaral et al., 2007, 
Burgueño et al., 2013, Menezes et al., 2013, Xie et al., 2013, Zhou et al., 2014)). The chemistry 
behind these assays is quite different. SYBR green dye binds to double stranded DNA, so as the 
PCR reaction progresses and the total amount of DNA increases, the fluorescence also increases 
accordingly. Because the dye binds to any double-stranded DNA non-specifically, the test and the 
reference assays need to be done separately, rather in duplex. This makes the method prone to 
subtle differences in amounts of starting template, and thus is less sensitive.  
In contrast, the TaqMan copy number assays use a fluorogenic probe specific to the target gene 
and reference, and are able to detect the fluorescence of both of these in a single tube. This 
specificity has definite advantages, however, clearly there are some issues with getting both 
probes working at similar efficiency in a duplex reaction. There is variability in the literature as 
to how people employ these probes and there is little standardisation as to how to quantify. 
Even with TaqMan probes, there are some laboratories that run the reactions singly (Grady et 
al., 2014), presumably to avoid problems with competition between the abundant mtDNA and 
the nuclear templates. Other laboratory groups appear to have got similar duplex (or indeed, 
multiplex, with two mitochondrial probes and a nuclear marker (Phillips et al., 2014)) assays 
working (Ashar et al., 2015), though with different mitochondrial probes and nuclear references. 
This indicates that with additional experimental modification, it is likely that the assay can be 
improved.  
In the meantime, the data presented here are interesting, especially in the context of other 
recent findings surrounding the role of the mitochondria, and mtDNA, in the establishment of an 
NLRP3 inflammatory response. 
 
6.4.3 Reasons for reduced mtDNA copy number in individuals with gout 
 
It was found that mtDNA copy number was reduced in people with gout compared to healthy 
controls. This trend was significant in males (OR 1.50 [1.09-2.10], P = 0.01), but not females (OR 
0.98 [0.58-1.66], P = 0.95), which may relate to differences in urate handling between males and 








and a reduced risk of gout (Hak & Choi, 2008)). Interestingly, it was possible to detect a stronger 
effect when testing for an association between gout status and mtDNA copy number in a subset 
of individuals possessing elevated serum urate levels. There was a two-fold higher risk of gout 
for each unit increase in ΔCt (OR 2.14 [1.22-3.90] P = 0.01) among individuals with serum urate 
levels equal to or exceeding 0.42 mmolL-1, compared to a 30% increase in gout risk in the 
unfiltered cohort which includes individuals with lower serum urate levels (OR 1.33 [1.03-1.75] 
P = 0.03). An increase of ΔCt represents a decrease in the amount of mtDNA. This indicates that 
the mechanism is likely something immunological rather than resulting from the elevated serum 
urate levels which predispose to gout. Given the role of mitochondria in the stimulation of the 
NLRP3 inflammasome, being directly involved in the co-localisation of NLRP3 inflammasome 
components (as discussed previously in Chapter 4, but also see (Misawa et al., 2013)), this 
reduction of mtDNA may be indicative of processes contributing to the inflammation itself. 
Given the regular distribution of nucleoid structures in the mitochondrial inner membrane, a 
reduction in mtDNA copy number may be indicative of a reduction of total mitochondria or total 
mitochondrial mass (since mitochondria come in a range of sizes) (D'Erchia et al., 2015). There 
are several different scenarios that could explain the decrease in mtDNA copy number in the 
individuals who have gout: 
a) The process of the disease itself is causing the decreased copy number. Under this 
scenario, a reduction in mtDNA copy number could be considered to be a marker of 
disease. 
b) Reduced mtDNA copy number results in susceptibility to disease, perhaps via reduced 
mitochondrial biogenesis and mitophagy. 
c) Reduced mtDNA copy number is unrelated directly to disease, but is related to 
confounding factors that contribute to susceptibility to gout. 
This study lacks data that could disentangle which of these scenarios is predominantly occurring 
– this would require more than just the genetic data presented here. One approach that could 
support our preliminary results would be the analysis of cell lines.  However despite this, each of 










6.4.5 Disease-induced mtDNA reductions? 
 
Reduced mtDNA among individuals with gout may in part be mediated by the inflammatory 
processes in gout, in particular the stimulation of the NLRP3 inflammasome. This may occur 
either by direct damage to the mtDNA of the peripheral blood mononuclear cells (PBMCs) from 
which the mtDNA was prepared, during the stimulation of the inflammasome with increased 
ROS production, or perhaps by the recruitment of neutrophils during the inflammatory process.  
IL-1E is one of the major cytokines produced as a result of the induction of the NLRP3 
inflammasome. This cytokine has been shown to recruit neutrophils and eosinophils (Mitroulis 
et al., 2011), which have been shown to react to MSU crystals by ejecting their mtDNA in a 
neutrophil extracellular trap (NET) (Yousefi et al., 2008, Yousefi et al., 2009, Schorn et al., 
2012a). NETs have been found to be part of the innate immune response against bacteria 
(Brinkmann et al., 2004), and can comprise nuclear DNA (complete with pro-inflammatory 
histones)(Saffarzadeh et al., 2012) or mtDNA (Yousefi et al., 2009). Their induction by MSU 
crystals suggests that they may be playing a role in gout (Schorn et al., 2012b). These NETs 
aggregate and effectively immobilise and degrade cytokines and chemokines, assisting in the 
localisation and resolution of inflammation (Farrera & Fadeel, 2013, Schauer et al., 2014). This 
may mean that this mechanism is important in the resolution of the inflammatory responses in 
gout. Interestingly, NETs have also been found in patients with atherosclerosis (Megens et al., 
2012, Borissoff et al., 2013), another NLRP3 inflammatory condition, which may lend credence 
to this hypothesis. 
Another possibility is that individuals with gout (and perhaps also other metabolic conditions) 
may have altered mitochondrial structure resulting from the pathology. There have been a 
number of studies that have found changes in mitochondrial conformation in pathological 
individuals (Widlansky et al., 2010, Sobenin et al., 2013). Widlansky et al. (2010)  noted that 
while the number of mitochondria in type 2 diabetes patients remained consistent, 
mitochondrial mass decreased, with the mitochondria in the individuals with type 2 diabetes 









Figure 6.9: Differences in mitochondrial morphology between patients with type 2 diabetes compared to 
healthy controls. The mitochondria from the participants with type 2 diabetes (A) are generally smaller and 
rounder compared with healthy controls (B). The white arrows point to representative mitochondria in each 
image (Widlansky et al., 2010)  
 
Furthermore, Sobenin et al. (2013) found structural abnormalities of the inner membrane of 
mitochondria belonging to patients with carotid atherosclerosis compared to healthy individuals 
(Figure 6.10). In the patients with atherosclerosis, there was a decreased mitochondrial inner-
membrane and fewer cristae, and in some cases, there were disruptions to the inner membrane 
entirely. A reduction in the number of mitochondrial cristae may also contribute to reduced 
amounts of mtDNA, given that it is this inner membrane to which the nucleoid structures 
containing the mtDNA are anchored. 
Given the connections between type 2 diabetes, atherosclerosis and the NLRP3 inflammasome 
(discussed in Chapter 4), it may be that other conditions with an NLRP3-mediated inflammatory 
response also have altered mitochondrial structure. Either reduced mitochondrial mass (as 
observed in type 2 diabetes patients (Widlansky et al., 2010)) or a disrupted inner membrane 
(exhibited by the reduced cristae in carotid atherosclerosis patients (Sobenin et al., 2013)) may 
account for the reduced mtDNA levels which are observed in people with gout in this study.  
Another thing that remains unclear is whether the changes in mitochondrial morphology 
observed in the patients with type 2 diabetes and atherosclerosis described above are a result of 












Figure 6.10: Different ultrastructural appearances in leukocytes obtained from healthy volunteers and 
patients (A) with carotid atherosclerosis (B-F). Note the well-defined cristae and well-preserved surrounding 
membranes in the mitochondria from the healthy volunteer (A). This contrasts with the reduced numbers of 
cristae and the oedema of the mitochondrial matrix observed in patients with carotid atherosclerosis (Image 
modified from Sobenin et al, 2013) 
The role of mitochondria in the induction of the NLRP3 inflammasome, and the importance of 
the production of radical oxygen species (ROS) as a means of cell signalling, might very well 
account for lower mtDNA copies (and therefore lower numbers of mitochondria) in individuals 
suffering from gout. Mitochondrial ROS production and oxidative stress (Tschopp & Schroder, 
2010, Tschopp, 2011) have been observed to correlate with NLRP3 activation. Mitophagic 
processes, removing damaged mitochondria from circulation, are required to prevent 
mitochondrial ROS and excessive NLRP3 signalling (Nakahira et al., 2011, Zhou et al., 2011). 
Uncontrolled production of ROS by the mitochondria may result in damage to mtDNA and 
therefore reduction in the amount measurable. 
 
6.4.6  Reduced mtDNA contributes to disease susceptibility? 
 
The reduction in mitochondrial mass, and thereby mitochondria, may be contributing to the 








have been studies that suggest reduced amounts of mtDNA precede the onset of type 2 diabetes 
(Lee et al., 1998).  
This certainly may be in line with a study that has suggested that the variant 16189C causes 
alteration of mtDNA copy number in human blood cells (Liou et al., 2010). As discussed in the 
previous chapter, this variant is one that defines the B macrohaplogroup, and was possessed by 
95% of the individuals whose mitochondrial genomes were sequenced in this study. 
Unfortunately there is only an overlap of 120 individuals between the whole mitochondrial 
genome dataset and the qPCR that has been carried out to assess mitochondrial DNA copy 
number, which is not enough individuals to robustly statistically assess whether mitochondrial 
genetic variants may be contributing to differences in mtDNA copy number, or whether the B 
macrohaplogroup has a reduced amount of mtDNA compared to other haplogroups. However, it 
is reasonable to speculate given the high frequency of this variant among Pacific peoples, that 
this may contribute to the high burden of metabolic disease – however, an inter-population 
study (or even an inter-mitochondrial haplogroup study) looking at relative amounts of 
mitochondria in peripheral blood has not yet been undertaken. 
As discussed earlier, reduced mtDNA copy number may come about through the reduction of 
mitochondrial biogenesis and mitophagy. The governance of mitochondrial mass is something 
which is not entirely understood, though there have been some contributing factors identified. 
Inhibition of mitochondrial autophagy has been found to have a pro-inflammatory effect 
(Nakahira et al., 2011).  
On the other hand, given that gout, and also many other metabolic diseases, are associated with 
age (Smith et al., 2014), and mitochondrial copy number is known to decrease with age, it may 
be that it is the reduction of mitochondria, which is contributing to the susceptibility to disease. 
There have been a number of compelling papers on the subject of telomere dysfunction and 
telomerase reverse transcriptase (TERT) deficiency and mitochondrial impairment (Haendeler 
et al 2009; Kovalenko et al 2010, Sahin et al 2011). Sahin et al (2011) found that in a TERT-
deficient murine model, there was a repression of the peroxisome proliferator-activated 
receptor gamma, coactivator 1 alpha and beta genes (PPARGC1A and PPARGC1B), which encode 
proteins important in mitochondrial biosynthesis, and therefore which may affect mitochondrial 
copy number.  
If a reduction of mitochondrial mass (as evidenced by the reduction in mtDNA copy number) is 
contributing to the development of gout, peroxisome proliferator-activated receptor gamma 
(PPARγ) agonists such as pioglitazone, which have been used in type 2 diabetes therapy 








shown to significantly increase mitochondrial copy number, as well as the expression of factors 
involved in biogenesis such as PPARGC1A and mitochondrial transcription factor A (TFAM) 
(Bogacka et al., 2005). 
In a gouty rat model, pioglitazone was found to reduce cytokine expression (Wang & Jiang, 
2014). This finding was supported by the work of Hong et al. (2015), who found that treatment 
with pioglitazone significantly reduced MSU crystal-induced NLRP3 inflammasome activation 
and IL-1β production in a HK-2 cell line. 
Likewise, a study of women suffering polycystic ovary syndrome found that upon treatment 
with pioglitazone, there was an up-regulation of OXPHOS genes, mediated by an increase in 
PPARGC1A expression (Skov et al., 2008). Granted, that the sample size in this study was small 
(10 cases and 13 healthy controls), treatment improved the insulin-stimulated glucose 
metabolism and plasma adiponectin, and reduced fasting serum insulin.  
As discussed previously in Chapter 4, mitochondrial biogenesis is protective of inflammation. If 
it is indeed the reduced number of mitochondria that is contributing to susceptibility to gout, it 
may mean that upregulation in mitochondrial biogenesis via therapies such as pioglitazone may 
prove to be a therapeutic option in treating gouty disease. Among the hyperuricaemics tested in 
the expanded cohort (Table 6.3), it was found that there was a significantly lower amount of 
mtDNA among the participants with gout compared to the asymptomatic hyperuricaemic 
controls.  
 
6.4.7 Reduced mtDNA is not directly related to gout, but instead related to lifestyle 
factors that contribute to gout? 
 
Other factors are known to affect mitochondrial mass/copy number as well, including exercise – 
it was nearly 50 years ago that Holloszy (1967) first observed that exercise training affects the 
biosynthesis of mitochondrial proteins. More recently, it has been shown that this is 
accompanied by an increase in mitochondrial volume (Irrcher et al., 2003, Wright et al., 2007, 
Geng et al., 2010). The general decline in physical activity is one environmental factor that has 
changed markedly in the last 50 years, and this increase in inactivity is probably related to an 
increased prevalence of a multitude of chronic metabolic diseases (Poulsen et al., 2001). Low 
cardio-respiratory metabolic fitness (generally measured as the maximum volume of oxygen 
that an individual can use, i.e. VO2max) is a strong independent risk factor for not only several 
cardiovascular diseases but also other metabolic conditions and indeed, all-cause mortality (Wei 








mitochondrial content has been observed in individuals with metabolic disease. This is not 
necessarily the total number of mitochondria, but certainly in their relative size. Type 2 diabetes 
and obese subjects have been found to possess smaller skeletal muscle mitochondria compared 
with those in lean controls (Kelley et al., 2002). While what has been discussed here relates to 
mitochondrial content of skeletal muscle, it has been shown that exercise can similarly affect 
mitochondrial biogenesis in peripheral blood (Lim et al., 2000), which is the tissue used in this 
study. 
As such, exercise may be a confounding factor – one that could not be accounted for because of 
insufficient data collected surrounding the activity habits of the study participants. There has 
been evidence to suggest that more active men are at less risk of developing gout (Williams, 
2008), however there is also the converse problem where minor damage associated with sports 
injuries may induce the onset of a gout flare (Baker & Synnott, 2010). Given the severe pain 
associated with gout, this may discourage gout-prone individuals from partaking in voluntary 
physical activity which may, in turn, account for these reduced amounts of mtDNA that are 
observed among this gout cohort.  
 
6.4.8 Concluding remarks 
 
While it is not possible to disentangle whether the reduction of mtDNA content among the 
participants with gout is causal of disease, a result of it or just some coincidental bystander, the 
finding may be significant in understanding the pathological processes in disease. For instance, 
as suggested previously, if the reduction in mtDNA and mitochondrial mass is playing a causal 
role in disease, drug therapies that induce mitochondrial biogenesis may be something that 
could be explored. This finding may provide valuable insight into the mechanisms that underlie 












This thesis had three main aims, all relating to understanding how the evolutionary and 
population history of Pacific peoples may have contributed to the high metabolic disease burden 
present among contemporary Polynesians.  
Gout is shown to be a disease with quite some antiquity in the Pacific, dating back to the earliest 
inhabitants of the region (Buckley, 2011). Through historical research it is established that these 
reports of gout from archaeological sites is unlikely to be coincidental. The condition is likely to 
have been common throughout time and space, not just a result of changing diets and lifestyles 
with western influence (or in the archaeological cases, a reaction to high purine diets among the 
earliest settlers prior to the establishment of horticultural food crops). This points to a genetic 
predisposition, probably predating the settlement of the region. 
A case for considering population history as being important when it comes to formulating 
hypotheses to explain the burden of genetic disease is also something that is stressed 
throughout this thesis. The archaeological and historic findings fall into a wider context wherein 
elevated serum urate levels can be seen in many Pacific populations, particularly those who 
speak Austronesian-languages and are descendants of a population expansion out of Asia that 
began some 5000 years ago. It is likely that these colonists possessed an innate genetic 
predisposition to high urate levels, which may contribute to the high burden of metabolic 
disease. 
With this background information, the ‘Thrifty Genotype’ hypothesis, a commonly applied 
explanation for metabolic disease susceptibility, was assessed in the context of the Pacific and 
found wanting. Not only is there no evidence to support the ‘Thrifty Genotype’ hypothesis 
among Pacific populations, but it is also not supported on a more global scale. There has been no 
genetic data that support it, despite it being more than 50 years since the hypothesis was first 
proposed and the wide-scale application of the hypothesis to many diverse populations. Other 
environmental exposures, such as infectious disease, have been established to have shaped the 
genome, so are more obvious causal factors to explore. Thus with consideration of the history of 
the Pacific and the island South East Asian homeland of the Austronesian-speaking populations 








the high prevalence of hyperuricaemia, gout and other related metabolic conditions. This 
proposed that exposure to malaria may have resulted in genetic selection for variants 
contributing to an up-regulated NLRP3 inflammatory response, which may manifest in part with 
elevated serum urate levels. It is important to be upfront that this hypothesis was not tested in 
this thesis, though it may be something worth exploring further in future. 
In light of the recent immunological findings surrounding the probable involvement of the 
mitochondria in the development of the NLRP3 inflammasome response, an immune pathway 
involved in not only the resolution of infectious diseases but a multitude of chronic auto-
inflammatory conditions, mitochondrial genetic variation may contribute susceptibility to 
disease development. Mitochondria more generally have also been suggested to play a role in 
the development of metabolic disease through imbalances in energy generation, given the 
mitochondria’s central role in oxidative phosphorylation and ATP production. Thus, complete 
mitochondrial genomes of 442 Polynesians were sequenced and associations between obesity 
(as a proxy for impaired mitochondrial energetics) and gout (as a proxy for inappropriate 
inflammatory responses) were tested. The mitochondrial genetic variation among Polynesians is 
relatively constrained, however it was possible to detect some associations between 
mitochondrial variation and gout. The SNP variant T16183C was found to associate with gout in 
this population and is likely to be a marker for a heteroplasmy in hypervariable region 1 (HVR1) 
spanning from positions 16179-16183. This heteroplasmy was found to associate with gout. 
Indeed this 16183C variant was in linkage disequilibrium with the variant 16189C, which had 
previously been associated with metabolic diseases in other populations (Poulton et al., 2002, 
Liou et al., 2007, Park et al., 2008). This variant contributes to a poly-cytosine tract which might 
be directly responsible for the heteroplasmy seen in this region as it is hypothesised that 
extended homo-nucleotide tracts may result in polymerase slippage (Verscheure et al., 2015). 
These variants may fall into a the wider genetic predisposition of those carrying the B4 
mitochondrial macrohaplogroup as being more prone to disease, something that was unable to 
be tested using this cohort because of the 96% frequency of the lineage among those genotyped. 
Previous studies of mitochondrial variation among Taiwanese have suggested that the B4 
lineage is more susceptible to type 2 diabetes than many other common mitochondrial lineages 
(Liou et al., 2007). Cybrid studies have suggested that this lineage may be more susceptible to 
oxidative stress (Lin et al., 2012), which may lend credence to this link.  
The distribution of mitochondrial variation in the Pacific appears to correlate with the 
Austronesian expansion, and the differences in derived B4 haplotypes may be indicative of 








Polynesian populations and occur at very low frequencies among West Polynesians. These sorts 
of differences in allele frequency may both provide evidence for population origins and 
settlement history and may further suggest different frequencies of risk alleles between 
populations. 
While only a few mitochondrial variants appear to be associated with an increase in risk of gout, 
a previously unreported decrease in mtDNA copy number in individuals with gout was found in 
this study. It is unclear as to whether this is the result of the disease processes i.e. mitochondrial 
damage sustained during the stimulation of the NLRP3 inflammasome, or whether it is providing 
risk in itself.  
This finding is significant in a number of ways, though clearly further research is necessitated. If 
the reduction in mitochondrial copy number precedes the onset of gout, it may prove useful as a 
diagnostic measure for those susceptible to developing gout. It also opens up possibilities for 
gout therapy, meaning that drugs that stimulate mitochondrial biogenesis, such as pioglitazone, 
may have some utility.  
 
7.2 Limitations of study 
 
Putting aside the obvious methodological problems from Chapter 6, which still require more 
work to optimise the qPCR, there are a few limitations to this thesis. A wider sampling of 
populations throughout the Pacific region would have improved what could be said regarding 
the evolutionary history of the region. For instance, there is the possibility that the B 
mitochondrial lineage in itself is contributing to risk of metabolic disease, something that due to 
the limited diversity among the Polynesians could not be tested. This is where a more genetically 
diverse study cohort would be useful. 
Furthermore, while evolutionary explanations for the high prevalence of metabolic disease 
among Pacific Islanders, largely the ‘Thrifty Genotype’ hypothesis, are critiqued, these are not 
explicitly tested in this work using quantitative methods. This could be done by looking for 
signatures of genetic selection at loci which have been associated with metabolic disease among 
Polynesians, using statistics such as Extended Haplotype Homozygosity (EHH) (Sabeti et al., 
2002) and the integrated haplotype score (iHS) (Voight et al., 2006), though a genome-wide 
approach would be more ideal. Bioinformatic testing for evidence of selection is underway by 
another postgraduate student in the Merriman laboratory that will shed further light on the 








hypothesis still remains an improbable driver of selection for the reasons presented in Chapter 
3. It remains an example of where the evolutionary history of the region has been overly 
simplified and not properly considered before the application of a ready-made hypothesis. 
Likewise, the malaria hypothesis proposed here, is not explicitly tested either, however it 
remains a tenable possibility for further investigation.  
 
7.3 Future directions 
 
A number of possibilities for further research arise from this thesis. Most notably, the case study 
of the ‘Thrifty Genotype’ hypothesis and its inappropriate usage (and over usage) really 
emphasises the need to explicitly test hypotheses. It was one of the aims when beginning this 
research to test the malaria hypothesis that is proposed in Chapter 3, however this did not end 
up occurring because of delays in getting research permits. If malaria had indeed been a 
selective pressure for elevated serum urate levels, it may be expected to see elevated serum 
urate in ancestrally-related Lapita-descendent populations still living in malarial regions – 
populations in which there are very little data on in the medical literature. Much time and effort 
has been put into acquiring funding, ethical approval and research permits from the Papua New 
Guinea Institute of Medical Research to undertake such research in Kavieng in the New Ireland 
Province of Papua New Guinea. Kavieng is the regional capital and has a major hospital and large 
resident and semi-resident populations from the off-shore islands. The people of Emirau, 
Mussau, Tabar and similar islands located off the coast of New Ireland are ideal candidate 
populations to test this malaria hypothesis. These islands are known to have been first colonised 
by Lapita peoples 3350 years ago, and have been occupied continuously since this time, so the 
current inhabitants are likely to be Lapita-descendants (i.e. ancestrally related to modern 
Polynesians). Malaria rates for the New Ireland region are some of the highest recorded for New 
Guinea (PNG National Department of Health, 2013).  
The research permits ultimately took too long to come through for the time frame of this thesis, 
which led to the need to explore other questions. Despite these bureaucratic problems with 
doing research in developing countries, it is important for research to be done in such regions, 
not only to shed light on evolutionary hypotheses like the ones discussed in this thesis, but also 
potentially highlighting chronic diseases among remote communities which may have gone 
unreported. Gout, and indeed type 2 diabetes, are debilitating diseases, which are increasingly 








assist in public education and to help develop strategies for dealing with such burdens of 
disease.  
Expanding the mitochondrial study into a more genetically diverse population (such as that from 
Kavieng, Papua New Guinea) is another interesting possibility. As shown here, it was possible to 
detect some variants within the mitochondrial genome that may be playing a role in the 
development of auto-inflammatory conditions like gout, though our cohort was admittedly small 
and further investigation is still required. While there have been an increasing number of 
studies of mitochondrial diversity in the Pacific region, and even more worldwide, few have 
focused on the implications of the mitochondria being a functionally important unit, despite this 
having been discussed by researchers like Douglas Wallace in the literature since the early 
1990s. Anthropological and medical research do not have to be done in a mutually exclusive 
manner, and indeed, acknowledgement of the population history and cultural particulars of a 
population may enhance medical studies, particularly medical genetics studies, markedly.  
The observed reduction of mtDNA in participants with gout and the recent immunological 
evidence surrounding a role for mitochondria in the generation of a NLRP3 inflammatory 
response is certainly something that requires further research and may be indicative of the 
processes underlying disease. This reduced mtDNA content may be indicative of a reduction in 
the size and/or number of mitochondria. As discussed in Chapter 4, mitochondria play an 
important role in the activation of the NLRP3 inflammasome, with the physical translocation of 
mitochondria to the endoplasmic reticulum via tubulin-mediated transport. The finding of 
reduced mtDNA copy number has several implications and opens up a number of possible novel 
therapeutic options – in both cases where reduced mitochondrial mass contribute to the 
development of disease and where disease contributes to reduced mitochondrial mass. For the 
former, therapies that increase the rate of mitochondrial biogenesis (such as pioglitazone) may 
be valuable (Bogacka et al., 2005). While the latter may indicate that therapies aimed at reducing 
the physical translocation of mitochondria to the endoplasmic reticulum during the induction of 
the NLRP3 inflammasome, for instance the targeting tubulin deacetylases such as HDAC6 or 
Sirtuins, may be of some utility (Akira et al., 2013). Indeed, the treatment colchicine for acute 
inflammatory gout is thought to be a tubulin deacetylase inhibitor (Misawa et al., 2013). 
In an evolutionary sense, the finding of the reduced mtDNA among the participants with gout 
may also suggest a potential mechanism underlying the high rates of gout and other metabolic 
diseases among Pacific peoples. Up-regulation of a tubulin deacetylase inhibitor, allowing for the 
more ready activation of the NLRP3 inflammasome, may be a trait susceptible to selection by an 








prevalence of hyperuricaemia in Pacific peoples. Recent research from the Merriman laboratory 
has found copy number variation at a locus putatively thought to be involved with tubulin 
polymerisation and organisation into microtubules, which associates with gout risk. This has not 
yet been explored among Pacific peoples. Given the past exposure of populations in this 
geographic region to this pathogen, it may have resulted in associated variants to occur at higher 
frequency in certain populations.  
The reduced mtDNA finding is not only relevant to gout, but possibly to other NLRP3-associated 
auto-inflammatory diseases which occur at high frequency among Pacific peoples, including type 
2 diabetes and cardiovascular disease. It would be worth investigating whether a similar 
reduction of mtDNA can be detected in individuals suffering these conditions, and whether there 
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8.1.2 Hyperuricaemia in the Pacific: why the elevated serum urate levels? Rheumatol. 

















































































































8.1.3 Pacific Populations, Metabolic Disease and ‘Just-So Stories’: A Critique of the 




























































































8.2 Appendix 2: Historic Newspaper articles regarding gout 
 
Excerpts from regional newspapers in New Zealand from the 19th and early 20th centuries 
mentioning gout in Maori persons, assessed via Papers Past 
(http://paperspast.natlib.govt.nz/cgi-bin/paperspast) 
New Zealand Herald, 28 June 1865 Another chief, Winiata, appeared to afford some amusement to his 
own confreres, by the fact of his having to come to Court with a long 
pole and his boot off, actually troubled by that peculiar disease only 
claimed by English aristocracy as their hereditary right - the "gout". 
Probably Uiniata [sic.] was aware of this complaint being a sign of 
good blood, for in spite of the twinges by which he evidently 
suffered during his stay in Court, he evidently bore the "chaffing" of 
his friends with the greatest nonchalance, and almost looked proud 
of being the possessor of such a proof of his descent. Dr Nicholson 
informed me it was the only case he ever met with among the 
natives, and is conclusive evidence that we can boast of the best 
blood among our Kaipara natives as well as amongst the Pakehas. 
Wellington Independent, 1 July 
1872  
When one hears of these Māoris purchasing steamers, owning flour 
mills, drawing large incomes from royalties on gold mines, and 
engaging in commerce and agriculture with intelligence and 
success, and when one sees the artistic and technical ability which 
many of them exhibit in the construction and decoration of their 
houses and canoes, as well as in their carvings of wood, bone and 
ivory, one is driven to acknowledge that here is a people whom it 
would be an act of folly to despise, and whom it would be a 
flagitious crime to exterminate, even supposing we could do so in 
fair and open warfare. There is lying before me at this moment a 
photographic portrait of a chief at Timaru, an elderly man with 
white hair, moustache, and Dundreary whiskers, whom I would be 
easy to mistake for an English gentleman farmer, with a remarkably 
fine head on his shoulders, and just a touch of gout in his feet... 
New Zealand Herald, 3 May 1879  Paul Tuhaere, of Orakei, is here, but ill with rheumatic gout. Sir 









The Press, Volume XXXI, 3 May 
1879  
Sir G. Grey and Mr Sheehan and five or six other Europeans arrived 
at 3 o'clock in the steamer Lily. They were received with three 
cheers by the crowd, and Te Wheoro's Natives assembled on the 
bridge……. Further on another assemblage of Paul's tribe from 
Auckland and Kaipara, gave a similar welcome. Minister's paid a 
visit to Paul, who has been suffering from an attack of gout.  
Thames Advertiser, 5 May 1879  On their arrival to Te Kopua the canoes were met by the chief Paul, 
of Orakei, and other friendlies, who greeted Sir George Grey from 
the river bank……. Paul, of Orakei, whose people were guests on the 
occasion, was mounted on a charger, as he suffers acutely from 
gout. 
New Zealand Herald, 1 December 
1882  
They were also entitled to the consideration that in what they had 
done or what they had alleged to have done, they were acting under 
the instigation of their chief, Henare Potae, who was equally if not 
more to blame than the defendants, although, from his being an 
infirm man, a martyr to gout and dropsy, he had kept in the 
background himself. 
New Zealand Herald, 1 April 1884  The reason why Paora Tuhaere, of Orakei, abandoned the idea of 
going to England with Tawhaio and party was a sudden access [sic.] 
of rheumatism and gout. It is said that the natives are not all 
satisfied on that head, and are under the belief that the Government 
in order to prevent Paul from going, have employed other Māoris to 
makutu him, and give him rheumatism and gout. The old leaven of 
superstition has evidently not yet been got out of the Māori mind.  
Wanganui Herald, 24 July 1884  The Māori party are very diverse in their appearance, although they 
are all able to maintain the same impenetrable reserve…… Topai 
Turoa, a chief of high rank, is the oldest and most infirm member of 
the embassy. He is afflicted with rheumatic gout, leans heavily on a 
stick, and moves about with some difficulty. 
Grey River Argus, 22 October 1885  Suicide of Ihaia Tainui [West Coast Times] 
An inquest was held at the Māori School House yesterday (Tuesday 
20th) morning, before J. Giles, Esq., Coroner, and a jury of six, over 
the body of Ihaia Tainui…….Dr King stated he had examined the 
body, and deposed that death was caused by asphyxia, induced by 
strangulation. He had attended Tainui recently for gout, and 
thought it likely that an attack of this might, in first instance, have 
caused some despondency and gloomy forebearings….  
Evening Post, 6 December 1886  We regret to have to chronicle the death of the influential chief Ihaia 
Porutu, who passed away last night at his residence, Pipitea Point,  
at the age of 69. The deceased has been subject to chronic 








complication of other disorders, his dissolution has been due.  
Taranaki Herald, 8 December 1886  Isaiah Porutu, the most important chief of the Ngatiawa tribe, and 
the firm friend, ally, and protector of the early colonists died last 
week. His family originally came from Taranaki, and he was a near 
relation of Te Whiti, his father having been a brother of Te Whiti's 
mother….. He had been an invalid for about 20 years, and for the 
last few years had been almost bedridden, except that on fine days 
he was wheeled in a chair about the town. He suffered from chronic 
rheumatic gout, and a complication of other disorders. 
Dominion, 30 September 1911  The House met at 2.30 pm. Mr A.E. GLOVER (Auckland Central) 
moved: "That fourteen days' leave be granted to Mr Kaihau, 
member for the Western Māori district on account of illness." ……. 
Mr Glover said that he had visited Mr Kaihau in Auckland a few days 
ago, and found that the member was suffering from a severe attack 
of gout, from which he would not recover for some months….. The 
desired leave was granted on the voices.  
Ashburton Guardian, 2 October 
1911  
Mr Glover (Auckland West) moved to grant fourteen days' leave of 
absence to the Western Māori member (Mr H. Kaihau), on account 
of illness……. Mr Kaihau was suffering from gout and a kind of 
rheumatic fever. 
Ellesmere Guardian, 27 April 1921  There was one man of 70 who had been crippled with gout for 15 
years. He got about with the aid of two crutches and was doubled 
up with his affliction. Ratana took his crutches away from him and 
told the patient to come to him…... 
NZ Truth, 13 August 1921  Two of his patients at the Pa claim that Ratana's work was 
successful in relieving them from their bodily ills. One of these was 
a venerable Māori of Rapaki - by the name of Hone Tikau. For many 
years he had been a martyr to gout and rheumatism, and latterly 
had been a victim to insomnia. He saw Ratana on the Sunday during 
the week-end visit of the Māori healer….. The old Māori who has not 











8.3 Appendix 3: Supplementary tables from Chapter 5 
 
Table 8.1: Distribution of haplogroups between gout cases and healthy controls. NB. The total number of 






    Combined Polynesians West Polynesians East Polynesians   
Haplogroup Gout (%) No gout(%) Gout (%) No gout(%) Gout (%) No gout(%) Total (%) 
  
n = 327 n=112 n = 177 n= 50 n = 150 n = 62 n = 439 
R 
 
317 (96.9%) 106 (94.6%) 144 (96.6%) 46 (92.0%) 146 (97.3%) 60 (96.8%) 423 (96.4%) 
 
B4a1a1 94 (28.7%) 26 (23.2%) 74 (41.8%) 16 (32.0%) 20 (13.3%) 10 (16.1%) 120 (27.3%) 
 
B4a1a1a 35 (10.7%) 9 (8.0%) 35 (19.8%) 9 (18.0%) … … 44 (10.0%) 
 
B4a1a1a1 1 (0.3%) … 1 (0.6%) … … … 4 (0.9%) 
 
B4a1a1a1c* … 3 (2.7%) … 3 (6.0%) … … 3 (0.7%) 
 
B4a1a1a8 9 (2.8%) 2 (1.8%) 7 (4.0%) 2 (4.0%) 2 (1.3%) … 11 (2.5%) 
 
B4a1a1a9 1 (0.3%) 1 (0.9%) 1 (0.6%) 1 (2.0%) … … 2 (0.5%) 
 
B4a1a1a11 2 (0.6%) … 2 (1.1%) … … … 2 (0.5%) 
 
B4a1a1a11a 3 (0.9%) … 3 (2.0%) … … … 3 (0.7%) 
 
B4a1a1a13 1 (0.3%) … 1 (0.7%) … … … 1 (0.2%) 
 
B4a1a1a14* 6 (1.8%) 3 (2.7%) 1 (0.7%) 1 (2.0%) 5 (3.3%) 2 (3.2%) 9 (2.1%) 
 
B4a1a1a15* 5 (1.5%) 4 (3.6%) … … 5 (3.3%) 4 (6.5%) 9 (2.1%) 
 
B4a1a1a16* 3 (0.9%) 1 (0.9%) 3 (1.7%) 1 (2.0%) … … 4 (0.9%) 
 
B4a1a1a17* 5 (1.5%) 2 (1.8%) 1 (0.6%) … 4 (2.7%) 2 (3.2%) 7 (1.6%) 
 
B4a1a1c 36 (11.0%) 17 (15.2%) 1 (0.6%) … 35 (23.3%) 17 (27.4%) 53 (12.1%) 
 
B4a1a1k 2 (0.6%) 1 (0.9%) 2 (1.1%) 1 (2.0%) … … 3 (0.7%) 
 
B4a1a1m 65 (19.9%) 18 (16.1%) 17 (9.6%) 7 (14.0%) 48 (32%) 11 (17.8%) 83 (18.9%) 
 
B4a1a1n 6 (1.8%) 2 (1.8%) 1 (0.6%) … 5 (3.3%) 2 (3.2%) 8 (1.8%) 
 
B4a1a1r** 9 (2.8%) 4 (3.6%) 3 (1.7%) … 6 (4.0%) 4 (6.5%) 13 (3.0%) 
 
B4a1a1x … 1 (0.9%) … 1 (2.0%) … … 1 (0.2%) 
 
B4a1a1z* 5 (1.5%) 4 (3.6%) 1 (0.6%) … 4 (2.7%) 4 (6.5%) 9 (2.1%) 
 
B4a1a1aa* 6 (1.8%) … 5 (2.8%) … 1 (0.7%) … 6 (1.4%) 
 
B4a1a1ab* 7 (2.1%) 2 (1.8%) 2 (1.1%) 1 (2.0%) 5 (3.3%) 1 (1.6%) 9 (2.1%) 
 
B4a1a1ac* 5 (1.5%) 2 (1.8%) 3 (1.7%) 2 (4.0%) 2 (1.3%) … 7 (1.6%) 
 
B4b1a2 2 (0.6%) … 2 (1.1%) … … … 2 (0.5%) 
 
P1d 2 (0.6%) 1 (0.9%) 2 (1.1%) 1 (2.0%) … … 3 (0.7%) 
M 
 
10 (3.1%) 6 (5.5%) 6 (3.4%) 4 (8.0%) 4 (2.7%) 2 (3.2%) 16 (3.6%) 
 
M28a 2 (0.6%) 2 (1.8%) 2 (1.1%) 2 (4.0%) … … 4 (0.9%) 
 
M28b 1 (0.3%) … 1 (0.6%) … … … 1 (0.2%) 








Table 8.2: Frequency of haplogroups in various Pacific sub-populations included in this study 
Haplogroup NZ Maori Cook 
Islands 
Pukapuka Samoa Tonga Niue 
B4a1a - - - 4 (0.03) 2 (0.04) 1 (0.04) 
B4a1a1 23 (0.16) 8 (0.12) - 53 (0.40) 17 (0.39) 8 (0.31) 
B4a1a1a 10 (0.07) 2 (0.03) - 36 (0.27) 6 (0.12) 5 (0.19) 
B4a1a1a1c* - - - 4 (0.03) 2 (0.04) - 
B4a1a1a5 - - - 1 (<0.01) - - 
B4a1a1a8 - 2 (0.03) - 2 (0.02) 1 (0.02) 6 (0.23) 
B4a1a1a9 - - - 2 (0.02) - - 
B4a1a1a11 - - - 2 (0.02) - - 
B4a1a1a11a - - - 2 (0.02) 1 (0.02) - 
B4a1a1a13 - - - 1 (<0.01) - - 
B4a1a1a14* 7 (0.05) 2 (0.03) - - - - 
B4a1a1a15* - - - 3 (0.02) 1 (0.02) - 
B4a1a1a16* 6 (0.04) 1 (0.01) - - 1 (0.02) - 
B4a1a1c 43 (0.30) 9 (0.13) 1 (0.07) - 1 (0.02) - 
B4a1a1k - - - 1 (<0.01) 2 (0.04) - 
B4a1a1m 32 (0.23) 28 (0.41) 11 (0.73) 4 (0.03) 7 (0.14) 2 (0.08) 
B4a1a1n 4 (0.03) 3 (0.04) - - 1 (0.02) - 
B4a1a1r* 8 (0.06) 2 (0.03) - 3 (0.02) - - 
B4a1a1x - - - - - - 
B4a1a1z* 6 (0.04) 2 (0.03) - - 1 (0.02) - 
B4a1a1aa* - 1 (0.01) - 2 (0.02) - 4 (0.14) 
B4a1a1ab* 3 (0.02) 1 (0.01) - 2 (0.02) - - 
B4a1a1ac* - 2 (0.03) 2 (0.13) 2 (0.02) - - 
B4b1a2 - - - - 1 (0.02) - 
M28a - - - 2 (0.02) 2 (0.04) - 
M28b - - - - 1 (0.02) - 
P1d - - - 1 (<0.01) 2 (0.04) - 
Q1 - 6 (0.09) 1 (0.07) 4 (0.03) - - 











Table 8.3: Results of linear regression testing for association between triglycerides, HDL, serum urate levels 
and mitochondrial haplogroup. Adjusted for age, East versus West Polynesian ancestry and self -declared 
proportion of Polynesian grandparents 
Population Haplogroup n Triglycerides 








β (std error) 
 
 P 
All B4a1a1+16126 13 -0.52 (0.58) 0.37 0.04 (0.11) 0.73 0.01 (0.03) 0.73 
(n = 394) B4a1a1a 78 0.17 (0.26) 0.51 -0.002 (0.05) 0.98 0.01 (0.02) 0.56 
 B4a1a1a8 9 1.51 (0.60) 0.01* -0.009 (0.12) 0.94 -0.03 (0.04) 0.38 
 B4a1a1c 53 -0.05 (033) 0.89 -0.05 (0.07) 0.46 0.05 (0.02) 0.01* 
 B4a1a1m 83 -0.31 (0.27) 0.24 0.04 (0.05) 0.40 0.02 (0.02) 0.19 
 Q1 11 0.89 (0.57) 0.12 0.12 (0.11) 0.30 0.02 (0.03) 0.65 
EP B4a1a1a 27 0.07 (0.37) 0.86 0.03 (0.08) 0.76 0.003 (0.02) 0.91 
(n = 188) B4a1a1c 52 -0.44 (0.38) 0.24 -0.03 (0.09) 0.70 0.003 (0.02) 0.91 
 B4a1a1m 59 -0.56 (0.34) 0.10 0.06 (0.08) 0.46 0.02 (0.02) 0.37 
WP B4a1a1a 51 0.22 (0.27) 0.42 -0.02 (0.06) 0.75 0.01 (0.02) 0.52 
(n = 171) B4a1a1m 24 0.003 (0.32) 0.99 -0.04 (0.11) 0.70 0.01 (0.02) 0.54 
 
Table 8.4: The results for linear regression predicting various metabolic markers by mitochondrial variants 

















β (std error) 
 
P 
C151T 0.28 -0.58 (0.34) 0.09 0.06 (0.06) 0.30 0.01 (0.02) 0.47 
310T/TC 0.91 0.71 (0.56) 0.21 -0.01 (0.10) 0.89 -0.01 (0.03) 0.65 
C1185T 0.24 -0.25 (0.39) 0.51 -0.01 (0.07) 0.83 -0.02 (0.02) 0.23 
A1692G 0.28 -0.52 (0.35) 0.14 0.07 (0.06) 0.29 0.01 (0.02) 0.49 
T2416C 0.28 -0.50 (0.35) 0.16 0.06 (0.06) 0.36 0.01 (0.02) 0.44 
A4769G 0.76 0.27 (0.38) 0.48 0.02 (0.07) 0.68 0.02 (0.02) 0.27 
T5465C 0.97 -0.90 (0.61) 0.14 -0.13 (0.11) 0.24 -0.005 (0.03) 0.88 
T6719C 0.97 -0.90 (0.61) 0.14 -0.13 (0.11) 0.24 -0.005 (0.03) 0.88 
A6905G 0.14 0.48 (0.37) 0.19 -0.02 (0.07) 0.78 -0.005 (0.03) 0.81 
G9123A 0.97 -0.90 (0.61) 0.14 -0.13 (0.11) 0.24 -0.005 (0.03) 0.88 
T10238C 0.97 -0.90 (0.61) 0.14 -0.13 (0.11) 0.24 -0.005 (0.03) 0.88 
C12239T 0.97 -0.98 (0.58) 0.10 -0.09 (0.10) 0.37 -0.02 (0.03) 0.51 
A14022G 0.97 -0.90 (0.61) 0.14 -0.13 (0.11) 0.24 -0.005 (0.03) 0.88 
A15746G 0.97 -0.90 (0.61) 0.14 -0.13 (0.11) 0.24 -0.005 (0.03) 0.88 
A16183C 0.93 -0.37 (0.49) 0.45 -0.07 (0.09) 0.42 0.01 (0.03) 0. 55 
T16189C 0.96 -0.99 (0.61) 0.11 -0.08 (0.11) 0.44 -0.004 (0.03) 0.91 
T16217C 0.96 -0.99 (0.61) 0.11 -0.08 (0.11) 0.44 -0.004 (0.03) 0.91 
A16247G 0.89 -0.57 (0.38) 0.14 0.00 (0.07) 1.00 -0.01 (0.02) 0.61 









Table 8.5: The results for linear regression predicting various metabolic markers by mitochondrial variants 
in 210 West Polynesian men. These have been adjusted by age and proportion of self-declared Polynesian 
grandparental ancestry 
 
Table 8.6: Mean metabolic characteristics for the 1019 Polynesians who were genotyped for position 6905 for 
replication  
Variable WP EP Combined 
 High BMI Low BMI High BMI Low BMI High BMI Low BMI 
n 233 173 251 362 484 535 
Sex (Male/Female) 150/83 116/57 98/153 165/197 248/236 281/254 
Age 43.2±0.9 38.4±1.1 49.9±0.9 48.5±0.9 46.7±0.7 45.2±0.7 
% Polynesian Ancestry 0.94±0.01 0.90±0.01 0.86±0.01 0.83±0.01 0.90±0.01 0.85±0.01 
BMI (kg/m2) 40.6±0.5 30.0±0.2 41.0±0.5 28.8±0.2 40.8±0.3 29.2±0.2 
Triglycerides (mmol/L) 2.31±0.11 2.10±0.11 2.43±0.11 2.11±0.08 2.37±0.08 2.11±0.06 
HDL (mmol/L) 1.06±0.02 1.15±0.03 1.12±0.03 1.22±0.02 1.09±0.02 1.20±0.02 

















β (std error) 
 
P 
C151T 0.12 -0.14 (0.28) 0.63 0.11 (0.06) 0.08 -0.01 (0.02) 0.51 
310T/TC 0.99 0.47 (0.40) 0.24 -0.04 (0.09) 0.66 0.03 (0.03) 0.36 
A1692G 0.09 -0.13 (0.29) 0.65 0.09 (0.06) 0.14 0.00 (0.02) 0.97 
T2416C 0.11 -0.18 (0.28) 0.53 0.10 (0.06) 0.12 0.00 (0.02) 0.90 
T5465C 0.93 -0.09 (0.54) 0.86 0.21 (0.12) 0.08 0.04 (0.04) 0.25 
T6719C 0.93 -0.09 (0.54) 0.86 0.21 (0.12) 0.08 0.04 (0.04) 0.25 
A6905G 0.33 0.10 (0.24) 0.67 -0.04 (0.05) 0.45 0.00 (0.02) 0.56 
G9123A 0.93 -0.09 (0.54) 0.86 0.21 (0.12) 0.08 0.04 (0.04) 0.25 
T10238C 0.93 -0.09 (0.54) 0.86 0.21 (0.12) 0.08 0.04 (0.04) 0.25 
C12239T 0.93 -0.09 (0.54) 0.86 0.21 (0.12) 0.08 0.04 (0.04) 0.25 
A14022G 0.93 -0.09 (0.54) 0.86 0.21 (0.12) 0.08 0.04 (0.04) 0.25 
A15746G 0.93 -0.09 (0.54) 0.86 0.21 (0.12) 0.08 0.04 (0.04) 0.25 
A16183C 0.92 0.28 (0.46) 0.55 0.09 (0.10) 0.37 0.03 (0.03) 0. 34 
T16189C 0.94 0.24 (0.54) 0.65 0.11 (0.12) 0.37 0.04 (0.04) 0.27 
T16217C 0.94 0.35 (0.57) 0.53 0.10 (0.13) 0.44 0.04 (0.04) 0.33 
A16247G 0.80 -0.32 (0.30) 0.28 0.03 (0.07) 0.70 0.00 (0.02) 0.82 









8.4 Appendix 4: Supplementary material from Chapter 6 
8.4.1 MtDNA qPCR standard curves  
After it became clear that the probes did not appear to be working optimally after creating a 
standard curve with a 1:2 dilution series (Figure 8.1), further standard curves were run with 
concentrations expanding over a wider log range that gives a more accurate calculation of PCR 
efficiency. 
Apparently high PCR efficiency usually results from some kind of inhibition going on in a PCR 
reaction. In this case, it seems that there may be competition going on between the 
mitochondrial assay and the reference assay – especially given that the mitochondria exist in 
such high copy number per cell compared to the nuclear genome. With an exponential increase 
in DNA, the reaction is likely to be quickly overrun with mtDNA product. 
To explore this problem further, standard curves were carried out with the mitochondrial and 
the references probes separately, as well as with a variety of dilutions of the mitochondrial 
probe to test whether this impacts the efficiency of the reference assay. Decreasing the amount 
of mitochondrial probe did seem to improve the assay down to a concentration of 0.25x, 
however past this point, the assay seemed to decrease in efficiency.  
 
 
Figure 8.1: 1:2 dilution series standard curve, efficiency calculated for mtDNA probe 97.6%; efficiency of the 










Figure 8.2: 1:10 dilution series standard curve, efficiency calculated for mtDNA probe 100.3%; efficiency of 
the RNase P probe 182.4% 
 
 
Figure 8.3: 1:5 dilution series standard curve with 0.5x mitochondrial probe, efficiency calculated for mtDNA 









Figure 8.4: 1:5 dilution series standard curve with 0.25x mitochondrial probe, efficiency calculated for mtDNA 
probe 93%; efficiency of the RNase P probe 114% 
 
Figure 8.5: 1:5 dilution series standard curve with 0.125x mitochondrial probe, efficiency calculated for 
mtDNA probe 99%; efficiency of the RNase P probe 149% 
 
Reducing the amount of mitochondrial probe used did initially look like it was improving the 
assay, and the calculated efficiency of the RNase P probe dropped closer to 100% (Figure 8.3, 
Figure 8.4), however, this effect dropped off as the mitochondrial probe was further decreased 
in amount (Figure 8.5).  
The efficiency of the assays were then tested in single-plex to make sure that without added 








RNase P reference probe, this appeared to be the case, with the efficiency tested at 94% (Figure 
8.6), however, the mitochondrial assay was less efficient with a calculated efficiency of 125% 
(Figure 8.7).  
This means that the assays, contrary to assumption, were not necessarily pre-optimised which 
has consequences regarding the data and the way it can be analysed.  
 
 
Figure 8.6: 1:10 dilution series standard curve with RNase P probe only (low concentrations of DNA failed to 
work here), efficiency calculated for probe was 94% 
 
 
Figure 8.7: 1:10 dilution series standard curve with mitochondrial ATP8 probe only, efficiency calculated for 









8.4.2  Supplementary statistics tables 
 
Table 8.7: qPCR results with those individuals who were sequenced in the Whole Genome and Resequencing 
Cohorts excluded 
Sample set n Gout cases/controls OR (95% CI) Pr (>|z|) 
All Polynesians 379 191/188 1.07 (0.78-1.46) 0.68 
East Polynesians 213 111/102 1.21 (0.82-1.79) 0.32 
West Polynesians 166 80/86 0.89 (0.49-1.58) 0.70 
Males 239 158/81 1.09 (0.75-1.61) 0.64 
Females 140 33/107 0.91 (0.50-1.64) 0.76 









8.5 Permission for reuse of images 
 
Figure 1.1: Pacific map showing settlement taken from Matisoo-Smith (2015) and modified for 
use in this thesis. Permission for image reuse obtained from RightsLink; License Number: 
3735670045024. Base map drawn by Ceridwen Fraser. 
Figure 2.4: Drawing of gout lesions from excavated human remains from the Ihumatao 
archaeological site. Originally published by Campbell & Hudson (2011). Permission for image 
reuse obtained from representatives of the tangata whenua of Pukaki and Makaurau Marae 
Figure 4.7: Figure showing the role of mitochondria in the activation of the NLRP3 
inflammasome. Originally published by Akira et al. (2013). Permission for image reuse obtained 
from RightsLink; License Number: 3713401310426 
Figure 4.8: Figure showing the mitochondrial genome and the subunits it encodes. Originally 
published by Schon et al. (2012). Permission for image reuse obtained from RightsLink; License 
Number: 3713410999321 
Figure 4.9: Figure showing the distribution of mitochondrial variation across the Pacific based 
on control region variation. Published by Kayser (2010).Permission for image reuse obtained 
from RightsLink; License Number: 3713420528462 
Figure 6.9: Electron microscope images of mitochondrial morphology in type 2 diabetes patients 
and healthy controls. Originally published by Widlansky et al. (2010). Permission for image 
reuse obtained from RightsLink; License Number: 3706210620533 
Figure 6.10: Electon micropscope images of mitochondrial morphology in carotid 
artherosclerosis patients compared with a healthy control. Originally published by Sobenin et al. 
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